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Cyclophilin A (CypA) is a member of the immunophilin family of proteins and 
receptor for the immunosuppressant drug cyclosporin A (CsA). CypA also catalyses 
the cis-trans isomerisation of peptidyl-prolyl (Xaa-Pro) amide bonds, biologically 
important in protein folding. CypA is a potential therapeutic target for areas 
including HIV replication and parasitic development. Although many natural and 
synthetic CsA derivatives are known to bind to and inhibit CypA, there are relatively 
few examples of small-molecule CypA ligands reported.
A number of low molecular weight ligands have been synthesised based upon O- 
acylated 5,5-dimethyl-l,3-cyclohexanedione and TV-acylated 3-amino-5,5-dimethyl- 
cyclohex-2-enone. Routes to C-6 alkylated derivatives were also investigated and 
derivatives synthesised. Mass spectrometry was initially used to identify 
CypA:ligand complexes, and was developed into a high-throughput primary assay. 
Ligands were ranked in order of their relative CypA dissociation constants, and this 
approach identified ligand I as a lead compound.
I
Further biological in vitro assays supported the relative ligand rank order of selected 
ligands, and in vivo studies using the nematode C. elegans revealed ligand I to have 
anti-parasitic activity. A fluorescently-labelled ligand derivative was synthesised that 
showed similar anti-parasitic properties upon screening, and revealed strong 
fluorescent staining of the gut lumen and surrounding tissues when the C. elegans 














CID collision induced dissociation 
CN calcineurin 
Cys cysteine (C) 
CsA cyclosporin A 
Cyp cyclophilin 
DAPI 4' ,6-diamidino-2-phenylindole 













ELISA enzyme-linked immunosorbent assay
ESI electrospray ionisation mass spectrometry




Glu glutamic acid (E)
Gly glycine (G)
H ATU O-(7-azabenzotriazol-1 -yl)-Ar,AyV',AMetramethyluronium
	hexafluorophosphate 
HBTU 0-(benzotriazol-1 -yl)-N, N, jV',7V'-tetramethyluronium
	hexafluorophosphate 
His histidine (H) 
HIV human immunodeficiency virus 
HMPA hexamethylphosphoric triamide 
HOBt 1 -hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
HTS high throughput screening 
Hz hertz 
IL-2 interleukin-2 
He isoleucine (I) 
J coupling constant 
LDA lithium diisopropylamine 
Leu leucine (L)
LIDAEUS ligand design at Edinburgh University
Lys lysine (K)





NF-AT nuclear factor of activated T-cells
NMM JV-methylmorpholine
NMR nuclear magnetic resonance
PBB protein database
Phe phenylalanine (F)
PPIase peptidyl-prolyl cis/trans isomerase











TBTU 2-( 1 //-benzotriazole-1 -yl)-1,1,3,3-tetramethyluronium
	tetrafluoroborate
TOS target-orientated synthesis












This thesis is concerned with the design and synthesis of high affinity ligands for 
cyclophilin A (CypA). The project incorporated aspects of structure-based design, 
medicinal chemistry and the emerging field of chemical genetics. As an introduction 
to the project these areas are discussed below, along with an overview of the 
functions of cyclophilin A. The previous work done on the project is also outlined, 
concerning the discovery of the original lead compound, dimedone, and subsequent 
ligand optimisation.
1.1 Drug discovery
1.1.1 Historical drug discovery
Drug research is a relatively new area, as a multidisciplined industrial endeavour it is 
not much older than a century. The field began in the late 19th century when 
chemistry was starting to advance and pharmacology had become a separate 
scientific discipline in its own right. By this stage some of the key principles of 
chemical theory had been established, Avogadro's atomic hypothesis had been 
accepted and the periodic table had been determined. Initially, it was the expansion 
in synthetic dye production that marked the first step in the industrialisation of 
organic chemistry. Coal tar, a previously inconvenient by-product of the manufacture 
of coke and town gas, was used as the starting material for a range of silk dyes 1 that 
were a commercial success and went on to have a profound influence on 
contemporary medicine.
It was the evolution of dye chemistry that led to some of the key principles of 
modern biology being discovered. Paul Ehrlich noted that biological tissue had a 
selective affinity for dyes, thus leading him to postulate the existence of 
"chemoreceptors". He went on to pioneer immunological studies, claiming that 
differences in chemoreceptors between parasites, micro-organisms and host tissues
13
could be exploited to treat illnesses.2 Clearly this was the starting point for modern 
receptor theory, and his contribution to the field of medicine was recognised by the 
award of the Nobel Prize in 1908.
The isolation and purification of the active ingredients of known medicinal plants 
was another key driving force in early drug discovery. Morphine was isolated from 
opium extract in the early 1800s by Friedrich Serturner3 and sparked the study into 
natural product chemistry. A host of other alkaloids were subsequently isolated, 
including caffeine and quinine in 1820, codeine and atropine in the 1830s and 
cocaine in I860.4 During the first half of the 20th century, the field of medicinal 
natural products continued to expand through the discovery of antibiotics. Penicillin 
was isolated by Alexander Fleming in 19295 and ushered in a new era in the 
treatment of bacterial infections. The emerging pharmaceutical industry that had 
grown out of pharmacies and dye companies embraced this new direction and started 
to include microbiology as a means of drug discovery.2 Of relevance to this project, 
the immunosuppressants cyclosporin A (CsA), FK506 and rapamycin were all 
discovered through such microbial screening. 6
The modern pharmaceutical industry approaches drug discovery in a 
multidisciplinary fashion. Chemistry, biochemistry, pharmacology and microbiology 
all interact to investigate biological processes and to discover new therapeutic drug 
candidates. Technological advances such as combinatorial chemistry and high- 
throughput screening (HTS) have allowed the synthesis and testing of an 
unprecedented number of new chemical entities against a broad range of targets. The 
drug discovery process often commences from research into a particular disease area 
leading to selection of a therapeutic target, followed by chemical lead compound 
selection and optimisation. This discovery period, if successful, is followed by a 
scale-up of drug production and in-depth in vitro and in vivo biological testing. 
Although drug development can be outlined as a linear process (Figure 1.1), in 
reality the process is based on cycles of synthesis and screening to obtain analogues 
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Figure 1.1: Simplified chart of successful drug discovery in the pharmaceutical industry. 7
1.1.2 Structure-based design
Structure-based design has emerged over the last few years to become a key tool in 
medicinal chemistry. Greater understanding of molecular recognition in protein- 
ligand complexes has led to the expansion in the area, aided by the exponentially 
increasing amount of information on the three-dimensional structure of proteins. If 
the three-dimensional structure of a given protein is known, this information can be 
exploited for the tailored optimisation of a known lead structure, or even applied to 
the de novo design of new ligands.
Structure-based ligand design is an iterative process. The process starts with an 
analysis of the binding site of the target protein, ideally with a ligand bound in place. 
Structural determination is accomplished mainly by X-ray crystallography, 8 or by 
multidimensional NMR spectroscopy, 9 and the number of solved protein structures 
has increased exponentially over the last ten years. In 1995 there were just over 
4,000 entries in the Research Collaboratory for Structural Bioinformatics (RCSB) 
Protein Database (PDB), the worldwide repository for the three-dimensional
15
structure of proteins. There are now over 31,000 solved protein structures listed. 10 
The three-dimensional protein-ligand structure is analysed to identify the binding 
mode and conformation of the ligand as well as the key protein-ligand interactions. 
This knowledge can then be used to modify an existing lead compound, or to design 
a new series of ligands. The proposed ligands are then synthesised and assayed using 
biochemical, spectroscopic and crystallographic methods. The next cycle of ligand 
design and optimisation is commenced upon analysis of these results (Figure 1.2). 11
Crystal structure 
of receptor







Figure 1.2: The iterative process of structure-based design. 12
Structure-based design can still be of relevance in the absence of crystallographic 
data. If the crystal structure of a particular protein-ligand complex is unobtainable a 
comparative analysis of known binding ligands can often reveal the key binding 
features. Ligands can then be designed to optimise these protein-ligand interactions. 
The ensuing assay results will validate the design if the binding affinity is increased, 
or lead to a new ligand design hypothesis if the new compounds are less active.
The vast majority of ligands bind to protein active sites through non-covalent 
interactions. Usually, opposite charged functional groups of the protein and ligand 
are paired, hydrogen bonds are formed and lipophilic ligand moieties are found in 
hydrophobic pockets of the protein. The binding affinity of a ligand is expressed in
16
terms of the equilibrium constant, K, which is thermodynamically related to the 
Gibbs free energy, AG (Equation 1.1). This in turn is composed of enthalpic and 
entropic contributions (Equation 1.2). Combining these two equations gives the van't 
Hoff equation (Equation 1.3), which shows that the binding affinity of a ligand is 
driven by both enthalpic and entropic factors. 13
Equation 1.1: AG = -RTlnK
Equation 1.2: AG = AH-TAS
Equation 1.3: InK = AH/RT+AS/R
The enthalpic component of the above equations is determined principally by 
electrostatic and van der Waals interactions, and the entropic portion measures the 
order of the entire system. The majority of this entropic portion correlates with the 
lipophilic surface, that of the ligand and the section of the protein that becomes 
buried upon binding."
Water often plays a key role in protein-ligand interactions with both the ligand and 
protein being solvated before complex formation. They lose part of their hydration 
shell upon binding, this having both enthalpic and entropic repercussions. If the 
binding of a ligand merely replaces tightly bound water molecules without yielding 
additional electrostatic interactions the desolvation effects can equal the new ligand- 
protein interactions, resulting in the net enthalpic contributions being close to zero. 
However, the replacement of loosely bound water molecules by a ligand can have a 
positive enthalpic effect due to the stronger protein-ligand interactions and the 
released water now being able to hydrogen bond with the bulk water. 14 The entropic 
repercussions arise from lipophilic interactions between the ligand and protein. Such 
hydrophobic interactions are beneficial to ligand binding mainly due to the 
replacement and release of ordered water molecules. Water molecules at 
hydrocarbon surfaces have been shown to be more ordered than water molecules in 
the bulk solvent, 15 therefore the release of water upon ligand binding would have a 
positive entropic effect. There are also enthalpic contributions to lipophilic
17
interactions as water molecules in protein hydrophobic areas are unable to form 
hydrogen bonds, upon release the molecules can hydrogen bond with the bulk 
solvent.
The flexibility of the ligand is another important factor in determining the strength of 
protein-ligand interactions. Generally, the formation of a non-covalent bond between 
a protein and a ligand corresponds to a favourable negative contribution to the 
enthalpy, favouring the binding process. However, this is often accompanied by a 
restriction of the translational and rotational motion of the ligand, corresponding to a 
negative change in entropy, this being unfavourable to the binding. This opposing 
interplay is known as enthalpy/entropy compensation, and is a fundamental property 
of non-covalent protein-ligand interactions. 13 Conformationally constrained ligands 
are often designed to limit this loss of entropy on binding. The binding affinities of 
ligands are increased if the ligands can be pre-organised into the conformation of that 
of the bound state. Ligands are often constrained by the replacement of open alkyl 
chains by ring structures, or the introduction of conformational locking groups into 
the ligand structure. 16 Macrocyclic and intramolecular hydrogen bonding structures 
have also been exploited to similarly enhance the pre-organisation. 17
1.1.3 Peptidomimetic design
The biological activity of peptides is of enormous interest to the pharmaceutical 
industry, but endogenous peptides have limited medicinal potential. Peptides and 
small proteins are generally easily proteolysed, rapidly excreted and have poor 
bioavailability, making them unsuitable candidates for pharmaceutical development. 
Peptidomimetics are peptide derived compounds that resemble peptides in some way 
and are designed to mimic the binding of the peptide to the receptor, but have 
enhanced drug profiles compared to peptides.
1 ftThree distinct classes of peptidomimetics have been described in the literature. 
Early peptidomimetics focussed on the geometry of the peptide bond and secondary 
structural feature of proteins such as a-helices and p-turns and are referred to as
18
type-I mimetics. Often these mimetics match the peptide backbone and focus on the 
replacement of the amide functionality with such groups as amines, 
a-difluoroketones and ethylene and ketomethylene isosteric groups.20 The second 
type of mimetic is called the functional mimetic, or type-II mimetic. This is a small 
non-peptide molecule that does not necessarily mimic the structure of the original 
peptides and binds to a subsite on the protein that is different from the original 
peptide receptor. The last class of peptidomimetics, type-Ill, are in some ways the 
ideal peptidomimetic as they are novel templates that are structurally unrelated to the 
original peptides, but mimic key features that allows the ligand to bind to the peptide 
functional site.
There is no standard systematic way of transforming the structure of an enzyme 
bound substrate into a peptidomimetic. A number of different techniques have been 
used including the replacement of amino acids in the peptide backbone with 
unnatural analogues, and the use of cyclic or bridging dipeptides to conformationally 
constrain the structure. Structure-based design techniques are also often used to 
design de novo type-Ill peptidomimetics in which the key peptide binding moieties 
are mimicked by the ligand. In this way peptidomimetic ligands are often structurally 
smaller than the original peptide as often only a few peptide residues make 
energetically significant contact to the protein binding site.
1.1.4 Chemical genetics
Chemical genetics is the name given to the study of biological systems through the 
interaction of exogenous ligands, instead of using genetic intervention. The area was 
founded in the mid-1990s by Stuart Schreiber21 and Timothy Mitchison22 as a 
method of emulating the principles of genetics with organic chemistry. Genetics has 
been traditionally used to study biological systems through perturbing the function of 
proteins by manipulation at the gene level. This is generally achieved by the 
mutation of a gene followed by observation of the physiological effect this has on the 
system, the phenotype. Chemical genetics uses small molecule ligands instead of 
mutations to alter the function of proteins in a similar manner.
19
Genetics can be divided into two categories: forward genetics that entails random 
mutagenesis followed by phenotypic screening and mutant gene identification; and 
reverse genetics that introduces a mutation into a specific gene of interest and is 
followed by a study of the phenotypic consequences.23 Thus forward genetics is from 
phenotype to gene, in reverse it is from gene to phenotype. A chemical genetics 
approach can be similarly sub-divided. Forward chemical genetics involves the use 
of small molecules to screen for a desired phenotype in a biological system under 
investigation. Once a ligand that induces a phenotype change has been selected it is 
necessary to identify the protein target of the molecule. Reverse chemical genetics 
starts with the screening of potential ligands against a known protein target. Once a 
binding ligand is identified it is used to study the phenotypic consequences of 
altering the function of this protein in a cellular context. In this manner, forward 






















































Figure 1.3: Comparison of genetics with chemical genetics.
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Traditional genetics has several limitations that are overcome by taking a chemical 
genetics approach. Most genetic mutations are not conditional; they cannot be 
reversed post mutagenesis. Conditional mutagens are available, but they are difficult 
to identify and the effect of modulating the mutant allele can cause environmental 
stress to the organism masking the original phenotypic consequences; for example a 
heat shock response from effecting a temperature sensitive mutation. Chemical 
genetics has the advantage that small molecules most often induce their biological 
effect reversibly due to in vivo metabolism, and temporal control is possible as 
ligands can be added at any time point in the experiment. Another key advantage of a 
chemical genetics approach is that the biological effect of small molecules is usually 
rapid allowing early phenotypic changes to be characterised, genetic studies in 
mammals are often time consuming due to a slow rate of reproduction. Small 
molecule ligands can also be introduced into biological systems at varying 
concentrations allowing for the collection of dose-response data by grading the 
phenotype change. The disadvantage of chemical genetics is that a ligand selective 
for a protein of interest is needed, and currently only a tiny fraction of known 
proteins have such a ligand partner identified.24
A chemical genetics study involves three aspects: a selective small molecule ligand, 
a protein partner and a biological screen capable of assessing the effect of the 
protein-ligand interaction. The small molecule ligand can either be sourced from a 
natural product or synthetically derived. For reverse chemical genetics studies 
structure-based design techniques can be used to guide ligand synthesis when the 
three-dimensional structure of the protein is known, however this approach is limited 
as often little is known about the structure of the target protein. Where a ligand for a 
protein is already known, retrosynthetic analysis of the molecule can be used to 
design synthetic routes to derivatives. Small libraries of derivatives can then be 
synthesised using target-orientated synthesis (TOS)25 and focussed combinatorial 
chemistry. 26 Forward chemical genetics has benefited from the screening of 
structurally-diverse small molecules via high-throughput protein binding screens.24 
Diversity-orientated synthesis (DOS) can be used to synthesise libraries of small 
molecules with the aim of broadly populating chemical space with diverse molecular
21
structures.27 Unlike TOS, diversity-orientated syntheses are not aimed at one 
particular target and involve the simultaneous synthesis of structurally complex and 
diverse compounds; the combinatorial technique of solid-phase split and mix 
synthesis is readily adaptable to this approach. This method was first introduced by 
Furka et al, to synthesise peptides,28 and involves cycles of synthesis, pooling, re- 
splitting and further chemistry to achieve structurally diverse compounds. Split and 
mix is also referred to the "one bead-one compound" approach, and in a chemical 
genetics context it can be seen as being analogous to genetic recombination.29
1.1.5 Conclusions
The introduction of structure-based design, combinatorial chemistry, high-throughput 
screening and the emerging field of chemical genetics have all added to the 
knowledge of how ligands interact with drug targets, and thus have helped to 
advance rational drug design. However, it is clear that for all these technological 
advances made in the late 20th century, organic synthesis remains the cornerstone 
upon which drug discovery is built.
In the last few years the structure-based design approach has expanded markedly in 
academia and the pharmaceutical industry, aided by dramatic improvements in 
computational capabilities and molecular modelling software. 30 Despite this 
progress, structure-based design still faces a number of limitations. The most 
important factor is the availability of three-dimensional structures of target proteins. 
Although there has been a huge increase in the number of published protein 
structures in recent years, there are still many pharmacologically relevant proteins 
that have not be resolved. In particular, the number of membrane bound proteins that 
have been structurally determined lags behind that of soluble proteins. 31 As stated 
previously, it is still possible to apply structure-based design techniques in the 
absence of crystallographic data by relying on ligand comparison, but as the level of 
information on the structural aspects of the protein-ligand system decreases, so does 
the reliability of any ligand design results.
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Medicinal chemistry generally considers ligands and their interactions with the 
biological target when using a structure-based design approach, but a perfect ligand 
is not necessarily a good lead for further pharmaceutical development. 
Considerations such as pharmacokinetics and ADME-Tox (adsorption, distribution, 
metabolism, excretion and toxicity) are not addressed by structure-based design and 
are responsible for a high rate of lead drug candidate attrition. The earlier in drug 
development these issues are considered, the greater the chance of a drug candidate 
being successfully brought to market. With this in mind, Christopher Lipinski et a/., 
reviewed successful drug candidates and found that 90% of orally active drugs that 
had achieved phase II clinical status shared four simple physiochemical parameters; a 
molecular weight of < 500, hydrogen bond donors < 5, hydrogen bond acceptors 
< 10 and a log P < 5, P being the n-octanol/water partition coefficient. 32 These 
parameters were called the rule-of-five (RO5) and the goal was to influence drug 
design from early on in the initial medicinal chemistry discovery phase. 33 Lipinski's 
RO5 has been largely accepted by the pharmaceutical industry as a guide for new 
ligand design with a trend towards considering ADME-tox issues early in lead 
optimisation.
Chemical genetics is proving itself to be a powerful approach, with the possibility of 
perturbing protein function reversibly and conditionally with temporal and 
quantitative control in diverse biological systems. The technique has so far been 
limited by a lack of suitable ligands for protein targets, a consequence of chemical 
genetics being a relatively new field. The area will no doubt expand, fuelled by a 
growth in diversity orientated synthesis and related combinatorial chemistry 
techniques.
Drug discovery has evolved into a multi-disciplined field, whist still keeping 
synthetic chemistry at its core. Structure-based design will continue to make a 
positive impact upon medicinal chemistry research for the foreseeable future, 
enhanced by a combination of emerging new techniques and traditional synthetic 
methods.
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1.2 Peptidyl-prolyl cis/trans isomerases (PPIases)
In the 1970s it was thought that protein folding was a spontaneous process, the three- 
dimensional structure of the protein reflecting the lowest free Gibbs free energy 
conformation determined by the primary amino acid sequence. 34 Refolding 
experiments of denatured proteins showed that refolding events of globular single- 
domain polypeptides occur in the millisecond to second timescale,35 apart from the 
cisltrans isomerisation of peptidyl-prolyl (Xaa-Pro) amide bonds (Figure 1.4). This 
conformational change takes longer, and has been demonstrated to be the rate 
limiting step in refolding experiments. 36
cis trans 
Figure 1.4: Cis-trans isomerisation of a peptidyl-prolyl bond.
In 1984 an enzyme was isolated that was found to catalyse the cis/trans isomerisation 
of peptidyl-prolyl bonds. Fischer et al., extracted the enzyme from porcine kidney 
cortex and it was classified as a peptidyl-prolyl isomerase (PPIase). 37 In the same 
year another 18 kDa protein from mammalian thymocytes was found to be the major 
intracellular receptor for the immunosuppressant drug cyclosporin A (CsA) (1,
•j o
Figure 1.5), and this receptor protein was named cyclophilin A (CypA). 
Subsequently further cyclophilins were characterised and in 1989 two groups 
independently demonstrated that cyclophilins were identical to PPIase. 39 '40 Another 
PPIase was discovered in this year during the search for the receptor of the 
immunosuppressant drug FK506 (2, Figure 1.5) and named FK506-binding protein 
(FKBP). 41 '42 FK506 is a polyketide isolated from Streptomyces tsukubaesis43 and is
24
structurally related to the anti-fungal drug rapamycin (3, Figure 1.5), found to also 
bind to FKBP. 44
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Figure 1.5: Structures of CsA, FK506, rapamycin and juglone.
The amino acid sequence of FKBP was found to be totally different to cyclophilin, 
and it became obvious that the prolyl isomerases were divided into separate classes; 
the cyclophilins which selectively bind CsA (1), and FKBPs which selectively bind 
FK506 (2) and rapamycin (3). CypA and FKBP are also known as immunophilins 
due to the binding of these immunosuppressants. A third class of PPIase was also 
discovered, the parvulins, initially isolated from Escherichia coli*5 and it was found 
that juglone (5-hydroxy-l,4-naphthoquinone) (4, Figure 1.5) irreversibly inhibited
the PPIase activity of this enzyme. 46
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The cyclophilins family are ubiquitous proteins that have been highly conserved 
during evolution, found to be widely expressed in many biological tissues in addition 
to bacteria, fungi and plants. Structural analysis of human cyclophilin A has revealed 
it to be a cytosolic protein with a molecular mass of 17.7 kDa, consisting of an eight- 
stranded anti-parallel (3-barrel that exists as two perpendicular four-stranded p-sheets. 
The p-barrel encloses a hydrophobic core and is capped at each end by two short 
a-helices. Other mammalian isoforms have also been characterised and have been 
found to share over 50 % sequence homology with CypA, but differ in their 
subcellular localisation. CypB is a 21 kDa protein found in the endoplasmic 
reticulum, as is the 23 kDa protein CypC. CypD is a 18 kDa protein found in cellular 
mitochondria. 35
1.2.1 PPIase activity
Most amide bonds in peptides adopt the trans configuration, however proline 
containing peptides are unusual in the fact that roughly 10 % of the peptidyl-prolyl 
bonds are in the energetically unfavourable cis conformation. This compares to an 
estimated occurrence of less than 1.5 % cw-amides in other amino acids.47 This fact 
may be explained by the free energy difference between the cisltrans conformations 
of Xaa-Pro bonds being less than other non-prolyl amide bonds. It is thought that 
PPIases catalyse this isomerisation of peptidyl-prolyl amide bonds using the same 
active site as that used to bind the respective immunosuppressants, this supported by 
the PPIase activity of the enzyme being abolished upon immunosuppressant binding.
There have been several studies into how the PPIase enzymes catalyse the cisltrans 
interconversion of peptidyl-prolyl bonds, resulting in several mechanisms being 
proposed. Cis/trans isomerisation of amide bonds is restricted by the C-N bond 
having double bond character. This results from conjugation of the C-N amide bond 
with the carbonyl group allowing amide/imine resonance. Consequently, cis/trans 
isomerisation of the prolyl amide bond has to overcome this energetic barrier to 
rotation.
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Initial mechanistic studies of cyclophilin led to the suggestion that PPIase catalysis 
was achieved by the formation of a covalent bond to the carbonyl of the peptidyl- 
prolyl amide with a cysteine-derived thiol.48 Loss of sp2 hybridisation at this 
carbonyl would eliminate amide resonance and thus lower the energy barrier to 
rotation about the C-N bond. However, subsequent site-directed mutagenesis of 
human recombinant cyclophilin allowed the systematic replacement of all four 
cysteine residues in cyclophilin with alanine. These mutant enzymes were found to 
be just as active at the cis/trans isomerisation of Xaa-Pro bonds, thus ruling out 
cysteine as a participating residue in catalysis. 49
A catalysis by distortion mechanism has also been proposed involving a "twisted 
amide" Xaa-Pro transition-state that is stabilised in the CypA active site (Figure 
1.6). 50 In this mechanism the twisted amide transition state has the carbonyl group 
and the nitrogen lone pair electrons of the Xaa-Pro amide bond in orthogonal 
orbitals. This lowers the energy barrier to rotation as resonance can no longer occur.
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Figure 1.6: Catalysis by distortion mechanism for Xaa-Pro isomerisation. 51
Another mechanism proposed that the amide nitrogen forms a hydrogen bond with a 
protonated CypA residue resulting in the prevention of resonance. Molecular orbital 
calculations supported this hypothesis as protonation of the amide nitrogen lowers 
the energy barrier to cis/trans rotation. 52 The desolvation mechanism proposed that 
the twisted amide intermediate is stabilised by the hydrophobic character of the 
PPIase active site as the rate of cis/trans isomerisation was found to be significantly 
accelerated in non-polar solvents. 53 Interestingly, a later study suggested a related but 
opposing mechanism after determining the crystal structure of CypA complexed with
27
the substrate Ala-Pro. A solvent-assisted mechanism was put forward in which 
initially the peptidyl-prolyl bond is desolvated in the ground state by binding to the 
hydrophobic CypA active site, followed by stabilisation of the intermediate through 
hydrogen bonding of the amide carbonyl with a water molecule. 54
1.2.2 Cyclosporin A
Cyclosporin A (1) is a non polar cyclic undecapeptide that was first isolated from the 
fungus Tolypocladium inflatum in 1976;55 its potent immunosuppressive properties 
first described by Borel et a/. 56 CsA has subsequently been developed into a major 
pharmaceutical product, sandimmune, marketed for the prevention of allograft 
rejection and for the treatment of autoimmune disease. 57
The conformation of CsA bound to cyclophilin is very different from the dominant 
conformation of free CsA in chloroform or in single crystals. Free CsA exhibits a cis 
MeLeu9-MeLeulO amide bond, whereas in the cyclophilin bound form all the 
peptide bonds are trans. Free CsA also has a tightly folded structure with a 
hydrophobic surface, brought about by four intramolecular hydrogen bonds. In the 
bound state, the CsA amino acid side chains are flipped over from the inside to the 
outside. This bound CsA open ring structure has only a single intramolecular 
hydrogen bond, between the hydroxyl group on the Bmt-1 side chain and the
CO
carbonyl group of MeLeu-4.
CsA binds to the PPIase active site of CypA with residues 9, 10, 11, 12, 1,2, and 3 
lying in the CypA active site; the remaining residues protrude out from the CypA 
surface. 56 This hydrophobic protrusion is termed the "effector loop" and is 
implicated with specific interactions with the phosphatase calcineurin (CN). 59 X-ray 
analysis of the CypA-CsA complex revealed that the CsA MeVal-11 residue fits very 
tightly into a hydrophobic pocket, and there are five direct hydrogen bonds between 
CypA and CsA, with an additional five water mediated intermolecular interactions. 60
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1.2.3 Mechanism of immunosuppression
Cyclosporin A and FK506 are both powerful suppressors of the immune system, 
exerting their major therapeutic effect by inhibiting the activation of T-cells, a subset 
of lymphocytes that are involved in the immune response. Studies have indicated that 
CsA and FK506 act as prodrugs, only becoming active when complexed to their 
respective immunophilin partner, with immunosuppression independent of PPIase 
activity. 61 Although the CypA-CsA and FKBP-FK506 complexes differ in structure, 
their mechanism of immunosuppression is very similar, with both complexes binding 
to and inhibiting the calcium and calmodulin dependant phosphatase calcineurin.62 In 
this mechanism, the immunosuppressants act like "molecular glue", bringing about 
the binding of normally non-interacting proteins, namely the immunophilin and
calcineurin (Figure 1.7). 63
CypA
Figure 1.7: Events associated with CypA-CsA and FKBP-FK506 mediated immunosuppression.
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During T-cell activation calmodulin (CaM) binds to the phosphatase calcineurin as a 
result of elevated levels of free intracellular calcium. This complex dephosphorylates 
the nuclear factor of activated T cells (NF-AT), which in the dephosphorylated form
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is able to cross the nuclear membrane. In the nucleus NF-AT acts as a transcriptional 
activator for interleukin-2 (IL-2) transcription; interleukin-2 is an immune response 
stimulator involved in the proliferation of T-cells. The CypA-CsA and FKBP-FK506 
complexes bind to calcineurin and block the phosphatase activity of the CN/CaM 
complex. As NF-AT is not dephosphorylated it is unable to cross the nuclear 
membrane, thus T-cell activation is inhibited.
Calcineurin is not inhibited by either drugs or immunophilins alone, only by the 
drug-immunophilin complex, indicating that it is the composite surface of the 
complex that interacts with calcineurin. 64 The crystal structures of the CypA-CsA- 
CN65 and FKBP-FK506-CN66 complexes have both been published and interestingly 
reveal that CypA-CsA and FKBP-FK506 are both bound to the same surface of 
calcineurin, with the majority of the CN residues involved in the binding common to 
both drug-immunophilin complexes.
1.3 Involvement of cyclophilin A in other disease areas 
1.3.1 Cyclophilin A as an anti-HIV drug target
It has been reported that the principal structural protein of the human 
immunodeficiency virus HIV-1, the Gag polyprotein, binds cyclophilins and that 
CypA is specifically incorporated into HIV-1 virions,67 comprising up to 10 % of the 
HIV capsid coat. Late in the infectious cycle, Gag accumulates at the membrane of 
an infected cell and assembles into immature virions that bud from the cell. As the 
virion buds and matures, the membrane bound Gag protein is cleaved by viral 
proteases into three new proteins; matrix, which lines the virion envelope; capsid,
/•Q
which forms the viral core; and nucleocapsid, which coats viral genomic RNA. The 
virus particle must subsequently disassemble when the virus infects a new cell in 
order to allow reverse transcription of the RNA genome and transport of the pre- 












Figure 1.8: Budding of HIV virions from an infected cell. 70
HIV-1 has been shown to be dependant on Gag-CypA for replication, mutation of a 
single Gag proline to alanine disrupts Gag-CypA interaction in vitro, CypA 
incorporation into virions and viral replication. 68 The crystal structure of CypA 
complexed with the TV-terminus domain of the HIV-1 capsid protein and various 
fragment lengths have been characterised. 70'71 The capsid protein was found to have a 
mobile loop of residues that bind in the same CypA active site responsible for 
peptidyl-prolyl isomerase activity, with Ala88, Gly89 and Pro90 buried in this grove. 
A 25-mer fragment of HIV-1 capsid was also found to bind to CypA in an equivalent 
manner, with the same amino acids Ala88 to Ile91 involved in the major binding 
interactions with CypA. Interestingly, in both of these structures Gly89-Pro90 was 
found to adopt an unusual trans configuration, compared to cis configuration seen in 
other known peptide complexes. Although the precise function of CypA in HIV-1 
replication is unknown, due to this interesting trans configuration of the binding 
capsid fragment, it has been hypothesised that CypA is functioning as a chaperone,
rather than a cis I'trans isomerase. 72
Cyclosporin A has been shown to block the binding of the HIV-1 Gag polyprotein to 
CypA and prevent its incorporation into the HIV protein coat, resulting in a markedly 
reduced level of viral proliferation. 72 The mechanism of action is thought to be via
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CsA disrupting the Gag-CypA interaction by competitive binding to CypA rather 
than via an immunosuppression pathway. A non-immunosuppressive analogue of 
CsA, SDZ NIM811 (5, Figure 1.9), was screened against HIV-1 and was found to 
selectively inhibit virion replication in vitro. 13 SDZ NIM 811 (5) is a derivative of 
CsA which is devoid of immunosuppressive activity but retains full capacity for 
binding to CypA, thus demonstrating the immunosuppressant function of CsA is not 
however responsible for the antiviral activity (Figure 1.10).
10 11
Figure 1.9: Structure of SDZ NIM 811 ((Me-Ile-4)cyclosporin) 5.





Figure 1.10: Treatment of HIV-1 infected cells with CsA or SDZ NIM811 results in poorly infectious
71vinons.
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Whilst CsA and derivatives show potential for the design of novel HIV treatments, 
especially the non-immunosuppressant analogues, there are some limitations with the 
approach. The concentration of CsA analogues required to inhibit HIV-1 replication 
may well be toxic to cellular events in vivo, and due to the ubiquitous nature of 
cyclophilins there may be broad range side-effects involved in such a drug treatment. 
Administration of sub-optimal doses of a CsA derivative as part of a combination 
therapy with other HIV pharmaceuticals would probably represent the most viable 
route to a CsA derived anti-HIV treatment.
1.3.2 Cyclosporin A rheumatoid arthritis therapy
Rheumatoid arthritis is a chronic autoimmune disease characterised by inflammation 
of the joints, resulting in chronic pain, loss of function and disability. One percent of 
the world population is affected, with women two to three times more likely than 
men to suffer symptoms. Initial non-specific complaints of fatigue, malaise and 
diffuse musculoskeletal pain are followed by stiffness and pain in specific joint areas. 
The more serious consequences of rheumatoid arthritis involve progressive 
destruction of joint cartilage, bone and supporting soft tissue. The etiology of the 
disease is not clear and is thought to involve genetic and environmental factors that 
lead to an autoimmune response. T-cells have been shown to be involved in the 
rheumatoid arthritis inflammatory process, with a massive infiltration of T-cells 
occurring in the affected synovial tissues. 74
As cyclosporin A is a potent T-cell activation inhibitor through its interaction with 
cyclophilin A and calcineurin there have been several rheumatoid arthritis clinical 
trials involving the immunosuppressor. 75 Trials treating patients at a dosage of 
6 mg/kg per day for 24 weeks led to a reduction in joint pain and swelling, but were 
accompanied with impaired renal function in all treated subjects, and hypertension in 
70 % of patients. The amount of cyclosporin A given was varied in other trials, and it 
was found that the drug was apparently effective at doses of >5 mg/kg day, but 
limited by nephrotoxicity at this level. Reduction of the dose to 2.5 mg/kg per day 
diminished the side-effects, but was seldom effective in treating symptoms. The
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overall consensus of the clinical trials was that cyclosporin A has too narrow a 
therapeutic index for effective clinical use in treating rheumatoid arthritis, although 
patient selection may be a factor in these unfavourable results. The majority of 
treated subjects were older individuals with advanced, long-standing symptoms and 
most typically in late and irreversible stages of the disease.76 Ideally cyclosporin A 
treatment would be investigated on a younger study population showing early stages 
of rheumatoid arthritis, however this group of patients generally respond well to 
treatment with non-steroidal anti-inflammatory drugs and physical therapy.
1.3.3 Anti-parasite activity of cyclosporin A
In the early 1980s parasitology researchers started to investigate the effect of 
cyclosporin A on various parasitic organisms. Initially, it was hypothesised that CsA 
treatment would favour the parasite by suppressing the host immune response, thus 
allowing parasite development and replication to proceed unchallenged. However, 
early research into schistosome and malaria infections showed that the drug had 
unexpected anti-parasite activity, with elimination of the parasites and extended host 
survival. 76 Since this initial discovery, CsA has been shown to adversely affect a 
wide range of protozoa and helminths both in vitro and in vivo 17 The precise 
mechanism by which CsA exerts its anti-parasitic effects is still subject to debate, but 
it is thought that CsA binds to parasite cyclophilin; the majority of parasite 
cyclophilins published in the literature possess a high degree of structural similarity 
to human CypA.78 The mode of action may involve inhibition of the PPIase activity 
of endogenous cyclophilin or inhibition of an essential signal-transduction pathway, 
perhaps by inhibition of a calcineurin homologue. CsA has been shown to retain anti- 
parasitic properties at sub-immunosuppressive levels in in vitro studies, ruling out 
the possibility that CsA exerts an indirect effect via an interaction with the host's 
immune system.77
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1.4 Review of cyclophilin A ligands
1.4.1 Cyclosporin A derivatives
There have been a plethora of cyclosporin derivatives described in the literature since 
the initial discovery of CsA, all being cyclic undecapeptides that differ from each 
other by minor differences in the amino acid sequence. A range of naturally 
occurring cyclosporins, labelled CsB to CsZ, have been insolated from the fungus 
Tolypocladium inflatum, in addition to the main metabolite CsA. 79 Synthetic 
cyclosporin derivatives have also been produced using solid-phase peptide coupling 
techniques. 80 '81 In an attempt to understand how the small chemical differences 
between cyclosporin derivatives influence their binding to CypA, Walkinshaw et a/., 











































































Table 1.1: Amino acid side chains for positions 1, 2, 3, and 4 are shown for 11 different CsA 
derivatives. The CypA binding value in column 6 is relative to CsA, for example derivative 6 binds 26 
times weaker than CsA. The IL-2 value in column 7 is a measure of the effect of suppressing the 
effect of interleukin-2 relative to CsA.
The cyclosporin derivatives outlined in Table 1.1 vary considerably both in their 
ability to bind to CypA and their immunosuppressant activity. In general, 
modification of residues 1 and 2 which change the cyclophilin-binding surface of 
CsA, diminish binding to CypA. This correlates with a slight reduction in 
immunosuppressive activity. Modification of residue 4 leads to a marked decrease in 
immunosuppression without substantially affecting CypA binding, this amino acid
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forming a sensitive site on the effector loop which protrudes from the CypA active 
site and binds to calcineurin. Modification at position 3 leads to stronger binding to 
CypA compared to CsA. The reason for this enhanced binding is not clear as there 
are no obvious pockets in the protein to accept residue-3 side chains. A possible 
explanation conies from the observation using NMR spectroscopy that ligand 10 
adopts the same conformation in aqueous solution as it does bound to CypA. 82 This 
pre-organisation into the bound conformation would reduce the entropy loss upon 
binding to CypA, and may result in an increase in binding affinity.
1.4.2 Sanglifehrins
Screening of microbial broth extracts for metabolites that could block CypA-CsA 
complex formation led to the discovery of a novel class of macrocylic compounds, 
the sanglifehrins (SF), produced by Streptomyces A92-308110. The structures of 
sanglifehrins A, B, C and D have been determined by NMR and X-ray 
crystallography of the CypA-SF complex (Table 1.2). 83 Sanglifehrins A and B are 
genuine metabolites whereas C and D are formed during the isolation process. 84 The 
sanglifehrins bind to the same site on CypA as CsA, with sanglifehrins A and B 
exhibiting approximately 10 to 20 fold higher affinity for CypA than CsA, whereas 
the affinity of sanglifehrins C and D for CypA is comparable to that of CsA. 5
The sanglifehrins inhibit the PPIase activity of CypA, but do not form a complex 
with calcineurin, thus having no effect on its phosphatase activity. However, the 
compounds are also immunosuppressants, with a mode of action that is unclear but 
known to be different to CsA. Unlike CsA, sanglifehrins do not inhibit IL-2 
transcription, and block T-cell proliferation at a later stage. Interestingly, the 
immunosuppressive properties of sanglifehrins are independent to binding to CypA; 
competitive binding of a non-immunosuppressant cyclosporin derivative had no 
effect on sanglifehrin activity. 86 Sanglifehrins also do not bind to FKBP12, with the 

































Table 1.2: Structure of Sanglifehrins A - D. CypA. Binding was measured by competitive ELISA 
format and is described relative to CsA. CsA had a CypA binding IC50 of 83 ± 16 nM and T-cell 
inhibition IC50 of 2.7 ± 1.4 nM when measured in the same manner. 86
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1.4.3 Peptide ligands
There have been several X-ray and NMR structures of CypA-peptide complexes 
published in the literature. The first cyclophilin-peptide structure to be solved was 
of the tetrapeptide substrate ac-Ala-Ala-Pro-Ala-amc 19 (ac, acetyl; amc, 
amidomethylcoumarin) (Figure 1.11) bound to the active site of CypA. 87 The proline 
residue was found to be bound in the cis configuration and occupied the CypA 
hydrophobic pocket defined by the side chains of Phe60, Met61, PhellS, Leul22, 
and His 126. Hydrogen bonding occurred between the backbone amide NH and O 
atoms of Asnl02 with the corresponding O and NH atoms of the substrate Ala2 
residue, and a third hydrogen bond was detected between Arg55 and the substrate 
prolyl carbonyl O atom.
O
19 
Figure 1.11: Structure of ac-Ala-Ala-Pro-Ala-amc.
The structures of CypA complexes with the dipeptides Ala-Pro, Ser-Pro, His-Pro, 
and Gly-Pro have been determined by X-ray crystallography and refined at high 
resolution. 88 It was found that a single dipeptide molecule bound to the same CypA 
hydrophobic binding pocket as CsA, and all dipeptides bound to CypA with similar 
interactions and in the cis conformation. The proline side chains of the dipeptides sit 
in the CypA hydrophobic pocket, the C-terminus of the proline forms two hydrogen 
bonds with Arg55, and N-terminus of the dipeptide hydrogen bonds to the backbone 
carbonyl oxygen of Asnl02 and a water molecule. The side chains of the TV-terminus 
amino acids were found to interact weakly with CypA and did not significantly 
contribute to the binding of the dipeptides; this implies that cyclophilin has a broad 
catalytic specificity with respect to Xaa in Xaa-Pro.
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The crystal structures of succinyl-Ala-Pro-Ala-p-nitroanilide89 20 and the structurally 
similar succinyl-Ala-Ala-Pro-Phe-p-nitroanilide90 21 (Figure 1.12) bound to CypA 
have been resolved and show a similar binding pattern to peptide 19 and the 
dipeptides Ala-Pro, Ser-Pro, His-Pro, and Gly-Pro. Both peptides were revealed to be 
again binding in the cis conformation in the CypA active site, with proline residing in 
the hydrophobic pocket, and the peptide bonds between Arg55, Asnl02 and the 
peptide substrates were conserved.
Q 
O
0 " H 6
21
Figure 1.12: Structure of suc-APA-na 20 and suc-AAPF-na 21.
There have been other peptide substrates of varying lengths that have been 
characterised binding to CypA, and interestingly the conformation of CypA does not 
significantly alter upon peptide binding. 91 The hydrogen bonding recognition pattern 
is conserved among different linear peptide substrates, with Asnl02 and Arg55 
forming key binding interactions with the peptides. Comparison of the CypA-peptide 
structures with the CypA-CsA complex structure also revealed that the prolyl of the 
peptides and MeVal-11 of CsA interact with the same hydrophobic pocket in the 
CypA binding site. 91
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1.4.4 Non-peptide ligands
There are few reported examples of non-peptide synthetic ligands that have been 
designed to bind to CypA, with CsA derivatives and peptide ligands predominating. 
The majority of interest in synthetic CypA ligands has arisen from attempts to 
investigate cyclophilin PPIase mechanisms. Good examples of this type of ligand are 
the first de novo ground-state and transition-state analogue inhibitors reported by 
Wang et al. These ligands were inspired by the structure of cis bound Xaa-Pro 
peptide ligands and the "twisted amide" transition state proposed by the catalysis by 
distortion mechanism (Figure 1.13). 51
CO,Me
22 23
ground state ground state analogue transition state transition state analogue
Figure 1.13: Ground- and transition-state analogue structures. 51
The ground state analogues were based on a bicyclic lactam structure that had 
previously shown structural similarity to the dipeptide cis Gly-Pro upon binding to 
CypA. 92 A number of derivatives incorporating aryl groups adjacent to the lactam 
carbonyl were synthesised; it was reasoned that increasing the ligand lipophilicity 
would result in a tighter binding within the CypA hydrophobic pocket (Figure 1.14).
Inspection of the general bicyclic lactam structure 22 revealed that the lactam 
nitrogen atom corresponded to the peptide substrate proline nitrogen that undergoes 
sp2 to sp3 rehybridisation in the course of cis/trans isomerisation. With this in mind, 
the transition state analogue 23 was designed around a tertiary amine structure; it was 
reasoned that the amine would be capable of forming a hydrogen bond with Arg55 in 




22a: R 1 = 2-CH 2C 10 H 7 22d: R, = 2-CH 2C 10 H 7
R2 = tert-BuO RZ = Me
22b: R, = CH2C6H 5 22e: R, = CH 2C6 H 5
R2 = Br|O R2 = tert-BuO
22c: R, = 2-CH2C 10 H7 22f: R, = H
Figure 1.14: Ligands based on a ground state structure.
CO2Me
23a: R, = H
23b: R! = 2-CH 2C 10 H 7
Figure 1.15: Ligands based upon a transition-state structure.
The ground state analogues followed the expected trend upon screening against 
CypA with binding affinity increasing as the hydrophobic nature of the ligand 
increased. However, the affinity of ligand 23b was found to be four times weaker 
than that of the corresponding lactam 22a. This conflicted with the expected outcome 
that the proposed transition-state analogue would bind more strongly to the CypA 
active site than the ground-state analogue. It was postulated that the carbonyl group 
of the lactam may be important for the stability of the CypA-ligand complex, or that 
the position of the nitrogen lone pair in 23b might not coincide with peptide's proline 
nitrogen lone pair upon binding to CypA.
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1.5 Previous ligand design and lead discovery
The previous research on this project initially focussed upon de novo ligand design 
using in silico screening; this was followed by virtual lead compound selection and 
optimisation. Synthesis and modification of lead compounds was carried out by 
Elizabeth Moir; this would allow for the screening of ligands to ascertain efficacy 
against CypA. Reiteration of the process allowed any structure activity relationship 
(SAR) information to be used in the design of subsequent ligands (Figure 1.16).
























synthes/se (proprietary methodology) £r
'directed' library of compounds
Figure 1.16: Schematic representation of ligand design and synthesis.93
The computer docking program used for the in silico screening was LIDAEUS 
(Ligand Design at Edinburgh University) in collaboration with Professor Malcolm 
Walkinshaw at the Structural Biochemistry Group at the University of Edinburgh. 
The LIDAEUS screening procedure uses a database of small molecule three- 
dimensional structures by fitting ligand atoms of each test structure onto site points
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representing the physiochemical nature and structure of the protein active site.94 The 
strength of protein-ligand binding depends on the complimentary of shape and 
charge between the ligand and the protein receptor site, as well as entropic factors. 
The ligand affinity for the protein can be graded using scoring functions that account 
for van der Waals, hydrogen bonding and hydrophobic interactions. The Maybridge 
Fine Chemicals database can then be searched to highlight commercially available 
ligands.
The LIDAEUS programme was used to discover the first non-peptide ligands that 
were found to bind to CypA. 91 The novel ligands were found to bind to the CsA 
binding pocket on CypA upon X-ray analysis, and belong to three structural groups: 
piperidines (3-acetyl-l-methyl piperidine 24 and ethyl piperidine glyoxylate 25); 
DMSO and derivatives (dimethyl sulfoxide 26, tetramethylene sulfoxide 27 and 
cyclopentanone 28) and dimedone (5,5-dimethyl-l,3-cyclohexanedione 29) (Table 
1.3).
















Table 1.3: Novel CypA ligands discovered by LIDAEUS programme.
44
1.5.1 Initial lead compound - dimedone
It was decided at an early stage in the project to focus on dimedone (29) as the core 
pharmacophore for subsequent ligand synthesis. The versatile reactivity of the 1,3- 
diketone moiety is well known and well suited to chemical derivatisation. Dimedone 
was tested experimentally for binding to CypA and a Kd of 22 mM was determined 
using a fluorescence assay, as outlined in Chapter 4. For comparison, CsA has been 
reported to have a K^ of 36.8 nM using the same assay conditions. 95 It was possible 
to obtain a crystal structure of the CypA-dimedone complex by soaking a crystal of 
CypA into a solution of dimedone and then subjecting the crystal to X-ray
CO
diffraction. Inspection of the structure revealed that dimedone binds in the same 
hydrophobic binding pocket as Pro-containing peptides and CsA. Superimposing the 
dimedone binding co-ordinates onto the crystal structure of CypA-CsA reveals that 
the dimedone geminal dimethyl groups bind in the same defined hydrophobic cavity 
as the MeValll of CsA. Also, one of the carbonyl groups of dimedone is in 
hydrogen bonding distance of Arg55, known to be a key hydrogen bonding residue 
in the CypA binding pocket (Figure 1.16).
,55
Figure 1.16: Crystal structure of CypA-CsA (white) and -dimdone (green).
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1.5.2 Lead optimisation
Comparison of the CypA-dimedone complex with the CypA-CsA structure revealed 
that although dimedone was binding in the same active site, CsA was able to bind to 
several more of the CypA residues via hydrogen bonding and hydrophobic 
interactions. As CsA is an undecapeptide it was hypothesised that attachment of 
amino acids to the dimedone core would result in a greater binding affinity by 
mimicking some of these CypA-CsA interactions. A variety of ligands based upon an 
O-acylated dimedone enol ester structure were synthesised by Elizabeth Moir, and 
upon screening against CypA, ligand 30 (Figure 1.17) was found to have a 
dissociation constant of 22 uM, a ca. 1,000 fold improvement on dimedone.94
30 
Figure 1.17: Structure of ligand 30.
An X-ray crystal structure of CypA-30 was obtained (Figure 1.18), and upon 
inspection of the complex it appeared that attachment of the Cbz-valine moiety to the 
dimedone core had reproduced several of the CypA-CsA binding interactions (Figure 
1.19). The dimedone core was still bound in the CypA hydrophobic pocket, and also 
the valine dimethyl groups appeared to be mimicking the CypA-CsA Abu2 
hydrophobic interaction. The probable hydrogen bond between the dimedone 
carbonyl group and Arg55 was conserved, with additional potential hydrogen 
bonding interactions between ligand 30 and Asnl02 and Glnl 11 of CypA.
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Figure 1.19: Structure of ligand 30 and CsA residues MeLeulO-MeValll-MeBmtl-Abu2. 
Hydrophobic interactions with CypA are highlighted in green, H-bonds in red.
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2. Results and Discussion I - Ligand Design and Synthesis
2.1 O-acylated dimedone enol esters
The initial objective of the project was to re-synthesise several O-acylated dimedone 
enol-ester ligands. The aim was to improve yields, confirm purity and to further 
develop assay methods. A variety of synthetic routes to the O-acylated dimedone 
enol ester type compounds had been previously utilised, 1 but it was found that 












Scheme 2.1: Synthesis of ligand 30
To re-synthesise the lead compound 30, dimedone was acylated using the N-Cbz- 
amino acid fluorination strategy described by Carpino et al., (Scheme 2.1). 2 
Commercially available 7V-benzyloxycarbonyl-L-valine 31 was firstly reacted with 
cyanuric fluoride 32 in the presence of pyridine to form the intermediate acid 
fluoride 33. 3 Acid fluorides were used in preference to acid chlorides as they are 
known to be more stable to hydrolysis than the chlorides. 4 Dimedone was then
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reacted with the acid fluoride in the presence of TvyV'-diisopropylethylamine base to 
give the enol ester product 30. It was found that the overall yields were improved by 
proceeding directly to the dimedone addition step after work-up of the acid fluoride 
reaction mixture, rather than isolation and full characterisation of the acid fluoride 
itself. Infra-red spectroscopy was used as the principle analytical tool, acid fluorides 
having a distinctive peak at around vmax 1845 cm" 1 .
The same acid fluoride strategy was used to make two further enol ester ligands, 37 
and 38 (Scheme 2.2). Phenylalanine and 1-amino-l-cyclopentane carboxylic acid 
were each protected as their alloc derivative by dissolving the amino acid in 4M 
sodium hydroxide solution and adding aliquots of allyl chloroformate at 0°C. The TV- 
protected amino acids were then activated as the acid fluoride and coupled to 
















Scheme 2.2: Synthesis of jV-alloc-amino acid dimedone derivatives. (R = benzyl in structures 35, 37 
or cyclopentyl in structures 36, 38)
Whilst the acid fluoride chemistry shown in Schemes 2.1 and 2.2 resulted in the 
synthesis of the desired products in acceptable yields, there were shortcomings 
deriving from the use of cyanuric fluoride. Although the fluorination reaction gives
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the crude acid fluoride in good yield, the by-product of the reaction is cyanuric acid 
39 (Scheme 2.3),5 which forms a sticky white precipitate that is sparingly soluble in 
dichloromethane and requires several aqueous wash and filtration steps to fully 
remove. Although ice-water is used there is still a risk of hydrolysing the acid 
fluoride, thus reducing the yield of the next coupling step.
32
OH






Scheme 2.3: Mechanism of amino acid fluorination by cyanuric fluoride and pyridine.
To overcome the problems posed by the formation of cyanuric acid it was necessary 
to investigate the use of other fluorinating reagents. Sulfur tetrafluoride,6 
benzoyl fluoride,7 selenium tetrafluoride8 and tetramethylfluorformamidinium 
hexafluorophosphate (TFFH)9 have all been used to fluorinate carboxylic acids, 
however diemylaminosulfur trifluoride (DAST) seemed the most promising reagent. 
Previously used to convert alcohols to fluorides, 10 DAST has also been shown to 
successfully fluorinate Fmoc-a-amino acids. 11 Using the procedure described by 
Suresh et al., n 7V-benzyloxycarbonyl-L-valine was reacted with DAST at room 
temperature to give the acid fluoride that was then coupled to dimedone to give the 
enol-ester product 30 as previously. This method was found to work well, requiring 
only one wash with ice-water to give the pure acid fluoride in excellent 94 % yield, 
and unlike in the case of cyanuric fluoride, no base was necessary.
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2.2 Alkyl-dimedone derivatives
Previous work on the project by Lizzie Moir revealed that the lead ligand 30 and 
CsA occupy similar positioning within the CypA active site. In an attempt to further 
probe the active site, the crystal structure of the CypA-ligand complex was analysed 
to see if it was possible to extend out from the dimedone core in more than one 
direction. Examination of the crystal structure indicated space available within the 
CypA active site outwith the binding site of dimedone (represented in Figure 2.1 by 
the red arrow). Alkylation at the C-6 position of dimedone would thus allow for 
preservation of the main interactions of the ligand with the active site, whilst 
introducing the potential for additional binding interactions.
Figure 2.1: Crystal structure of CypA-CsA (white) and -30 (green). Dimedone ring numbering 
scheme for o-acylated compounds shown on the right.
A review of the literature revealed that Harwood and co-workers, had successfully 
alkylated 1,3-cyclohexanediones at the C-4 position using various alkyl halides. 13 
The method involved the generation of the dimedone dianionic species using lithium 
diisopropylamide (LDA) and hexamethylphosphoric triamide (HPMA) as a
complexing agent, followed by alkylation (Scheme 2.4). Alkylation at C-4 is 
accomplished through reaction of the kinetic enolate at low temperature, as opposed 












R = CH3 , CH2CH2 CH3 , CH(CH3 )2 , cyclohexyl, benzyl 
Scheme 2.4: Harwood et al., strategy for alkylation of dimedone at C-4. 13
However, despite the literature precedence this approach proved to be very 
problematic. The yields were low, due to the reaction giving a mixture of O and C- 
alkylated products, and after column chromatography often only the starting material 
dimedone (29) was isolated. 12 In an attempt to improve the reaction, the procedure 
was repeated using sodium iodide to effect in situ halogen exchange (Scheme 2.5). 
Hexamethylphosphoric triamide was also replaced by the less toxic Nfl'- 




3) H 3 O+ 
Scheme 2.5: Synthesis of 4-benzyl-5,5-dimethyl-cyclohexane-l,3-dione 40 from dimedone (29).
Although the addition of sodium iodide did increase the yield of the reaction, 
unreacted dimedone and a mixture of products were still present prior to 
chromatography. A key problem with the reaction was the poor solubility of
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dimedone in THF/DMPU at -78°C, thus resulting in incomplete enolate formation. 
To overcome the solubility problem it was decided to try the reaction using 3- 
methoxy-5,5-dimethyl-2-cyclohexene-l-one (41). This derivative of dimedone is a 
non-viscous oil at room temperature formed in quantitative yield by reacting 
dimedone with chlorotrimethylsilane in methanol (Scheme 2.6).
TMS-CI




Scheme 2.6: Synthesis of 3-methoxy-5,5-dimethyl-cyclohexe-2-enone 41.
Enone 41 was reacted with various alkyl bromides using similar methodology as 
Harwood and co-workers. This approach proved to be a significant improvement 





























Scheme 2.7: Alkylation of 3-methoxy-5,5-dimethyl-cyclohexe-2-enone (41).
The alkyl bromides used were selected to introduce alkyl groups of differing sizes, 
from a small methyl group to the sterically more demanding cinnamyl moiety. This 
study would investigate the size limit of groups at this position tolerated by the active
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site of CypA. The tert-butyl ester moiety was chosen not only due to its steric bulk, 
but also as a possible site for future derivatisation.
Additional advantages of alkylating enone 41 was that only one equivalent of lithium 
diisopropylamide was needed to form the required enolate, and it was found that high 
yields could be attained without the need for sodium iodide. N,N'- 
dimethylpropyleneurea was added purely as a co-solvent, its role as a chelating agent 
is needed only when generating dianionic species. Harwood et al., found that 
omission of chelating agent resulted in the absence of dianion formation, 13 and 
kinetic enolate anions of 3-alkoxy-2-cyclohexen-l-ones have also been generated 
without the use of chelating agents. 14
The reactions outlined above gave alkylation exclusively at the desired C-6 position 
of enone 41, owing to lithium diisopropylamide being a strong enough base to 
irreversibly generate the kinetic enolate by deprotonating the a'-proton (C-6) of the 
a, p-unsaturated ketone. It is known that the abstraction of the y-proton (C-4) from an 
a, (3-unsaturated ketone results in a dienolate anion that is more stable than its cross- 
conjugated isomer generated by abstraction of the a'-proton (Figure 2.2). 15 Thus 
under conditions where equilibration can take place the thermodynamically 
controlled a-alkyl-p, y-unsaturated ketone product dominates.
Kinetic enolate: cross-conjugated isomer 
generated by irreversible abstraction of
Thermodynamic enolate: conjugated 
unsaturation leads to greater stability and 
Mecr ^ lower reactivity.
Figure 2.2: Kinetic and thermodynamic anions of 3-methoxy-5,5-dimethyl-cyclohexe-2-enone 41.
The regioselective alkylation of ligands 23-46 was confirmed by 13 C NMR 
spectroscopy, the distinctive peak of the C-4 CH2 at 5C 50 ppm being absent from the
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13C spectra of the ligands. This was conclusively proven by x-ray crystallography of 
ligand 44 (Figure 2.3).
CUDB)
H3C-0 CH6A) CH4BI
Figure 23: X-ray crystal structure of ligand 44.
The benzylated analogue of lead compound 30 was synthesised by first reacting 
ligand 44 with hydrochloric acid in THF to give the diketone in excellent 91 % yield. 
The DAST acid fluoride strategy used previously was employed to make enol ester 
type ligand 47 (Scheme 2.8).
47 70 %
Scheme 2.8: Synthetic route to ligand 47.
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One of the key advantages of this strategy was the total regioselectivity of the 
chemistry employed. It is interesting to note that none of the alternative enol ester 
regioisomer 48 was seen during analysis, this being attributed to energetically 
unfavourable steric crowding of the benzyl and enol ester moieties (Figure 2.4). 
However, the limitation is that the alkyl dimedone derivatives were generated as a 
mixture of enantiomers, thus ligand 47 was synthesised as a 1:1 diastereomeric 
mixture, as confirmed by NMR analysis.
48 
Figure 2.4: Sterically hindered regioisomer 48.
2.3 Amide-linked derivatives
Compounds based around the lead structure ligand 30 do not make particularly 
suitable drug candidates due to the presence of the enol ester group. This linkage can 
be readily hydrolysed to reform the amino acid and dimedone starting materials. To 
overcome this problem another focus of the project was to make complementary 
ligands based upon the replacement of the ester linkage with the more stable amide 
group (Scheme 2.9, 49). Interestingly this modification would also reverse the 
potential hydrogen bonding interaction at this point of the molecule from acceptor to 
donor. Retro synthetic analysis of 49 suggested that analogues could be synthesised 
by coupling activated amino acids to enaminone 50 (Scheme 2.9).
0
H f|J I I M 
, .N. >V >^x A.. ————————^> _i^N. , R'
R2 ' 
49
Scheme 2.9: Retrosynthetic analysis of amide-linked ligand 49.
R2
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Enaminone 50 was readily synthesised in good yield by reacting dimedone with 
ammonium acetate (Scheme 2.10). 16 The reaction is carried out by refluxing the 
components in the presence of acetic acid in toluene solution with azeotropic 
removal of water using a Dean-Stark apparatus.
NH 4OAc
Toluene 
29 50 94 %
Scheme 2.10: Synthesis of 3-amino-5,5-dimethyl-2-cyclohexen-l-one 50.
It was envisioned that the coupling enaminone 50 to jV-protected amino acids could 
be carried out using standard peptide coupling reagents and protocols. In a typical 
coupling reaction, the carboxylic acid moiety of an TV-protected amino acid is firstly 
activated by a suitable peptide coupling reagent, and then reacted with the amine 
moiety of a C-protected amino acid (Scheme 2.11).
NH Q couolina reaaent NH ,, OO







O R3 "'' OR
Scheme 2.11: Generalised peptide coupling reaction.
The most commonly used coupling reagents are the carbodiimides, widely used 
because they show good activity and are reasonably inexpensive. Of these, 1,3- 
dicyclohexylcarbodiimide (DCC) (51) was the first reported and still the most 
frequently used. 17 Problems associated with carbodiimide couplings include 
unwanted side reactions such as jV-acylurea formation and racemisation via 
formation of an oxazalone intermediate. To alleviate these problems coupling 
additives were developed, of which the most common is 1-hydroxybenzotriazole 
(HOBt) (52). 18 HOBt reduces racemisation by rapidly forming a
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Scheme 2.12: General mechanism of a DCC/HOBt peptide coupling reaction.
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Typically, DCC is added to an equimolar solution of carboxylic acid, amine and 
HOBt in dichloromethane or dimethylformamide, the by-product being 
dicyclohexylurea (DCU) (53) which precipitates out of solution. However, 
sometimes a quantity of DCU remains in solution, making purification of the product 
more difficult. Water-soluble derivatives such as l-(3-dimethylaminopropyl)-3- 
ethylcarbodiimide (EDCI) (54) (Figure 2.5) were developed to obviate this 
problem, 19 the urea produced being water soluble and easily removed by extraction. 
Another reagent, 1,3-diisopropylcarbodiimide (DIG) (55), has a urea by-product that 
is soluble in organic solvents. This is used when the insolubility of DCU could cause 










Figure 2.5: Structures of EDCI 54 and DIG 55.
Another type of commonly used coupling reagents are the uronium salts based upon 
a benzotriazole structure. In general these offer complementary reactivity to the 
carbodiimides, often being employed to successfully couple peptides when the use of 
carbodiimides had been ineffective. The first to be introduced was (9-(benzotriazol- 
l-yl)-jV,MA^',A^'-tetramethyluronium hexafluorophosphate (HBTU) (56),20 the active 
structure of which was found to be based upon the ./V-guanidium rather than the O- 
uronium salt. 21 The mechanism of peptide coupling is similar to that of 
carbodiimides, the carboxylate anion attacking the guanidium/uronium carbon, with 
the release of benzotriazolyloxy anion (BtO~). The BtO" then attacks the 
acyloxyuronium intermediate via two pathways to afford the corresponding 
benzotriazolyl activated ester and a small amount of 7V3 -acylbenzotriazole 1-oxide 
intermediate. The benzotriazolyl ester intermediate can spontaneously rearrange into 
the corresponding jV-acylated isomer. The amine component of the reaction mixture 









O R3 + baseH BtO
Scheme 2.13: General mechanism of a HBTU peptide coupling reaction. 22
Normally these reagents are used with an equimolar amount of the acid and amine, in 
the presence of a non-nucleophilic base such as diisopropylethylamine. The 
advantage of using this type of reagent is that the racemisation-suppressing HOBt is 
formed in situ, negating the need for its separate addition. Structural modification of 
HBTU has led to many variants being produced and used in peptide synthesis. 
Common reagents include TBTU (57) where the hexafluorophosphate counter ion is 
replaced by tetrafluoroborate, and HATU (58) where the hydroxybenzotriazole 
moiety has been replaced by hydroxyazotriazole (Figure 2.6). 23
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x rr sV\, PF;N ^J-^.^N'
o-
N(CH3 )2 N(CH3 ) 2
X = PF6 HBTU 56 HATU 58 
X = BF4 TBTU 57
Figure 2.6: Common uronium based coupling reagents (active species in brackets).
The coupling of jV-benzyloxycarbonyl-L-valine and enaminone 50 to make the amide 
linked analogue of lead compound 30 was attempted using the standard peptide 
coupling conditions outlined above. However, the synthesis of this ligand proved to 
be more problematic than first envisaged. The reaction was tried using the 
carbodiimide reagents DCC and EDCI in the presence of HOBt, and also the 
uronium reagent TBTU. Each method failed to give the coupled product in detectable 
yield, TLC analysis and mass spectrometry indicating starting material only. This 
was ascribed to enaminones such as 50 having decreased nitrogen nucleophilicity 
compared to the amines that are usually used in peptide couplings. Enaminones have 
only ambient nitrogen nucleophilicity due to the interaction between the amino group 
and the electron-withdrawing carbonyl group via the vinyl group, the other common 
term for this type of functionality being vinylogous amide. This "push-pull" type 
resonance results in decreased jV-nucleophilicity (Figure 2.7). 24
O O"
H 2 N ^ R
Figure 2.7: Enaminone resonance resulting in lower ?V-nucleophilicity.
Enaminone systems can undergo a range of chemical reactions as there are three 
nucleophilic sites (a, c and e, Figure 2.8) and two electrophilic sites (b and d). While
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this makes the moiety synthetically useful, there is the potential for alternate 
reactions to occur leading to lower yields and impurity formation.
H 2N
Figure 2.8: Possible enaminone reaction centres.
In an attempt to investigate the regioselectivity of reaction of enaminones, Kascheres 
et al., reacted benzyldiazoketone with enaminone 50 and acyclic enaminone 59 
(Scheme 2.14). 25 It was found that reaction with 59 formed the ot-acyl- 
enaminoketone 60 principally, a product of reaction at a-C of the enaminone. 
However, the enaminone 50 reacted via nucleophilic attack of the amino group to 





Scheme 2.14: Literature reaction of benzyldiazoketone with enaminones 50 and 59. 25
The alternate regioselectivity of the reactions can be rationalised by considering the 
geometric form of the two enaminones. Acyclic enaminones such as 59 exist 
predominantly in the Z,s-Z form in apolar solvents allowing for intramolecular 
hydrogen bonding (Figure 2.9). However, cyclic enaminones such as 50 are fixed in 
a E,s-E geometric form. Intramolecular hydrogen bonding is not possible, decreasing
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conjugation compared to acyclic Z,s-Z enaminones, which would result in increased 
electron density on nitrogen compared to the Z,s-Z systems, and thus favour reaction 
at this site.26
Z,s-Z E,s-E 
Figure 2.9: The effect of geometric form on intramolecular hydrogen bonding.
Although not as nucleophilic as an amine functional group, it was encouraging to 
have the precedent of enaminone 50 reacting via the nitrogen. A review of the 
literature revealed that compounds based upon an amide-linked structure had been 





R = Cl, CH 3 , OCH 3 , CN
Scheme 2.15: Literature reaction of enaminone 50 with acid chlorides. 27
Scott and co-workers reacted enaminone 50 with various p-substituted benzoyl 
chlorides in the presence of triethylamine as an acid scavenger under reflux 
conditions to give amide-linked enaminones.27 Although of interest, this method was 
deemed not to be applicable to the synthesis of amide-linked ligands based upon an 
amino acid structure due to the problems of oxazolone formation with the use of 
protected acid chlorides during peptide synthesis. Acid fluorides are known to be 
more resistant to this conversion, 8 therefore it was decided to use the same acid
68
fluoride strategy previously employed. Amide-linked analogues of the enol ester 
compounds 30, 31 and 32 were successfully synthesised by using DAST to generate 
acid fluorides of the relevant JV-protected amino acid, followed by reaction with 

















Scheme 2.16: Synthesis of amide-linked ligands via acid-fluorides.
The difference in the isolated yield of the ligands shown in Scheme 2.16 may be due 
to the nature of the amino acids used. Valine and 1-amino-l-cyclopentane carboxylic 
acid are sterically hindered compared to phenylalanine, this being reflected in the 
lower yields. It is postulated that ligand 64 was synthesised in the lowest yield due to 
the fact it is based on an a,a-dialkyl-amino acid structure, the structurally similar a- 
aminoisobutyric acid has long been recognised as a difficult amino acid to use in
7Qpeptide synthesis due to steric hindrance.
69
In an attempt to increase the yield of the coupling step, it was decided to substitute 
enaminone 50 with the methylamino derivative 65 (Figure 2.10). It was envisioned 
that the use of a secondary enaminone would increase electron density on nitrogen 
due to the positive inductive effect of the methyl group, although the extra methyl 
group would increase the steric crowding on the nitrogen.
-o
65 
Figure 2.10: 3-Methylamino-5,5-dimethyl-cyclohex-2-enone 65.
Enaminone 65 was readily synthesised by reacting dimedone with methylamine 
using the same re fluxing conditions as previously used (Scheme 2.10). However, as 
with enaminone 50, all attempts to react enaminone 65 with TV-protected amino acids 
using standard peptide coupling reagents resulted in the recovery of starting material 
only. When the same acid fluoride approach as Scheme 2.16 was used it was found 
that enaminone 65 was even less reactive than enaminone 50, only the TV-alloc- 
phenylalanine derivative ligand 66 being successfully isolated, albeit in low yield 
(Scheme 2.17). The extra steric hindrance of the methyl group appeared to have 
outweighed any positive electronic inductive effect, this being highlighted by only 





Scheme 2.17: Synthesis of ligand 66.
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An aim of this project was to develop synthetic methodologies that would allow the 
synthesis of compounds in a library format using combinatorial chemistry 
techniques. Whilst the acid fluoride strategy outlined above provided a route into the 
amide linked compounds, the chemistry employed was not ideal for parallel 
synthesis. The intermediate acid fluoride had to be pre-formed, resulting in an 
additional reaction step, and the ice-water wash involved risked hydrolysis back to 
the amino acid starting material with subsequent loss of overall product yield. A 
route involving a one pot, in situ amino acid activation strategy would have obvious 
synthetic advantages. A class of peptide coupling reagents that remained untried 
were the phosphonium reagents. An early example was BOP (67) (Figure 2.10) 
introduced by Castro and co-workers. 3 This was found to be an excellent coupling 
reagent, and has been widely used in peptide chemistry, also involving the synthesis 
of sterically hindered and longer chain peptides. 31
°~P(NMe2 ) 3 
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Figure 2.10: l-Benzotriazolyoxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) (67).
However, the disadvantage of BOP is that its use involves the generation of 
carcinogenic hexamethylphosphoric triamide (HMPA). In the search for a non-toxic 
derivative Castro and co-workers replaced the methyl groups on the phosphorus with 
pyrrolidino groups. The resulting reagent, nicknamed PyBOP (68) (Figure 2.11), 
yielded coupling rates comparable, or better than, those observed with BOP. 32
68 
Figure 2.11: l-Benzotriazolyoxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) (68).
71
The synthesis of ligand 62 was attempted using PyBOP in order to investigate the 
suitability of phosphonium reagents for synthesising amide-linked derivatives. A 
solution of TV-benzyloxycarbonyl-L-valine and enaminone 50 was reacted with 
PyBOP in the presence of diisopropylethylamine at room temperature for two hours 
(Scheme 2.18). After work-up and purification via column chromatography, ligand 
62 was isolated in modest yield. The result was encouraging as for the first time in 
situ amino acid activation had resulted in the synthesis of a desired amide-linked 








DCM 62 47 %
Scheme 2.18: Synthesis of ligand 62 using PyBOP.
Whilst being an excellent general peptide coupling reagent, Coste et al., found 
PyBOP to have low efficacy in coupling hindered or TV-methylated amino acids. 
However, the related halogenated reagent PyBroP (69) (Figure 2.12) was found to
give excellent yields. 33,34
3 PF«
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Figure 2.12: l-Bromotris(pyrrolidino)phosphonium hexafluorophosphate (PyBroP).
Coste et al., also showed that dimethylaminopyridine (DMAP) could be used to 
catalyse PyBroP couplings of highly hindered amino acids. The synthesis of Boc- 
Aib-Aib-OMe was achieved in 61 % yield with PyBroP/DMAP, this coupling having 
failed with PyBOP. Interestingly for the possible synthesis of the enaminone amide- 
linked compounds, it was also shown that PyBroP/DMAP could couple Cbz-Aib 70 








2hr 72 65 %
35Scheme 2.19: Literature coupling of Cbz-Aib 70 with benzocaine 71 using PyBroP/DMAP.
Coste and co-workers proposed three mechanistic pathways involved in phoshonium 
reagent peptide couplings (Scheme 2.20).35 In a general case with BOP or PyBOP an 
acyloxyphosphonium salt is first formed, which is aminolysed to give the C- 
protected amino acid (Scheme 2.20, Pathway a). If coupling involved two hindered 
Aib residues or a weakly nucleophilic amine then the oxyben/otriazole anion firstly 
reacts with acyloxyphosphonium salt to produce an oxybenzotriazole ester, this then 
reacts slowly with the amine to give the product (Pathway b). In couplings involving 
PyBroP a mechanistic route via the symmetric anhydride was proposed (Pathway c). 
The PyBroP reactions were found to be accelerated by the addition of DMAP, a 























Scheme 2.20: Proposed mechanistic routes of phosponium reagent mediated peptide couplings. 35
The mechanistic proposals in Scheme 2.20 might explain the modest yield of ligand 
62 when the coupling was attempted with PyBOP. As enaminones have only ambient 
nucleophilicity a reaction route similar to pathway b could be envisioned. With the 
above mechanisms in mind, the coupling of 7V-benzyloxycarbonyl-L-valine 31 and 
enaminone 50 was attempted using PyBroP/DMAP (Scheme 2.21). After some 
refinement, it was found that the reaction proceeded in excellent yield when one 
equivalent of enaminone 50 was reacted with one and a half equivalents of Cbz- 





DCM 62 92 %
Scheme 2.21: Synthesis of ligand 62 using PyBroP/DMAP.
The result shown in Scheme 2.21 represented a significant synthetic breakthrough as 
for the first time an amide-linked ligand was synthesised in high yield. The 
additional benefit was the use of a one pot, in situ amino acid activation strategy that 
would be readily amenable to future ligand synthesis.
2.4 C-6 alkylated amide-linked derivatives
It was deemed that ligands based upon an alkylated enaminone 50 core were of 
interest as they would combine the greater stability of the amide group with the 
potential to probe the active site in more than one direction. A combination of 
strategies that were found to be successful previously were employed in the synthesis 
of such ligands. The alkylated enone derivatives 42 - 46 were first hydrolysed to the 
1,3-diketone, followed by reaction with ammonium acetate with azeotropic removal 






































Scheme 2.22: Synthesis of ligands 77-81.
Ligands 77-81 were purified via a simple recrystallisation from ethyl acetate, and 
the reactions were found to be completely regioselective; comparison of the ' C 
NMR data with that of ligands 42 - 46 showed that the ligands were structurally 
similar. Regioselectivity was conclusively proven by X-ray crystallography of ligand 
78 (Figure 2.13).
Figure 2.13: X-ray crystal structure of ligand 78.
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It is interesting that none of the other regioisomers (Figure 2.14) were synthesised 
via the enamination reaction. It is postulated that the alkyl group sterically shields the 
adjacent carbonyl group from the nucleophilic attack of ammonia, thus directing the 
substitution to the opposite side of the dimedone ring.
Figure 2.14: Regioisomers not synthesised via Scheme 2.22.
In order to see if alkylated amide-linked compounds could be synthesised using the 
previous PyBroP/DMAP strategy, two trial reactions were attempted. The coupling 
of 4-amino-6-allyl-5,5-dimethylcyclohex-2-enone (78) and 4-amino-6-((£)-3-phenyl- 
allyl)-5,5-dimethylcyclohex-2-enone (80) with jV-benzyloxycarbonyl-L-valine (31) 
using PyBroP/DMAP was found to proceed satisfactorily, the products being 





Scheme 2.23: Synthesis of ligands 82 and 83 using PyBroP/DMAP.
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The coupling of 3-amino-6-benzyl-5,5-dimethylcyclohex-2-enone (79) with TV- 
benzyloxycarbonyl-L-valine (31) was also attempted using the previously used acid 
fluoride chemistry as a comparison (Scheme 2.24). As expected, the yield of the 




Scheme 2.24: Synthesis of ligands 84 using DAST.
The aim of having a synthetic route robust enough to allow the parallel synthesis of 
ligands was achieved by using the reagents PyBroP and DMAP in combination. With 
amenable chemistry in place, a library of ligands based upon a valine template was 
synthesised. The five alkylated enaminone building blocks, 77-81, prepared in 
Scheme 2.22 and enaminone 50 were reacted with valines with varying TV-protection 
(Scheme 2.25). The library was designed to investigate the effect of different TV- 
protecting groups upon ligand binding, whilst exploring the active site steric limits 












































Scheme 2.25: Parallel synthesis of alkylated amide-linked ligands.
The parallel synthesis carried out in Scheme 2.25 was accomplished using the 
Bohdan MiniBlock™ apparatus. 36 This consists of a multi-well reaction vessel, the 
MiniBlock, and an accompanying Shaker Station (Figure.2.15). The MiniBlock™ is 
a compact parallel synthesiser that is compatible with solution or solid phase 
synthesis. Chemistry is carried out in individual vessels that at a turn of a key can 
drain through a frit into a standard 48 well microtitre plate. Agitation of the reaction 
vessels is accomplished via vortex mixing on the shaker station.
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Figure 2.15: Bohdan MiniBlock™ reaction vessel and shaker station.
The ligands shown in Scheme 2.25 were synthesised by firstly making up stock 
solutions of the starting materials and coupling reagents in dichloromethane. Equal 
aliquots of the PyBroP and DMAP solutions were then manually dispensed into each 
of the 18 MiniBlock vessels that were used in the array. Aliquots of the valine 
derivatives were then manually dispensed into a vertical line of 6 reaction vessels, 
followed by separate addition of the enaminone 50 and derivatives 77-81 into the 
horizontal line of 3 tubes. After overnight agitation, purification was carried out by 
draining the MiniBlock into a 48 well plate followed by manual transfer of the DCM 
solution onto pre-packed silica columns. Column chromatography was then carried 
out using the Biotage Quad 3™ system (Figure 2.16). This is an automated flash 
chromatography system that runs up to 12 pre-packed silica cartridges in parallel. 
Fractions are collected by an automated fraction collector, allowing unattended 
operation.
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Figure 2.16: Biotage Quad 3 automated flash column chromatography apparatus.
The parallel synthesis of the array was a success, each ligand being isolated in good 
yield. However, the yields were not as high as those seen in the previous individual 
PyBroP/DMAP couplings. This was largely as a result of utilising the Quad 3 system 
for purification. Although the apparatus is an excellent way of accomplishing 
moderately high-throughput column chromatography, it uses a common solvent 
stock for the elutions. Thus solvent gradients cannot be individually tailored towards 
the optimum purification of each compound. However, this was not an issue for the 
purposes of this project as the amount of ligand synthesised was sufficient for 
biological assay applications.
2.5 Alternate dimedone-based ligands
All the ligands that contain an amino acid moiety synthesised so far have involved 
the coupling of an TV-protected amino acid with dimedone or an enaminone. Ligands 
based upon the attachment of amino acids to the dimedone core via the TV-terminus 
would make a complementary family of ligands to the type previously described 
(Scheme 2.26). To investigate ligands of this type, O-protected phenylalanine, valine 
and tyrosine were reacted with dimedone using the same Dean-Stark conditions 




















Scheme 2.26: Condensation of O-protected amino acids with dimedone under Dean-Stark conditions.
The condensation of the Oprotected amino acids with dimedone was found to 
proceed in good yield, the previous Dean-Stark conditions providing a robust general 
route into such enaminone-type ligands. It is worth noting though that these ligands 
lack the amide carbonyl group present in the previous amide-linked ligands, which 
would possibly have a detrimental effect on the binding affinity to CypA due to the 
loss of a potential hydrogen bonding acceptor site.
An alternate point for derivatisation of the dimedone core structure was provided 
through the modification of ligand 46. The tert-buty\ ester group was hydrolysed to 
the carboxylic acid in good yield using trifluoroacetic acid and triethylsilane as a 
cation scavenger. 37 The resulting acid moiety gave a versatile handle onto which the 
peptide couplings of amines and amino acids could be carried out (Scheme 2.27).
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Scheme 2.27: Hydrolysis of ligand 46 and subsequent peptide couplings.
Ligand 102 was coupled to I-valine methyl ester, (5>a methylbenzylamine and 
2-methylpiperidine in good yield using PyBoP as the coupling reagent. The amines 
were chosen to introduce amino acid and sterically demanding primary and 
secondary amine moieties.
2.6 Ligand Optimisation 
2.6.1 Lead compound selection
A key aim of this project was to establish electrospray ionisation mass spectrometry 
(ESI-MS) as a primary screening tool through the analysis of CypA-ligand 
complexes. Any ligands found to bind to CypA could then be fast-tracked into 
biological testing and used as a base for subsequent ligand design. The results are 
reported in Chapter 3, and initial findings from the ESI-MS screen highlighted C-6 
allyl ligand 82 as an early lead compound. Interestingly, it was found that the 
structurally similar C-6 cinammyl ligand 83 did not give a protein-ligand complex 
under ESI-MS conditions. In an attempt to rationalise this finding the ligand
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structures were modelled into the CypA active site using the modelling package 
Insight II®.38 The X-ray crystal structure of ligand 30 bound to CypA was used as a 
template over which the structures of ligands 82 and 83 were manually docked 
(Figure 2.17). The 5-diastereomer of each ligand was used for the modelling as the 
C-6 alkyl chain of the J?-diastereomers was found to sterically clash with the CypA 
active site when overlaid upon the ligand 30 scaffold.
Figure 2.17: Manual docking of ligands 82 and 83 using Insight II®.
Upon inspection of the modelling data for ligand 83 it appears that the cinnamyl 
moiety is too large to fit into the defined hydrophobic cavity occupied by the 
dimedone core, sterically clashing with the His 126 and AlalOl residues. The allyl
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group of ligand 82 is sterically less demanding, and is thus tolerated at that position 
in the active site. The modelling suggests that the binding of ligand 82 to CypA 
preserves the same interactions as ligand 30; the dimedone dimethyl moiety resides 
in the hydrophobic binding pocket, the enaminone carbonyl can hydrogen bond to 
Arg55 and the amide NH can hydrogen bond to Gln63. Ligand 82 may also benefit 
from a hydrogen bonding interaction between the enaminone NH and Asp 102, and 
the allyl group may have a positive effect on binding affinity through a possible 
hydrophobic interaction with Leul22.
While the images shown in Figure 2.17 helped to rationalise the initial ligand binding 
data, their limitations should be acknowledged. The modelling of ligands 82 and 83 
was based upon the crystal data for ligand 30, this structure having an enol ester link 
between the dimedone and Cbz-valine moieties. Ligands 82 and 83 have the alternate 
amide link, resulting in the amide and the enaminone moieties being in the same 
geometrical plane through resonance. Thus the amide-linked ligands would be 
expected to be structurally more rigid than their enol ester analogues and potentially 
have a different binding mode in the CypA active site. However, in the absence of X- 
ray crystallographic data showing ligand 82 binding to CypA the molecular 
modelling was used as the primary tool to visualise ligand binding.
It was decided to use the new lead compound ligand 82 as a template for subsequent 
ligand synthesis as the initial mass spectrometry screening hit was supported by the 
modelling outlined above. Subsequent ligands could be structurally varied at three 




X - Cbz or functionalised aryl groups 
Y - valine or different amino acids 
Z - allyl or alternate hydrophilic groups
Figure 2.18: Potential sites of derivatisation using a template based upon ligand 82.
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group of ligand 82 is sterically less demanding, and is thus tolerated at that position 
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in the hydrophobic binding pocket, the enaminone carbonyl can hydrogen bond to 
Arg55 and the amide NH can hydrogen bond to Gln63. Ligand 82 may also benefit 
from a hydrogen bonding interaction between the enaminone NH and Asp 102, and 
the allyl group may have a positive effect on binding affinity through a possible 
hydrophobic interaction with Leul22.
While the images shown in Figure 2.17 helped to rationalise the initial ligand binding 
data, their limitations should be acknowledged. The modelling of ligands 82 and 83 
was based upon the crystal data for ligand 30, this structure having an enol ester link 
between the dimedone and Cbz-valine moieties. Ligands 82 and 83 have the alternate 
amide link, resulting in the amide and the enaminone moieties being in the same 
geometrical plane through resonance. Thus the amide-linked ligands would be 
expected to be structurally more rigid than their enol ester analogues and potentially 
have a different binding mode in the CypA active site. However, in the absence of X- 
ray crystallographic data showing ligand 82 binding to CypA the molecular 
modelling was used as the primary tool to visualise ligand binding.
It was decided to use the new lead compound ligand 82 as a template for subsequent 
ligand synthesis as the initial mass spectrometry screening hit was supported by the 
modelling outlined above. Subsequent ligands could be structurally varied at three 
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Z - allyl or alternate hydrophilic groups
Figure 2.18: Potential sites of derivatisation using a template based upon ligand 82.
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Preservation of the backbone structure should enable the key interactions between 
ligand and the CypA binding site to be conserved, as shown in red in Figure 2.18. In 
order to assess the effect of derivatisation at a particular site of the ligand it was 
decided to modify the ligand structure one site at a time, as outlined below.
2.6.2 Alternate amino acids
Ligands based upon substitution of the valine moiety with alternate amino-acids were 
prepared in good yield by utilising the same PyBroP/DMAP chemistry successfully 



























Scheme 2.28: Synthesis of alternate amino-acid ligands
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The Cbz-protected amino acids D-valine, leucine, isoleucine and Cbz-(boc)-lysine 
were chosen in order to introduce a slight structural change to the ligand 82 core 
structure. Cbz-proline was chosen to provide a second ring to the ligand structure to 
investigate the effect upon binding of this extra structural rigidity. In each case the 
Cbz-group and the allyl moiety were retained to focus just on the effect of changing 
the amino acid.
2.6.3 Hydrophilic ligands
An alternate synthetic strategy focussed on the retention of the Cbz-valine moiety 
and replacement of the C-6 allyl group. The majority of the previously synthesised 
ligands had hydrophobic groups at this position, replacement with hydrophilic 
moieties would afford an interesting subset of contrasting ligands. The tert-butyl 
ester functionalised ligand 96 provided a route into one such hydrophilic ligand. 
Hydrolysis of the tert-butyl ester moiety was achieved in good yield using 
trifluoroacetic acid and triethylsilane to give the free carboxylic acid containing 
ligand 111 (Scheme 2.29).
0 OH
96 111 83% 
Scheme 2.29: Removal of the tert-butyl ester group to give ligand 111.
Ligand 82 was also used as the starting material for the synthesis of two hydrophilic 
ligands (Scheme 2.30). The allyl group was firstly converted to the c«-l,2-diol via 
an osmium-catalysed dihydroxylation using the procedure of Kolb et a/. 39 Here A/­ 
methyl morpholine TV-oxide was used as an oxidant to regenerate the active osmium 
(VIII) species required for the dihydroxylation. A sample of the resulting ligand 112 
was then treated with a combination of sodium periodate and wet silica gel resulting 
in the cleavage of the 1,2-diol moiety to give the aldehyde ligand 113. 40
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Scheme 2.30: Synthesis of hydrophilic ligands 112 and 113.
The hydrophilic ligands shown above should retain the same hydrogen bonding 
interactions with the CypA binding site as ligand 82 and could potentially benefit 
from an additional hydrogen bond with the imidazole ring of His 126.
2.6.4 Cbz group replacement
Ligands designed to retain the valine and C-6 allyl scaffold, whilst introducing 
functionality at the amino acid ,/V-terminus, were synthesised using ligand 82 as the 
starting point. The Cbz carbamate group was firstly cleaved using 
iodotrimethylsilane to give the deprotected amine containing ligand 114 (Scheme 
2.31). The first step of this reaction is proposed to be a fast complexation of the 
trimethylsilyl group with the carbamate oxygen, followed by cleavage of the benzyl 
group via attack of the iodide to give benzyl iodide. Treatment with acidic methanol 
cleaves the oxygen-silicon bond of the silyl carbamate formed to give a carbamic 
acid, which spontaneously decarboxylates to give the free amine. 41 With a free amino 
group in place it was decided to introduce differing aryl groups at this position via 
the reductive amination of various aldehydes. Reductive amination reactions are 
thought to proceed through an imine or iminium intermediate, followed by an in situ 
reduction to an amine of higher order by a reducing agent. 42 A variety of
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borohydride-based reducing agents have been used for this transformation, with 
sodium cyanoborohydride widely used. Under neutral conditions in methanol there is 
negligible reduction of aldehydes using this reagent, thus it is possible to selectively 
reduce the intermediate imine.43 It was decided to use a commercially available 
polymer-supported cyanoborohydride (PS-CBH) reagent to synthesise a small library 
of ligands from the starting point of ligand 114 (Scheme 2.31). The use of resin- 
bound cyanoborohydride is advantageous as the polymer retains the toxic residues,44 
the beads then separated from the reaction mixture through filtration. The reactions 
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Scheme 2.31: Replacement of the Cbz group via reductive amination reactions.
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The amine starting material ligand 114 was dissolved in methanol and equal aliquots 
were manually dispensed into nine reaction vessels of the MiniBlock. The aldehydes 
were then individually added to each reaction vessel, along with 4A molecular 
sieves, added to promote dehydration and imine formation. A slight excess of 114 
was used to restrict tertiary amine formation, the aldehyde being the limiting reagent. 
The MiniBlock was agitated for an hour, then PS-CBH was added and the MiniBlock 
returned to the shaker station overnight. Purification was attempted by firstly adding 
4-benzyloxybenzaldehyde polystyrene resin to the reaction vessels and agitating 
overnight. This electrophilic scavenger resin has been shown to selectively sequester 
primary amines in the presence of secondary amines,45 and was intended to remove 
the excess primary amine starting material 114. In principle, filtration through the 
MiniBlock reaction vessel frits would then allow the collection of pure ligand 
solutions in a microtitre plate. However, analysis of the filtrate solutions by thin layer 
chromatography indicated that the ligand solutions contained impurities, 
necessitating additional purification. This was achieved by using the Biotage Parallex 
Flex preparative HPLC system. 46 The apparatus consists of an automated sample 
injection module, up to four reverse phase HPLC columns, and an automated UV- 
triggered fraction collection module. The relevant fractions were collected into deep- 
well sample plates; this was followed by evaporation of solvent to afford ligands 
115-123. A limitation of using the Flex system is that generally the isolated yields 
are lower than might be expected, as found in Scheme 2.31. Product yields are 
dependent on the threshold set for the UV-triggered collection of fractions; a lower 
threshold results in more product being collected, but increases the potential for 
contamination from any neighbouring impurity peaks.
2.6.5 Fluorescently labelled ligands
At this point in the project it became desirable to synthesise a ligand containing a 
fluorescent marker that could be used in in vivo screening studies. Amine 114 
provided a useful scaffold for this purpose as there are many commercially available 
amine-reactive fluorescent probes that are widely used to modify proteins, peptides, 
ligands and other biomolecules. One of the most commonly used amine-reactive
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dyes is fluorescein isothiocyanate (FITC) which forms a stable thiourea upon 
reactions with amines. However, when this reaction was attempted with amine 114 
no product was detected. Analysis by thin layer chromatography and mass 
spectrometry indicated that FITC starting material was present, along with a 
compound that had a mass of the desired product minus enaminone 78. It was 
proposed that during the reaction of amine 114 with FITC a spontaneous cyclisation 




Scheme 2.32: Proposed reaction of FITC with ligand 114.
The in situ cyclisation outlined in Scheme 2.32 is possible as ligand 78 could act as a 
good leaving group due to electron resonance through the enaminone conjugated 
structure. To avoid this problem, it was decided to react the commercially available 
dansyl-L-valine (125) with enaminone 78 using the same PyBroP/DMAP chemistry 
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Scheme 2.33: Reaction of dansyl-L-valine 125 with enaminone 78.
Dansyl groups are also commonly used fluorescent probes, dansyl chloride being 
widely used for the end-group analysis of proteins, amino acid analysis and HPLC
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fluorescence detection. As expected, the reaction of dansyl-L-valine with ligand 78 
was successful, the dansyl labelled ligand 126 being synthesised in good yield.
The next stage of the project was to screen the ligands prepared against CypA to 
determine any biological activity. This was achieved by using electrospray mass 
spectrometry as a primary screen, with any ligands displaying binding to CypA then 
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3. Results and Discussion II - Mass Spectrometry Screening
3.1 Introduction
One aim of this project was to develop electrospray ionisation mass spectrometry 
(ESI-MS) as a primary screening technique to detect protein:ligand binding, in 
collaboration with the Barran research group at the University of Edinburgh. 2 The 
plan was to use mass spectrometry to highlight any ligands that bound to CypA; 
these ligands could then be subject to further biological testing. Mass spectrometry is 
adept at this role as it is versatile, fast and low on sample consumption. In this 
chapter the general principles of mass spectrometry are outlined, followed by a 
discussion of the ligand screening techniques and results.
3.2 Mass spectrometry
Mass spectrometry relies on a method of ionising the sample; once the compound is 
ionised the ions are then separated by their mass to charge ratio and then counted by 
an ion detector. To achieve this, mass spectrometers are generally comprised of the 
following component parts:
i) Sample introduction - either direct injection or capillary infusion, for
example post HPLC;
ii) an ionisation source for the generation of ions in the gas phase; 




The earliest ionisation method used was electron impact (El). The sample is firstly 
heated to facilitate evaporation; the gaseous sample is then ionised in an electron
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ionisation region. This is achieved by striking the analyte with an electron beam, 
causing ionisation through electron ejection. However, the usefulness of El decreases 
for compounds with a molecular weight of greater than about 400 Da. This is largely 
due to the involatility of larger molecules leading to thermal decomposition of the 
sample prior to vaporisation, and fragmentation of the molecules during the electron 
ionisation process.
Alternate ionisation techniques have been developed to overcome the limitations of 
electron impact. Fast atom bombardment (FAB)3 generates ions by bombarding a 
matrix/analyte mix with a fast particle beam of an inert gas such as argon or xenon. 
When the particle beam strikes the surface of the matrix energy is transferred to the 
surroundings, setting up momentary collisions and disruptions. This results in the 
ejection of some species off the surface as positive and negative ions, a process 
known as sputtering. The polarity of the source extraction can be switched depending 
on what species are to be analysed. Matrix assisted laser desorption ionisation 
(MALDI) is a similar matrix based technique but uses a laser to ionise the analyte 
sample.4 The matrix used is typically an aromatic acid with a chromophore that 
strongly absorbs at the laser wavelength resulting in desorption of bulk portions of 
the analyte sample. Both FAB and MALDI are comparatively soft ionisation 
techniques that tend to limit fragmentation upon ionisation, typically producing large 
peaks for the pseudo-molecular ion species [M+H] + and [M-H]".
The ionisation technique used in this project was electrospray ionisation (ESI). This 
is an exceptionally versatile method of ionisation enabling the study of a wide range 
of molecules including large biomolecules. The sample is dissolved in a volatile 
solvent at low concentration which is then pumped through a fine capillary at a rate 
of 0.1-0.3 ml/hr. A high potential is applied to the tip of the capillary, either positive 
or negative depending on the mode chosen, resulting in the creation of a fine 
electrostatic spray of charged droplets. This is sprayed through a warm nitrogen 
stream to promote evaporation and to reduce the droplets in size. The actual 
mechanism of ionisation is subject to two theories, the charge residue mechanism 
(CRM)5 and the ion evaporation mechanism (IBM). 6 In both theories the droplets
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decrease in size due to evaporation, increasing the charge density on the droplet until 
the coulombic repulsion between the species eventually equals that of the surface 











field lifts ion 
from droplet
,. Ion desorption
Figure 3.1: Electrospray ionisation process in positive ion mode. 7
The charge residue mechanism depicts a series of fission events that ultimately leads 
to the production of final small droplets that bear one or more excess charges, but 
only a single analyte molecule. As the last few solvent molecules evaporate the 
analyte molecule retains this droplet charge, forming a free gas-phase ion. The 
alternate ion evaporation mechanism contends that gas phase ions are emitted 
directly from charged droplets after the radii of the droplets decrease to a suitable 
size (radius <10 nm). 8 Some of the droplet's charge is carried by the molecule as it 
desorbs from the droplet, thereby relieving coulombic repulsion. The exact 
mechanism of desorption of small molecules is still subject to debate between 
proponents of the two theories, but for very large molecules such as proteins a 
consensus has emerged which favours the charge residue model. 9" 9
A distinctive feature of ESI is that multiply charged ions can be produced. As all 
mass analysers differentiate on the basis of mass to charge ratio (m/z) the effective 
mass range can be extended by detecting these multiply charged ions. For example, a
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protein with a molecular weight of 10,000 Da would be detected at several different 
















5+ 4+ 3+ 2+
[M+5H]5+ [M+4H]4 * [M+3H]3+ [M+2H]2+
m/z = 10005/5 m/z = 10004/4 m/z = 10003/3 m/z = 10002/2
m/z = 2001 m/z = 2501 m/z = 3334 m/z = 5001




The ion sources described above produce ions either by ionising a neutral molecule 
though protonation, cationisation, or deprotonation for ESI, FAB and MALDI; or 
through electron capture or ejection when El is used. Protonation involves the 
addition of a proton to an analyte molecule to give a net positive charge of +1 for 
every proton added. The charge tends to reside on the more basic residues, but 
because of the covalent nature of proton binding the charge can be delocalised from 
the proton onto the molecule, potentially destabilising the molecular ion resulting in 
fragmentation. Cationisation is similar to protonation but involves the non-covalent 
addition of a positively charged ion to a neutral molecule, for example Na+ . This 
ionisation method is useful for molecules that are not stable to protonation as the 
charge remains localised on the cation. Deprotonation involves the ejection of a 
proton from a molecule, resulting in a net negative charge of -1 for each proton 
ejected. This method is typically used for ionising acidic species, for example 
carboxylic acids. Electron ejection is usually performed on relatively non-polar, low 
molecular weight molecules and involves the ejection of an electron to produce a net
99
positive charge of +1. The related electron capture involves the absorption of an 
electron to produce a net negative charge of -1, and is primarily observed in 
molecules with a high electron affinity.
3.2.2 Analysers
The analyser is the component of the mass spectrometer that separates ions according 
to their mass to charge ratio, thus influences the sensitivity, range and accuracy of 
the equipment. There are several different types of analyser available, the type used 
in this project were quadrupole and time of flight analysers.
Quadrupoles are widely used analysers that can scan over a fairly wide mass to 
charge range (typically 10 to 4000 Da) with good accuracy (0.1 to 0.2 Da)." The 
apparatus consists of four parallel rods to which a direct current voltage is applied 
and a radio frequency (RF) potential is imposed. Ions entering the field region will 
oscillate depending upon their mass to charge ratio. At a specific RF and voltage, 
only ions at a given m/z will pass through the quadrupole to the detector, other ions 
will be destabilised and will impact on the side of the apparatus (Figure 3.3). By 
changing the RF potential the field on the quadrupole can be changed enabling the 




Figure 3.3: Quadrupole analyser at a fixed RF.
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Time of flight (TOP) analysis is based upon the principle of accelerating ions via a 
set voltage through a field free region. 12 The time taken for the ions to travel from the 
source to the detector can be related to their m/z. The TOP apparatus consists of a 
drift tube through which the ions are accelerated, the distance between the ion source 
and the detector being fixed (Figure 3.4). As the accelerating voltage is also fixed, 
the time taken for the ion to pass through the analyser is dependant on the square root 
of the mass to charge ratio. The resolution of a TOP analyser is dependant on the size 
of the drift tube, this can be increased by extending the tube length or through fitting 
a reflectron. This acts as an electronic mirror and consists of a series of charged 
plates that deflect ions back on a different trajectory towards the detector, thus 










Figure 3.4: Schematic of a time of flight analyser. 13
3.2.3 Tandem mass spectrometry
lonisation techniques such as ESI, FAB and MALDI are relatively gentle and do not 
produce a significant amount of fragment ions, in contrast with El. Tandem mass 
spectrometry (MS/MS) has been developed to induce fragmentation and then mass 
analyse the fragments, this potentially revealing useful structural information. 
Fragmentation is achieved by inducing ion-molecule collisions by a process called 
collision induced dissociation (CID). CID is accomplished by selecting an ion of 
interest with the first mass analyser, and introducing the ion to a collision cell. The 
cell is filled with an inert gas, typically argon, and the selected ion collides with the 
gas atoms, resulting in fragmentation. The fragment ions are then analysed in a 
second mass analyser.
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A commonly used tandem mass spectrometer is the triple quadrupole mass 
spectrometer, which uses the first and third quadrupoles as mass analysers and the 
second quadrupole as a collisions cell to generate fragment ions. Another common 
instrument is the quadrupole-time of flight (Q-TOF) mass spectrometer. This is 
similar to the triple quadrupole, however replaces the third quadrupole with a TOP 
mass analyser. Both of these instruments are extensively used in peptide and 
carbohydrate sequencing.
3.2.4 Detectors
Detectors operate by converting kinetic energy from incident ions into secondary 
electrons, which are further amplified to produce a signal. There are three common 
types of detectors used in commercial mass spectrometers; electron multipliers, 
photomultipiers and microchannel plates. Electron multipliers use a series of dynodes 
maintained at increasing potentials. Ions strike the surface, generating an emission of 
electrons. These secondary electrons are attracted towards the next dynode, 
generating more electrons, ultimately resulting in a cascade sequence that typically 
amplifies the current by 106 . Photomultiplier detectors operate in a similar manner to 
electron multipliers; ions initially strike a dynode resulting in electron emission. 
These secondary electrons then strike a phosphorus screen, this generates photons 
which are in turn detected by a photomultiplier. This type of detector has the 
advantage of being sealed in a vacuum, unexposed to the environment inside the 
mass spectrometer and thus resistant to contamination. Both photomultipliers and 
electron multipliers are commonly used with quadrupole analysers.
Time of flight analysers are often coupled to microchannel plate (MCP) detectors. 
These consist of a glass plate with many individual channels. Each channel is 
comparable to a single electron multiplier, and an incident ion hitting a channel on 
one side of the plate produces a charge pulse of about 1000 electrons from the other 
side. MCPs have a large planar detection area with only a few channels out of 
thousands being affected by the detection of a single ion. It is therefore possible to
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detect many ions at the same time, ideal for laser ionisation where hundreds of ions 
can be created within a few nanoseconds.
3.3 Detection of protein complexes by ESI-MS
The first reported detection and analysis of a receptorligand complex by mass 
spectrometry was by Ganem et al., in the early 1990s. The group utilised ion-spray 
mass spectrometry to investigate the binding of the immunosuppressants FK506 and 
rapomycin with the cytoplasmic receptor FK binding protein. 14 Ion-spray is also 
known as pneumatically assisted electrospray, but in contrast to electrospray can be 
performed in water without co-solvent. 15 It was found that multiple charging 
produced a family of molecular ions and dramatically reduced the mass to charge 
ratio enabling a quadrupole mass spectrometer to analyse the high molecular weight 
complexes, as outlined earlier in Figure 3.2. When FKBP was mixed with a slight 
excess of FK506 at pH 7.5 a signal was detected at m/z 1803.1, corresponding to a 
FKBP:FK506 complex in the 7+ charge state. A much weaker signal for the same 
complex in the 6+ charge state was also evident at m/z 2103.5. As a control, a sample 
of FK506 combined with denatured FKBP was analysed. This did not give a signal 
for the complex, implying that the FKBP:FK506 complex seen in previous 
experiments resulted from genuine binding and not merely non-specific adduct 
formation.
The subject of whether the proteinrligand complexes observed under ESI-MS 
conditions represent specific binding or non-specific adduct formation has been 
debated since the initial work of Ganem et al. One limitation of the technique is that 
simple observation of ions indicative of a complex by ESI-MS is insufficient 
evidence for a structurally specific protein:ligand interaction. An early 1990s paper 
by Smith et al., attempted to review the initial literature on the analysis of 
protein:ligand complexes by ESI-MS to see if specific and non-specific non-covalent 
associations could be distinguished. 16 An opinion of the authors was that while it 
may be impossible to prove beyond doubt that a specific protein :ligand association
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exists solely on the basis of ESI-MS, several kinds of evidence could be employed to 
support such a conclusion:
i) Complex relative intensity and preferred stoichiometry - complexes should be 
observed with preferred or reasonable stoichiometry, i.e. without random 
aggregation.
ii) Gas-phase lability - complexes due to weak non-specific intermolecular 
interactions should be labile and readily dissociated under more severe ESI- 
MS or tandem mass spectrometry conditions.
iii) Complex dissociation due to modification of solution conditions - changes in 
solution temperature, pH, the addition of organic solvents etc., can destroy 
specific protein:ligand associations and should produce a corresponding 
change in the ESI mass spectra.
iv) Sensitivity to modification of complex components - a substantial change in 
the relative intensity of the complex in the mass spectrum following alteration 
of either the protein (i.e. though denaturing) or ligand provides good evidence 
of a specific protein:ligand interaction.
The use of mass spectrometry to observe and analyse protein complexes has 
expanded rapidly since the initial reports of Ganem et al., and the early perspective 
of Smith et al. This is largely due to the advantages of the technique such as 
sensitivity, specificity and speed, and due to the widespread availability of mass 
spectrometry equipment. Compared to other techniques such as NMR and X-ray 
crystallography, mass spectrometry is very fast and can be performed on a very small 
amount of sample. Of direct relevance to this project, mass spectrometry has found 
use in the screening of libraries of potential ligands. An example of this research was 
carried out by Smith and co-workers who screened a combinatorial library of 
benzenesulfonamide based compounds for binding with the protein carbonic 
anhydrase II (CAII, molecular weight 28,996 Da). 17 It was found that the relative 
abundance of the ligand:CAII complex ions observed were consistent with the 
binding constants of the ligands in solution. A control experiment using denatured
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protein resulted in no complexes being observed, again showing that the complexes 
observed with mass spectrometry were the result of active site binding.
Swayze et al., extended the principle of ESI-MS ligand screening to investigate 
structural activity relationships by mass spectrometry, and successfully incorporated 
this approach in drug design. This "SAR by MS" process was a development of 
previous high-throughput ESI-MS screening methods used by the group for the study 
of non-covalently bound drug candidates to model RNA sequences. 18' 19 The process 
began by screening a set of compounds to identify hits against a RNA target of 
interest The structural activity relationships between the ligands and RNA targets 
were then explored through synthesising ligand derivatives and/or additional MS 
experiments; the SAR data being used as a guide to the synthesis of more elaborate 




Figure 3.5: SAR by MS ligand-based lead discovery strategy as outlined by Swayze et al. 1 - Ligands 
are screened against a RNA subdomain, ligands that bind are highlighted by MS. 2 - Simple 
derivatives of the most interesting ligands are prepared. 3 - The compounds are re-screened using the 
MS assay, and any observed SAR data provides information about the binding site. 4 - The SAR data 
is used to guide the synthesis of higher affinity compounds via the linking of individual ligands. 20
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Through the initial screening of combinatorial libraries, Swayze et al., discovered 
two classes of compounds that displayed an interesting SAR towards the RNA target; 
a D-amino acid and a quinoxalin-2,3-dione class. Following the strategy outlined in 
Figure 3.5, Swayze et al, discovered that some members of the two ligand classes 
seem to bind co-operatively. To test this hypothesis, several fused compounds were 
prepared, and all were found to bind markedly tighter to the target RNA than the 
parent ligands, thus supporting the process summarised in Figure 3.5.20 The "SAR by 
MS" method has also been used by Ockey et al., to discover a novel class of non- 
peptide inhibitors of the matrix metalloproteinase stromelysin (MMP-3). Here a 
similar approach to Swayze et al., was used and competition studies between ligand 
fragments using ESI-MS were carried out; novel inhibitors of the target protein were 
then constructed by chemically linking promising ligand fragments.21
A key factor in detecting non-covalent protein complexes is the preservation of the 
protein tertiary structure. The native structure of proteins may be lost while in 
solution prior to analysis or during the ESI process, and optimum mass spectrometry 
conditions may not correspond with the optimum conditions for protein folding, for 
example the pH range. To maintain native protein structure and thus hopefully detect 
genuine ligand binding it is often necessary to use volatile organic buffers. 
Ammonium acetate and ammonium bicarbonate are generally the most popular 
choices for ESI-MS experiments because they do not often form extensive gas phase 
adducts with the analyte macromolecules, unlike phosphate- and sulfate- based 
buffers. 22 Typically buffer concentration is in the range of 2 - 50 mM, although 
higher concentrations are sometimes used.
3.4 Analysis of cyclophilin A by ESI-MS
Initial mass spectrometry research in this project focussed upon the analysis of CypA 
alone. This was necessary in order to optimise experimental conditions, enabling the 
native tertiary structure of CypA to be retained during ESI-MS analysis. The mass
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spectrometer used for the analysis of CypA and the screening of ligands was the 










Ammonium acetate, pH 6.8
90 °C
65 °C
50 V (+/- 2 V)
3.5 kV
Table 3.1: Experimental conditions used for mass spectrum analysis. 8
CypA was analysed by ESI-MS at various pHs to investigate if the tertiary structure 
was retained in the gas phase after ionisation. Acidic conditions would denature the 
protein by interrupting the intermolecular forces that govern the tertiary structure, 
allowing greater accessibility of charging to inner residues. This would result in 
higher charge states observed in the mass spectra. The pH was altered by adding 1% 
v/v formic acid to CypA buffered in an aqueous ammonium acetate solution. Upon 
























Figure 3.6: Mass spectra of CypA at various pHs. The values labelled A denote the +ve charge. 8
107
The mass spectrum of CypA at the near physiological pH 6.8 shows a compact 
charged ion series of+7 to +9 indicating conservation of the CypA tertiary structure. 
As the pH is lowered CypA unfolds exposing more amino acid residues to 
protonation. This results in the higher charge states of+16 to +20 dominating the 
spectra.
3.5 Analysis of cyclophilin A complexes by ESI-MS 
3.5.1 Cyclophilin A:cyclosporin A
The first complex to be investigated by ESI-MS in this project was CypA:CsA. With 
the mass spectrometry conditions for cyclophilin A optimised, the CypA:CsA 
complex would be used as a positive control to show that ligand binding could be 
seen by mass spectrometry. CypA (20 jaM) was incubated with CsA (20uM) at a 1:1 
ratio at room temperature for 30 minutes in a mix of aqueous ammonium acetate 
buffer (pH 6.8), and 10 % methanol to aid CsA dissolution. Identical mass 
spectrometry conditions to those used previously for CypA were used, as outlined in 
Table 3.1. Upon analysis by ESI-MS it was found that the CypA:CsA complex gave 
clear m/z signal peaks (figure 3.7).
108
Cydophilin-Cydosporin








Figure 3.7: Mass spectra of CypA:CsA complex and CypA under identical conditions.
Figure 3.7 shows the mass spectra of CypA and the CypA:CsA complex at pH 6.8. 
As seen in Figure 3.6, CypA is preferentially detected as the +7 to +9 charge states. 
The CypArCsA complex produced a very similar spectrum under ESI-MS 
conditions, with the +8 and +9 charged complex dominating, although at the 1:1 ratio 
uncomplexed CypA peaks remained in the spectra. In order to investigate the effect 
of ligand concentration upon binding the experiment was repeated with an increased 
concentration of CsA (200 uM), a ratio of 1:10 (Figure 3.8).
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Figure 3.8: Mass spectra of CypA:CsA at increased concentration of CsA (1:10).
2600 2660
When the concentration of CsA was increased the amount of uncomplexed CypA 
was reduced, resulting in a smaller peak area, as shown in the top spectrum of figure 
3.8. Interestingly, peaks corresponding to a two ligand:CypA complex were also 
detected. It was thought that these peaks could due to ligand aggregation at the 
higher concentration, with one ligand residing in the active site and another ligand 
aggregating to the residues lying outside the site, or alternatively due to non-specific 
binding of one ligand to the CypA surface.
In an attempt to gain an understanding of the mechanisms of binding involved in the 
two ligand complex, tandem mass spectrometry was utilised. The MS/MS analysis 
was carried out using a tandem quadrupole-time of flight (Q-TOF) analyser. The 
complex peak at approximately m/z 2308 was selected using the quadrupole, this 
corresponding to [Cyp+2CsA+9H]9+ . The ligands were then dissociated from the
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protein by accelerating the complex into a cell filled with pressurised argon gas 
positioned between the quadrapole and TOP detectors. The acceleration voltage was 
stepped up to increase the impact energy in the dissociation cell, the collision 
induced dissociation data could then be used as a guide to assess the strength of 
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Figure 3.9: MS/MS data showing the fragmentation pattern of the removal of the two CsA ligands as 
the collision voltage is increased.
Figure 3.9 shows that at an acceleration voltage of 20.0 V the two-ligand complex in 
the +9 charge state is predominant, but with a peak corresponding to 
[CypA+CsA+8H] 8+ also present (Figure 3.9, A). This shows at a relatively low 
acceleration energy there is some dissociation of one ligand. When the voltage is 
increased to 30.8 V the one ligand:CypA complex increases in size showing a greater 
degree of one ligand dissociation, and there is a small peak corresponding to 
[CypA+7H]7+ due to both ligands dissociating (Figure 3.9, B). As would be
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expected, further increases in the acceleration voltage results in almost complete 
dissociation of firstly the two ligand complex (Figure 3.9, C), then the one ligand 
complex (Figure 3.9, D). It can be seen from this data that low acceleration energies 
result in the facile loss of one ligand, this ligand thus being held by weak 
intermolecular forces. The second ligand requires higher collisional energy to 
dissociate, and it is hypothesised that this ligand is tightly bound in the active site of 
CypA. Whilst it is not possible to draw definite conclusions as to whether the first 
dissociated ligand is binding to CypA non-specifically or forming ligand aggregates, 
it is clear that two ligands are not binding in the same manner, and only one is 
relevant to active site binding.
3.5.2 Cyclophilin Arsynthetic ligands
Having observed CypA:CsA complexes by ESI-MS, the next step was to take the 
optimised mass spectrometry conditions and apply them to the screening of the 
synthetic ligands. Ligands 30 and 62 were initially used at a concentration of 20 uM, 
a ratio of 1:1 with CypA, using the same conditions as the previous CsA screening; 
however it was found that no binding was seen at these concentrations. When the 
experiment was repeated at an increased concentration of 100 uM, a Hgand:CypA 
complex was seen for ligand 62, but ligand 30 seemed to fragment under the ESI 
conditions to give a complex spectrum (Figure 3.10).
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Figure 3.10: Mass spectra for CypA:ligand complexes for ligands 30 and 62, 1:5 ratio, 30 min 
incubation.
The enol-ester linked ligand 30 gave a m/z peak at 2327 Da which corresponded to 
[CypA+252Da+8H] 8+ . This mass increase corresponds to that of Cbz-valine, it would 
appear that ligand 30 fragmented under the electrospray conditions to yield the 
amino acid starting material. Encouragingly, when the experiment was repeated with 
ligand 62, peaks corresponding to 1 and 2 ligand:cyclophilin complexes were 
detected, with the ligands binding to the protein in the +8 charge state. It was 
presumed that the two ligand complexes were a result of the increased ligand 
concentration, the same phenomenon as seen in the previous CsA screening. 
Interestingly, no protein:ligand complexes were seen for the other CypA charge 
states, the peaks associated with the +7 charge state did not correspond to the mass of 
ligand 62 and were hard to differentiate against the background noise.
Further ESI-MS experiments were carried out using in an attempt to optimise the 
ligand screening conditions. The concentration of ligand 62 was initially varied from 
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Figure 3.11: Mass spectra of CypA:62 at varying concentrations, 30 min incubation.
Inspection of the spectra in figure 3.11 shows that the CypA:ligand complex is 
initially detected in the presence of excess ligand at a ratio of 1:2. This contrasts with 
the CypA:CsA complex which gave a strong complex peak at a ratio of 1:1, 
reflecting the stronger binding affinity of CsA compared to the synthetic ligand 62. 
Increasing the concentration to a 1:5 protein:ligand ratio resulted in an increased 
peak intensity at the m/z corresponding to [CypA+ligand+8H] 8+ and also gave a 
small peak for the two ligand complex. Further increasing the concentration to 
150 |^M to give a 1:7.5 ratio did not lead to an increased peak size for the complex. 
Indeed, it was found that the signal to noise ratio was reduced at the higher ligand 
concentration, and ligand solubility in the 10 % methanol/ammonium acetate buffer 
solution became problematic at this concentration. As the best results were seen at 
the 1:5 CypA:ligand ratio it was decided to use this concentration as the standard for 
future ligand screening.
With a standard ligand concentration set, it was then necessary to investigate the 
effect of incubation time upon ligand binding. Ligand 62 was incubated with CypA
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in a 10 % methanol/ammonium acetate buffer at pH 6.8 and left standing at room 
temperature for 30 minutes, 3 hours and overnight followed by analysis by ESI-MS 
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Figure 3.12: Effect of incubation time upon ligand binding for CypA:62 at a 1:5 ratio.
Analysis by ESI-MS showed that there was no significant difference in the spectra 
between the sample incubated for 30 minutes or 3 hours, both showed clear peaks at 
the m/z corresponding to one and two ligand:CypA complexes. This finding was 
seen as beneficial to the prospect of screening multiple ligands as the incubation time 
would vary according to the ligand screening order. An overnight incubation period 
resulted in degradation of the protein:ligand peak and led to an increase in the 
background noise of the spectrum.
The mass spectrometry experiments outlined above were used to define a set of 
standard experimental conditions that would be used for the screening of other 
synthetic ligands. It was decided to screen the ligands at a ratio of 1:5 CypA:ligand, 
with an incubation time between 30 minutes and 3 hours. Although the use of 
standard conditions would not allow for the optimisation of the experiment
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parameters for every ligand, it would allow for a higher throughput of ligands and 
suited the needs of an initial screen. To investigate the suitability of the standard 
conditions to the testing of other synthetic ligands, ligands 82 and 83 were screened 
(Figure 3.13).
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Figure 3.13: Mass spectra for CypA-ligand complexes for ligands 82 and 83, 30 min incubation. 
Peaks 1,2,3 & 4 correspond to [CypA+ x ligand+8H] 8+ , peak 5 corresponds to [CypA+Hgand+7H] 7+ .
Ligand 82 gave the most positive synthetic ligand result so far when screened against 
CypA under the standard ESI-MS conditions. It was found that the ligand produced a 
strong ligand:CypA complex peak at the +8 charge state, and interestingly peaks 
corresponding to two, three and four Hgand:CypA84 complexes were also observed. 
Ligand 82 is more lipophilic compared to ligand 62 due to the extra allyl group, 
possibly resulting in decreased solubility in the methanol/ammonium acetate buffer 
solution with subsequent micelle formation and ligand aggregation. As with the 
previous two CsA:CypA complex, it is not clear whether a ligand aggregate is 
binding to the active site, or just one ligand binds and the other complex peaks are 
due to non-specific binding. A peak was also detected for a [CypA+ligand+7H]7+ 
complex. Ligand 83 did not give a signal for any protein:ligand complexes. As
116
outlined in Chapter 2.6.1, molecular modelling suggested that the cinnarnyl moiety 
does not fit into the hydrophobic cavity occupied by the dimedone core, resulting in 
the ligand being too sterically demanding to bind in the CypA active site.
It is worth noting that both ligand 82 and 83 were screened against CypA as a 1:1 
mixture of both diastereomers. The molecular modelling in Chapter 2.6.1 predicted 
that the S-diastereomer of ligand 82 would preferentially bind to CypA due to 
possible steric clashing of the /?-diasteromer C-6 allyl moiety with the active site. 
Although both ligand 82 diastereomers were separated by using a HPLC fitted with a 
chiral column, unfortunately the control experiment of screening both diastereomers 
independently against CypA was not carried out due to time constraints.
3.5.3 Measuring dissociation constants by mass spectrometry
The binding affinity between a protein and a ligand can be measured in terms of the 
association constant, Ka, or the dissociation constant Kd. The association constant is 
the measure of the extent of the reversible association between a protein (P) and a 
ligand (L) at equilibrium (Equation 3.1). 4
Iherefore
[P] [L] 
Equation 3.1: Association constant.
The association constant is measured in the units of concentration" 1 , therefore the 
reciprocal dissociation constant is more often used, the units being quoted in terms of 
concentration (equation 3.2).
PL x P + L therefore
[PL] 
Equation 3.2: Dissociation constant.
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The dissociation constant is a useful way of describing the affinity of a ligand for a 
protein, for when the concentration of ligand equals that of the Ka then half of the 
ligand receptors will be occupied at equilibrium. Thus if the ligand has a high affinity 
for the protein the Ka will be low, as it will take a low concentration of ligand to bind 
half the receptors.
The dissociation constants for the one and two ligand:CypA complexes were 
calculated separately from the mass spectra peak intensities using Equation 3.3:
K =
[PL] [PL]
[P] represents the peak area for the +8 charge state of free CypA
[L] represents the peak area of the free ligand
[PL] represents the peak area for the +8 charge state of the CypA:ligand complex
[Lj] is the initial concentration of ligand
25Equation 3.3: Equation used to calculate mass spectrometry derived Kd values.
It was possible to substitute the mass spectrometry peak areas for concentrations in 
Equation 3.3 based on the fact that the total protein concentration used, [Ptotai], is 
known. For a protein with one binding site, such as CypA, [Ptotai] is equal to the sum 
of both [P] and [PL] peak areas. 25 Thus, the peak areas can be converted to 






P is the free CypA peak area
PL is the CypA:ligand peak area
Ptotai is the free and complexed CypA peak areas
[Pjnit] is the initial CypA concentration
Equations 3.4: Equations relating mass spectrometry peak areas to concentrations. 7
Equations 3.3 and 3.4 were used to calculate the Kd values for ligands 62 and 82 and 
CsA (Table 3.2). The ratio of CypA to ligand was varied in order to calculate Kd 
values at differing concentrations, and the experiments using the synthetic ligands 















































Table 3.2: Kd values calculated for 62, 82 and CsA at various ratios against 20 
to the one ligand:CypA complex, Kd2 refers to the two ligand complex. 26
CypA. Kd i refers
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It is clear from looking at the data in Table 3.2 that the measurement of Kd values by 
ESI-MS is not without its limitations. There was a certain amount of variability 
between repeated experiments, albeit with exceptions. Also, the calculated Kd values 
for CsA are significantly higher than the reported Kd value of 46 nM.27 It was found 
that an increase in the concentration of ligand led to a decreased Kdi value, implying 
a greater degree of binding. This was to be expected as an increased ratio of ligand to 
protein would improve the binding probability, thus decrease the binding constant. 
This trend was also mirrored in the Kd2 values, with the exception of ligand 62, 
where the increased concentration gave higher Kd2 values.
3.5.4 High throughput ligand screening
The ultimate aim of the mass spectrometry research in this project was to develop a 
high throughput system that could be used as the primary ligand screen. Ideally, this 
would involve a minimum of manual intervention, and would be capable of 
screening ligands multiple times to ensure the results are statistically reproducible. 
To fulfil these requirements a Waters 2700 auto-sampler was coupled via a Waters
1 R
600 HPLC pump to the ZMD mass spectrometer. However, this particular 
apparatus is primarily a preparative mass directed HPLC purification system, 
designed for larger injection volumes and flow rates than those used for the previous 
mass spectrometry screening. At smaller volumes the aspiration of sample by the 
injection needle was found to be inaccurate, so all injection volumes were regulated 
by using a 50 |nl sample loop.
As the previous experimental conditions had been optimised and had already 
produced CypA:ligand complex peaks, the conditions in Table 3.1 were maintained. 
With any high throughput system it is important to limit any residual sample carry 
over between runs as this could led to contamination of subsequent ligand screening 
results. To avoid this, a solvent gradient was used that incorporated an organic 
solvent flush to remove any residual sample (Table 3.3). The solvent dead volume in 
the interface tubing accounted for 2 minutes of the solvent run; at this point the
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solvent flow was switched to the organic mobile phase for a period, then conditions 


























Table 3.3: Solvent gradient conditions for high throughput analysis.
The ligand dissociation values were calculated in a slightly different manner to the 
previous values in Table 3.2. It was decided to use deconvoluted mass spectrometry 
data in which the spectrum is converted from the multiply-charged spectra into the 
overall masses of protein and ligand. The purpose of the high throughput screen was 
to give a relative binding affinity for the ligands tested; therefore it was decided to 
sum the CypA:ligand peak areas and to calculate the Kd values using Equation 3.5:
[PLi+PL2+PL3 ....]
PLn represents the peak area for the CypA:(ligand x n) complex 
Equation 3.5: Equation used to calculate the Kd values for the high throughput screen.
The high throughput system was used to successfully screen a selection of ligands, 
with a throughput of around 9 ligands an hour. The ligands were then ranked 
according to their calculated relative dissociation constants (Table 3.4).
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Table 3.4: Calculated Kj values for various ligands using data collected by high throughput analysis 
using the Waters ZMD system. All incubations were between 30 - 90 minutes, using a 1:5 ratio of 
CypA (20nM):Ligand (lOOuM). * Ligand fragmentation was observed in the mass spectrum.
Ranking the ligands in order of dissociation constants revealed that ligand 82 had the 
highest binding affinity, with a Kj value slightly larger than the values previously 
calculated and shown in Table 3.2. The structurally similar ligand 62 and the 
hydrophilic ligand 111 also ranked highly, both with dissociation constants below 
150 uM. It is difficult to determine any relationships between ligand structure and 
the corresponding Kd value for the remaining ligands, for example ligand 87 varies 
from ligand 62 by just an extra methyl group at C-6 on the dimedone ring, yet was 
found to have a Kd value almost three times higher. However, it is worth noting that 
the technique was not intended to elucidate trends in activity but to function as a 
primary ligand screen, and was found to be well suited to this role.
3.6 Conclusions
The initial mass spectrometry research outlined in this chapter focussed upon the 
analysis of CypA alone, followed by the successful characterisation of CypA:CsA 
complexes by ESI-MS. Although this data may appear unconnected to the screening
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of small molecule ligands, it was necessary in order to optimise experimental 
conditions and acted as a proof of principle introduction to the detection of 
CypA:ligand complexes in the gas phase. Tandem MS/MS analysis of the CypA:CsA 
complex revealed that although two CsA:CypA complexes were observed under 
screening conditions, the ligand affinity for the protein is different, with one of the 
ligands more weakly bound than the other.
It has also been demonstrated that electrospray mass spectrometry is able to identify 
CypA synthetic ligands complexes using a standard set of experimental conditions. 
The successful detection of CypA complexes with ligands 62 and 82 led to the mass 
spectrometry derived dissociation constant being determined, giving a method of 
quantifying the observed interactions with the protein. Once the binding of a ligand 
to CypA could be quantified, it allowed different ligands to be directly compared to 
each other, thus forming the basis of a screen. The goal of a functional high 
throughput screen using ESI-MS was achieved through the use of HPLC auto- 
sampler, and by using Equation 3.5 the dissociation constants of the screened ligands 
could be determined.
After ranking the ligands in terms of their calculated dissociation constants, it was 
decided to focus primarily on further biological screening of the top three ligands, 
ligands 82, 62 and 111. These results are outlined in Chapter 4.
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4. Results and Discussion III- Biological Assays
4.1 Introduction
The mass spectrometry screening technique outlined in Chapter 3 provided a useful 
method of measuring the relative ligand binding affinities. Through ranking the 
ligands in terms of their calculated dissociation constants an order of binding could 
be determined, promising ligands were then subject to further testing. In vitro 
fluorescence and PPIase assays were carried out in collaboration with the 
Walkinshaw research group at the University of Edinburgh, 1 and in vivo testing 
against the nematode worm Caenorhabditis elegans was carried out by Dr. Tony 
Page at the University of Glasgow. 2
4.2 Intrinsic fluorescence binding assay
All proteins are fluorescent in the ultraviolet region due to the presence of three 
aromatic amino acids in their structures: phenylalanine, tyrosine and tryptophan. 3 Of 
these, tryptophan dominates the fluorescence with a higher quantum yield than the 
other amino acids. Fluorescence spectroscopy can be used to detect interactions 
between proteins and ligands, provided that the optical properties of the protein- 
ligand complex differ from those of free ligand and free protein.
CypA has a single tryptophan residue (Trpl21) located about 8 A from the centre of 
the substrate proline binding pocket of the active site. The structure of CypA-CsA 
complex shows a strong H-bonded interaction between Trpl21 and the carbonyl 
oxygen of MeLeu9 in CsA. 4 In addition to this interaction contributing to the binding 
affinity and specificity of CsA for CypA, it accounts for the spectra changes in the 
fluorescence of Trpl21 observed upon complex formation. 5 Binding of CsA 
produces an enhancement and roughly an 8 nm blue shift in the emission maxima, 
from 350 to 342 nm. This perturbation of the fluorescence spectra upon 
immunophilin binding has been used to estimate the dissociation constant between
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various CsA derivatives and CypA,6 and was used to calculate the dissociation 
constant of synthetic ligands highlighted by the mass spectrometry binding screen. 
The assay depends on ligands binding close enough to Trpl21 (within 5 - 6 A) to 
alter the polar environment around the residue and cause specific and saturable 
changes in the intrinsic tryptophan fluorescence, either through enhancement or 
quenching.
4.2.1 Experimental methods
Fluorescence emission spectra for CypA were obtained on a PTI Quantmaster™ 
spectrofluorometer,7 using a 160 ^1 cuvette at 25°C. Tryptophan fluorescence was 
excited at 295 nm (5 nm band pass), and emission was scanned from 310 to 430 nm 
(5 nm band pass). CypA (0.3 (J.M) was incubated in the absence or presence of 
increasing amounts of either CsA or synthetic ligand in 25 mM tris (hydroxymethyl) 
aminomethane buffer, pH 7.5; 100 mM NaCl; 1 % ethanol; 1 mM NaN3 , for 60 
minutes at 25°C, and the emission spectra measured. Each spectrum was obtained 
from a separate incubation mixture, not sequential additions of ligand to the same 
sample of CypA. Any change in the fluorescence signal was assumed to be 
proportional to the concentration of CypA-ligand complex. The observed 
fluorescence was buffer background subtracted, and corrected for dilution and inner
Q
filter effects by Equation 4.1.
Equation 4.1: /corr = {(vol0+voladd/vol0) x /obs} /
J-2.303 x E295nm x I x [Lig])
Where fCOTT is the corrected fluorescence signal, /0bS is the observed fluorescence 
signal, S295nm is the ligand extinction co-efficient at 295 nm, L is the path length (0.5 
cm) and [Lig] is the molar ligand concentration. The corrected fluorescence signal, 
fwn (in arbitrary units), upon complex formation can be defined by Equation 4.2.
Equation 4.2: /C0rr ~ff + (fb ~/f)
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Where/f is the fluorescence of free uncomplexed CypA and/b is the fluorescence of 
the CypA-ligand complex at infinite concentration of ligand.
The jtarr data was plotted versus the total concentration of ligand. At any total 
concentration of CypA [CypA],/depends on the total ligand concentration [Lig] and 
the dissociation equilibrium constant (K^) for the complex according to Equation 4.3. 
The dissociation constants for the CypA-ligand complexes were determined by 
fitting the data to Equation 4.3 using Kaleidagraph v3.6 software.9
Equation 4.3: /corr -/f + (/b -/f) x {(Kd + [CypA] + [Lig]) - V((Kd + [CypA] 
+ [Lig])2 - (4 x [CypA] x [Lig])) / 2 x [Lig])}
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Figure 4.1: The fluorescent enhancement at 342 nm of 0.25 CypA (0.3 uM) plotted against 
concentration of CsA. Each point is the mean of three separate measurements ± standard error. The 
points were least squares fit to Equation 4.3, shown by the red line. 8
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4.2.2 Results and discussion
Table 4.1 shows the dissociation constants calculated by the fluorescent assay for the 
three top-ranking ligands as determined by the MS screen, ligands 62, 82 and 111. 
The Kd values of the enol-ester ligand 30 and fluorescent ligand 126 were also 
determined, with the Kd of CsA calculated in the same manner as a comparison.
Ligand Structure Remarks
Cyclosporin A 0.03 ±0.01
Enhancement at












X.em max of 346
nm
III OH 29.0±21.3 Quenching at l.em max of 
346 nm
126 22*
Quenching at "kem 
max of 
348 nm
Table 4.1: Apparent KA values of CsA and synthetic ligands for CypA in vitro. Each Kd value is the 
mean of three measurements ± standard error. * Assay complicated due to ligand fluorescence.
The intrinsic fluorescence binding assay revealed that whilst none of the synthetic 
ligands could compare to the binding affinity of CsA, ligands 62, 82 and 111 were 
found to retain the same relative dissociation constant ranking as observed in the 
mass spectrometry screen. Ligand 62 had a lower Kd value than the original enol-
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ester lead ligand 30, a comparison of the two ligands using the mass spectrometry 
screen was limited by the fragmentation of enol-ester 30 under the ESI-MS 
conditions. The amide moiety in ligand 62 may exert an effect upon binding through 
reversal of the hydrogen bonding potential at this point on the ligand from acceptor 
to donor, and the increase in the planar rigidity of the ligand via resonance may also 
contribute to the lower Kd.
Ligand 82 was found to have the lowest Kd out of the ligands tested, suggesting that 
the extra allyl moiety has a positive effect upon ligand binding. This finding is not 
only consistent with the MS screening results, it also supports the molecular 
modelling outlined in Chapter 2.6.1; analysis of the modelling suggested that the 
allyl group may have a positive effect on binding affinity through a possible 
hydrophobic interaction with Leu 122. Interestingly, ligand 82 gave an enhancement 
of fluorescence upon screening, whereas the other small molecule ligands quenched 
the fluorescence. The allyl group of ligand 82 may potentially displace a water 
molecule from the vicinity of the Trpl21 upon ligand binding. Tryptophan 
fluorescence is known to be susceptible to quenching by water, 10 thus fluorescent 
enhancement may be a result of the increased hydrophobic environment upon ligand 
binding. Although both diastereomers of ligand 82 were also screened separately, the 
results were inconclusive due to problems with the solubility of the batch of CypA 
used for the assays. Unfortunately these assays were not repeated due to time 
constraints. The hydrophilic ligand 111 was found to have a larger Kd than ligand 82, 
again suggesting that the allyl moiety of ligand 82 is involved in a positive 
hydrophobic interaction with the CypA active site.
Upon screening ligand 126 it was found that the assay was complicated by ligand 
auto-fluorescence. The dansyl fluorophore has an emission wavelength of ca. 340 
nm, the same region as the CypA fluorescence emission. Although an attempt was 
made to correct the dissociation constant value for ligand 126 due to this auto- 
fluorescence, it was decided to use the fluorescence assay as an indication of ligand 
126 binding, rather than a quantitative figure.
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The main limitation with the intrinsic fluorescence assay results was the large 
amount of variation between the calculated Kj values upon repetition of each ligand, 
reflected in the large error margins shown in Table 4.1. The variation was largely 
related to slight differences in the solubility of ligand and the particular batch of 
CypA used for each repeat. As a consequence of this variation it is difficult to 
ascertain any conclusive structure activity relationships for the ligands, but 
nonetheless the assay served as a useful guide to the binding of ligands to CypA and 
helped to corroborate the finding of the mass spectrometry screen.
4.3 Peptidyl-prolyl cis-trans isomerase (PPIase) assay
The peptidyl-prolyl isomerase activity of CypA can be monitored in vitro through the 
measurement of an a-chymotrypsin-coupled cleavage of a synthetic peptide 
substrate. 11 The substrate used was Suc-Ala-Ala-Pro-Phe-pNa, which exists in 
equilibrium between the cis and trans forms. a-Chymotrypsin selectively cleaves the 
C-terminal 4-nitroaniline group only if the Ala-Pro bond is in the trans form (Figure 
4.2). This isomer-specific cleavage can be monitored by measuring the absorbance of 
the released 4-nitroaniline chromophore at 400 nm as a function of time. CypA 
catalyses the cis-trans isomerisation of the peptide substrate resulting in the release 
of 4-nitroaniline, the pre-existing trans peptide is cleaved within the assay deadtime, 
so this cleavage does not contribute to the assay results. Any inhibition of the PPIase 
activity of CypA through competitive ligand binding would retard the rate of 4- 
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Figure 4.2: Mechanism of the assay to monitor peptidyl-prolyl cis-trans isomerisation based upon 
isomer-specific proteolysis. 12
One limitation of this assay is that only one direction of the reversible isomerisation, 
from cis to trans, can be followed. In standard aqueous conditions only 10 % of the 
peptidyl-prolyl bonds are in the energetically unfavourable cis conformation, 
resulting in a poor assay signal-to-noise ratio. Kofron et al., found that the use of 
lithium chloride in trifluoroethanol (TFE) as a co-solvent perturbed the cis/trans 
equilibria in favour of cis from 10 % up to 70 %. 13 This significantly improved the 
signal-to-noise ratio and thus the sensitivity of the PPIase assay.
4.3.1 Experimental methods
The synthetic peptide substrate was initially suspended in a solution of LiCl/TFE 
(0.02 mg/ml). CypA (10 nM) was incubated with varying concentrations of inhibitor 
(typically a range of 10 to 100 uM of synthetic ligands, nM range for Cyclosporin A) 
in a HEPES/NaCl buffer and organic solvent solution. The mix was transferred to a 
plastic cuvette, and the reaction initiated by addition of chymotrypsin (23 nM), 
followed by 120 uM peptide substrate to make a final reaction volume of 1 ml. The 
reaction was rapidly mixed, and the change in absorbance at 400 nm was measured 
over a 2 minute period after addition of chymotrypsin and substrate. Measurements 
were taken every 0.1 seconds using a Perkin Elmer Lambda 20 spectrophotometer 
fitted with a thermostatted Peltier cell holder, 14 which cools the reaction to 4 °C to 
limit thermal isomerisation of the peptide substrate. The initial rate for each 
condition at a set concentration of substrate was then calculated. A plot of the rate of
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enzymatic isomerisation against ligand concentration was used to determine the total 
concentration of ligand at which 50 % inhibition occurred, the IC 50 value (Figure 
4.2). The calculation assumes that the rate of cis to tram isomerisation is directly 
comparable to the rate of 4-nitroaniline release.
4.3.2 Results and discussion
Table 4.2 shows the IC5o values calculated by the PPIase assay for ligands 62, 82, 
and 111, with comparisons made to the CsA (1), dimedone (29) and ligand 30 IC 50 
values calculated in the same manner.
Ligand Structure IC50 (uM) Solubility Solvent
1 Cyclosporin A 0.009 Good EtOH
29 22,000 Fair MeOH




82 22 Fair DMSO
111
o
OH 21 Fair DMSO
Table 4.2: IC50 values of CsA and synthetic ligands for CypA in vitro.
Unlike the previous ESI-MS screen and intrinsic fluorescence assay, the PPIase
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assay results outlined in Table 4.2 show that ligands 30, 82 and 111 all have similar 
activity towards CypA; all three ligands have ICso values in the low- to mid- 20s uM 
range. These figures represent a marked improvement over the original lead 
compound dimedone that had an IC 50 of 22mM, but again the activity of the 
synthetic ligands trails behind that of CsA; the calculated IC50 of 9 nM closely 
matches the published figure of 6 nM. 15
The main restriction in the use of the PPIase assay was the limited solubility of the 
synthetic ligands in the solvent conditions required for the assay. Ligand insolubility 
often resulted in an increase in absorbance at ca. 400 nm due to the ligand 
precipitating out of solution during the assay, this was a particular problem when 
methanol was used as solvent, and ligand 62 was unable to be assayed due to poor 
solubility. DMSO was used to dissolve ligand 82 and 111 successfully, but its use 
resulted in other complications. Previous work within the group has shown that 
DMSO actually binds to CypA, the X-ray crystal structure showing one molecule 
located in the proline binding pocket. 16 The use of DMSO as solvent may have 
resulted in competitive binding between solvent and ligand, thus affecting the assay 
results.
4.4 In vivo activity assay
Five of the diseases currently in the Tropical Diseases Research Programme (TDR) 
of the World Health Organisation (WHO) portfolio are caused by parasites. Malaria, 
leishmaniasis, trypanosomiasis, schistosomiasis and filariasis, along with other 
human diseases caused by protozoans and helminths, present intractable problems of 
control, 17 disproportionally affecting poor and marginalised populations. Many anti- 
parasitic drugs currently in use suffer from serious deficiencies, especially those of 
toxicity and resistance, so the development of new approaches for treating and 
controlling such infectious diseases remains an important medicinal area. The 
unexpected finding that cyclosporin A showed promising anti-parasitic activity has 
prompted the drug to be used in seminal research into parasitic infections. 17 Whilst it
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is unlikely that CsA could ever be used clinically to control parasites due to its 
immunosuppressive properties and toxicity, non-immunosuppressive CsA analogues 
or synthetic small molecule mimics may potentially lead to novel anti-parasitic 
therapies.
Caenorhabditis elegans, a free-living nematode worm, has been used extensively as 
a model for studying nematode parasites as well as higher eukaryotes. It is multi- 
tissue organism that is not only genetically tractable, but is easily and quickly 
cultured in liquid media and has a relatively rapid reproductive life cycle, of the 
order of 24 hours. C. elegans expresses 18 cyclophilin isoforms, the greatest number 
of isoforms described in a single species. 18 These multiple isoforms of cyclophilin 
appear to play important roles in reproduction and larval development, body-wall 
muscle formation and in the proper folding and processing of proteins, for example 
the collagens involved in the formation of the extra cellular matrix and cuticle. 19 
Whilst the precise mechanism of the CsA anti-parasitic activity is yet to be 
elucidated, its interaction with parasite cyclophilin is suspected to be a key factor, 
thus making C. elegans an interesting in vivo model to investigate the anti-parasitic 
effects of CsA and synthetic ligands.
An in vivo screen was developed to examine the biological effects of CsA and the 
lead compound, ligand 82, on C. elegans. The biological effects were assessed by 
several parameters. These included morphological and developmental abnormalities 
such as cuticle shedding defects and gut malformation, loss of motility, and loss of 
reproductive efficiency judged by counting larval numbers. Affected worms were 
then further analysed under light microscopy to allow a more detailed assessment of 
the observed defects.
Sexually mature worms were cultured at 25°C in liquid media, with OP50 E. coli as a 
food source, and exposed to varying doses of CsA and ligand 82. Analyse took place 
over the course of five days to allow for several reproductive cycles. Compared to 
control conditions (Figure 4.3 A), worms exposed to ligand 82 had growth defects, 
the worms were shorter and "dumpier" in general (Figure 4.3 B), and showed
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reduced motility. The worms treated with ligand 82 also had cuticle shedding defects 
similar to those observed in organisms treated with CsA (red arrows in Figure 4.3B 
& 4.3C, respectively). Furthermore, exposure to ligand 82 or CsA markedly affected 
the reproductive abilities of the worms, reflected in a reduction of larvae numbers, 
with an apparent IC50 of 190 uM for ligand 82 and 28 uM for CsA (Figure 4.3 D).
A: control B: 300 uM ligand 82
C: SOuMCsA D: Dose response curve
SOjAICyctosporln• -•• 10 100 1000 
82 or CsA concentration [uM]
Figure 4.3: Representative light-micrographs of worms grown in the absence or presence of either 82 
(300 uM) or CsA (50 uM) are shown in panels (A), (B) and (C), respectively. In (B) and (C), the 
cuticle shedding defect, absent in (A), is highlighted by red arrows. (D) Dose response curves for 82 
(open circles) and CsA (closed triangles) after 48 hrs exposure. Each data point is the mean from three 
separate measurements. The ICso values for 82 and CsA are 190±60 uM and 28±13 uM, respectively. 
Larvae numbers are plotted against the concentration of 82 or CsA in uM. The apparent IC50 values 
were derived by non-linear fitting of a standard four-parameter logistic model where the IC 50 
corresponds to a response halfway between the upper and lower asymptotes.
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C. elegans were also exposed to the fluorescently labelled ligand 126 using the same 
in vivo screening conditions as previously. The worms were observed under light 
microscopy using a DAPI (4',6-diamidino-2-phenylindole) filter set. DAPI is a 
fluorescent marker normally used to visualise DNA and had a relatively broad 
emission spectra, allowing the filter sets to be used to visualise dansyl fluorescence 
(Figure 4.4).
A: 200 uJVI ligand 126 B: 25 nM ligand 126
Figure 4.4: Representative light-micrographs of C. elegans nematodes grown in the presence of 
ligand 126 and observed through a fluorescence microscope using a DAPI filter set. At concentrations 
of ligand 126 between 50 - 200 nM (A) a very strong green fluorescence in pharyngeal gut lining was 
observed, with deep blue vesicles in the gut tissues. Exposure to UV caused these vesicles to lyse and 
turn the entire gut purple. Higher concentrations resulted in some ligand precipitating out of solution 
(red arrow, A). Lower concentrations of ligand 126 resulted in the ligand still being taken up but with 
less intense staining in the gut (B).
Visualisation of the fluorescent ligand 126 upon ingestion by the C. elegans worms 
revealed strong fluorescent staining of the gut lumen and surrounding tissues, as 
shown by the representative light-micrographs in Figure 4.4. Exposure to ligand 126 
also resulted in the worms displaying the same phenotypic changes as seen with CsA 
and ligand 82, namely stunted growth, loss of mobility, cuticle shedding defects and 
a reduction in fecundity. Unfortunately, it was not possible to visualise the exact 
localisation of ligand 126 in terms of organelle specificity as a higher magnification
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microscope would be required. However, as the worms displayed the same 
phenotype upon exposure to CsA and both synthetic ligands, it is felt that ligand 126 
did not merely stain the gut lumen of C. elegans as the ligand was ingested and 
excreted, but was being taken up into the same tissues and organelles as CsA and 
ligand 82.
Whilst it is clear that ligands 82 and 126 display anti-nematode activity towards C. 
elegans due to the phenotypic changes outlined above, it can only be inferred that 
they act by inhibiting the function of nematode cyclophilins through circumstantial 
evidence. For instance, the cuticle shedding defect observed in ligand treated 
C. elegans may be due to the inhibition of cyclophilin and/or a related protein 
disulfide isomerase (PDI) enzyme. 20 Both enzymes are important catalysis of 
collagen folding and are expressed in the cuticle synthesising tissue, the hypodermis, 
and have peaks of expression corresponding to the moulting cycle. 21 As the enzymes 
play a key role in the folding of the structural proteins that form the nematode 
cuticle, the observed cuticle shedding defects strongly suggest an interaction of these 
proteins with the ligands. The staining of the gut lumen of C. elegans upon exposure 
to fluorescent ligand 126 also suggests an interaction with cyclophilin; the gut cell 
cytoplasm is known to be rich in cyclophilin-5, the structure of which closely 
resembles human cyclophilin B. 18
4.5 Conclusions
The incorporation of an initial mass spectrometry screen, two different in vitro assays 
and in vivo testing into this project was found to be a success, and the process is 
represented schematically in Figure 4.5. After a period of optimisation and analysis 
of CypA and CypA:ligand complexes, electrospray ionisation mass spectrometry was 
developed into a moderately high throughput screening technique. Through 
calculation of the Kj values for the ligands a relative rank order of ligands could be 
compiled, allowing the most promising ligands to pass through the screen and into in 
vitro assays. The intrinsic fluorescence assay was found to concur with the ligand
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ranking order from the mass spectrometry screen and although it was not as 
constructive as the fluorescent assay, the PPIase assay was still useful as it showed 
that the synthetic ligands tested had ICso values 10'3 times that of the original lead 
compound, dimedone (29).






In vivo assay 
—> C. elegans
Structure - activity data 
—> molecular modelling
Figure 4.5: Schematic representation of the ligand synthesis and biological assay process.
The positive in vivo assay results were especially encouraging and added credence to 
the overall project approach. The fluorescent studies using ligand 126 demonstrated 
it was possible to synthesise fluorescent ligand derivatives that are taken up by the 
nematodes, and cause phenotypic changes concurrent with anti-nematode effects. 
Further development of this method, perhaps involving higher power microscopy 
and/or the use of an alternate fluorescent group, may allow the identification of 
specific cyclophilin-rich C. elegans organelles. Such an approach may be useful in 
identifying the location and function of the C. elegans multiple cyclophilin isoforms, 




(1) Walkinshaw research group members involved were Alan Paterson, Dr.
Martin Wear, Dr. Brian McHew and Prof. Malcolm Walkinshaw, Institute of 
Structural and Molecular Biology, University of Edinburgh.
(2) Dr. Tony Page, The Page Laboratory, The Anderson College, University of 
Glasgow.
(3) J. Galban, Y. Andreu, J. F. Sierra, S. de Marcos, J. R. Castillo, Luminescence, 
2001, 16, 199.
(4) J. Kallen, C. Spitzfaden, M. G. M. Zurini, G. Wilder, H. Widmer, K. 
Wuthrich, M. D. Walkinshaw, Nature, 1991, 353, 276.
(5) M. Gastmans, G. Volckaert, Y. Engelborghs, Proteins, 1999, 35, 464.
(6) H. Husi, M. G. M. Zurini, Anal Biochem., 1994, 222, 251.
(7) Photon Technology International, Unit Ml Rudford Industrial Estate, Ford 
Road, Ford, West Sussex, BN18 OBF.
(8) M. A. Wear, A. Patterson, K. Malone, C. Dunsmore, N. J. Turner, M. D. 
Walkinshaw, A nal. Biochem., 2005, in press
(9) Synergy Software, 2457 Perkiomen Avenue, Reading, PA 19606, USA.
(10) A. S. Ladokhin, Encyclopedia of Analytical Chemistry, John Wiley & Sons 
Ltd, Chichester, 2000, 5762.
(11) J. L. Kofron, P. Kuzmic, V. Kishore, E. Bonilla-Kolon, D. H. Rich, 
Biochemistry, 1991, 30, 6127.
(12) S. F. Gothel, M. A. Marahiel, CellMol Life Sci., 1999, 55, 423.
(13) J. L. Kofron, P. Kuzmic, V. Kishore, G. Gemmecker, S. W. Fesik, D. H. 
Rich, J. Am. Chem. Soc., 1992, 114, 2670.
(14) PerkinElmer UK, Chalfont Road, Seer Green, Beaconsfield, HP9 2FX.
(15) J. Liu, C.-M. Chen, C. T. Walsh, Biochemistry, 1991, 30, 2306.
(16) P. Taylor, G. Kontopidis, M. D. Walkinshaw, unpublished results.
(17) A. Bell, H. C. Roberts, L. H. Chappell, Gen. Pharmac., 1996, 27, 963.
(18) N. C. Picken, S. Eschenlauer, P. Taylor, A. P. Page, M. D. Walkinshaw, J. 
Mol. BioL, 2002, 322, 15.
(19) A. P. Page, K. MacNiven, M. O. Hengartner, Biochem. J., 1996, 377, 179.
141
(20) A. P. Page, DNA Cell Biol, 1997, 16, 1335.




TLC was performed using plastic backed plates coated with 0.2 mm thick silica gel 
60F2 54 (Mackerey-Nagel). Plates were visualised using UV light (254nm) or 
permanganate dip. Chemicals were purchased from Sigma-Aldrich, Acros or 
Novabiochem unless otherwise stated. All reagents were standard laboratory grade 
and solvents anhydrous, and used as supplied unless otherwise stated. IR absorption 
spectra were recorded on a Jasco-FT/IR-410 Spectrophotometer using standard 
techniques and vmax values are quoted in cm" 1 . 'H-NMR and 13 C-NMR were recorded 
on a Bruker AC250, AC360 or AC600 spectrometer. The following abbreviations are 
used: 5, chemical shift; d, doublet; dd, doublet of doublets; dt, doublet of triplets; J, 
coupling constant; m, multiplet; q, quartet; s, singlet; t, triplet; br, broad. Chemical 
shifts (8) are reported in parts per million (ppm) and coupling constants (J) in Hz. 
Residual protic solvent, CHCli (§H 7.26, s) was used as the internal standard in *H 
NMR spectra, and 13 C NMR shifts were referenced using CDC13 (5C 77.0, t) with 
broad band decoupling. Nominal mass spectra were recorded on a Micromass 
Platform-2 instrument under positive and negative ion electrospray conditions. Fast 
Atom Bombardment (FAB) high resolution mass spectra were recorded on a Kratos 
MS50TC instrument. Flash chromatography was carried out using silica gel 60H 
(Merck 9385, 0.04-0.063 mm, 230-400 mesh) or in parallel using pre-packed silica 
columns in a Biotage QUAD 3 purification system. High performance liquid 
chromatography (HPLC) was carried out using a Waters 486 tunable absorbance 
detector and Waters 600E controller and pump. A Chiralcel OD-H column with 
dimensions 25 x 0.46 cm was used. Samples were injected via a 20 ul loop and a 
flow rate of 1 ml/min was employed for elution using an isocratic system of 
hexane/ethanol (95:5) detecting at a wavelength of 254nm. Preparative HPLC was 
performed on a Biotage Parallex FLEX system using a Supercosil ABZ plus reverse- 
phase column of dimension 25 cm x 2.12 cm, particle size 12 uM. Samples were 
eluted using 10-90 % water (0.05 % TFA)/acetonitrile gradient over 30 minutes
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using a flow rate of 20 ml/min. Melting points were obtained on Gallenkamp melting 
point apparatus and are uncorrected. Optical rotations were performed on an Optical 
Activity Ltd AA1000 polarimeter and concentrations are given in g/100 ml.
5.2 Experimental procedures
5.2.1 N-benzyloxycarbonyl-L-valinylfluoride (33) '
O
Method A
To a stirred solution of 7V-benzyloxycarbonyl-L-valine (0.5 g, 2.0 mmol) and 
pyridine (0.16 ml, 2.0 mmol) in anhydrous DCM (5 ml) under N2 atmosphere was 
added cyanuric fluoride (0.84 ml, 10.0 mmol) at -15°C. A white precipitate formed 
after 5 minutes. The reaction mixture was allowed to warm to room temperature and 
stirred for 2 hours. Ice-cold water (5 ml) was added along with DCM (10 ml), and 
the white precipitate was removed by filtration. The organic layer was separated and 
the aqueous layer extracted with DCM (5 ml). The combined DCM layers were 
washed twice with ice-cold water (5 ml), dried (MgSO4) and the solvent removed in 
vacua to afford a colourless oil (0.45 g, 89 %) which was used in subsequent 
reactions without further purification; Rf 0.75 (10 % MeOH in DCM), vmax (thin 
film) 3323 (N-H), 1845(acid fluoride), 1738 (urethane, C=O), 1522 (amide II); 8H 
(250 MHz, CDC13) 1.03 (3H, d, J = 7.0, CH(CA//3 C BH3 )), 1.06 (3H, d, J = 7.0, 
CH(CAH3 C B//3 )), 2.17-2.26 (1H, m, C//(CH3 )2), 4.44-4.49 (1H, m, NHC/f), 5.12- 
5.14 (3H, m, OC//2Ph & N//), 7.36 (5H, s, Ar-//); MS ES (+ve) m/z 253.0 (M+H)+ .
Method B
To a stirred room temperature solution of A^-benzyloxycarbonyl-L-valine (0.5 g, 2.0 
mmol) in anhydrous DCM (5 ml) under NI atmosphere was added
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dimethylaminosulfur trifluoride (0.31 ml, 2.4 mmol). After stirring for 2 hours ice- 
cold water (5 ml) was added. The organic layer was separated and the aqueous layer 
extracted with DCM (5 ml). The combined DCM layers were washed twice with ice- 
cold water (5 ml), dried (MgSC>4) and the solvent removed in vacua to afford a 
colourless oil (0.47 g, 94 %) which was used in subsequent reactions without further 
purification; analysis identical to Method A.
5.2.2 3-(N-benzyloxycarbonyl-L-valinyl-oxy)-5,5-dimethyl-cydohex2-enone(30)
To a stirred room temperature solution of 7V-benzyloxycarbonyl-L-valinylfluoride 
(0.45 g, 1.79 mmol) in anhydrous DCM (20 ml) was added dimedone (0.25 g, 1.79 
mmol) and DIPEA (0.62 ml, 3.58 mmol). The solution went from yellow to 
blue/purple after 5 minutes. After stirring for 30 minutes, the solution was washed 
with IN HC1 (2x5 ml), saturated NaHCO3 solution (2x5 ml), water (2x5 ml), 
dried (MgSO4) and the solvent removed in vacua to give a yellow oil (0.64 g). Flash 
column chromatography on silica gel using 30 % ethyl acetate in petroleum ether 40- 
60 as eluent afforded a pale yellow oil (0.50 g, 75 %); Rf 0.60 (30 % EtOAc in 
petroleum ether 40-60); vmax(NaCl) 3326br (N-H), 1769 (vinyl ester), 1715 (urethane 
CO), 1668 (a,p-unsaturated ketone), 1532 (amide II); 5H (250 MHz, CDC13 ) 0.95 
(3H, d, J= 7.0, CH(CA//3 CBH3)), 1.02 (3H, d,J= 7.0, CH(CAH3 CB//3 )), 1.09 (6H, s, 
C(C//3 )2), 2.26-2.28 (3H, m, C#(CH3 )2 & C/6C(CH3 )2), 2.39 (2H, s, C(CH3 )2C#2), 
4.36 (1H, dd, J= 5.0, 7.5, NHCfl), 5.12 (2H, s, OC#2Ph), 5.24 (1H, d,J= 7.5, Nfl), 
5.89 (1H, s, CO=C#CO), 7.35 (5H, s, AT-//); oc (63 MHz, DEPT, CDC13 ) 17.5 
(CH(C"H3 CBH3 )), 19.0 (CH(CAH3 CBH3 )), 28.0 (C(CAH3 C BH3 )), 28.1 
(C(CAH3 CBH3 )), 30.0 (CH(CH3)2), 33.1 (C(CH3 )2), 41.9 (COCH2 C(CH3 )2), 50.7 
(C(CH3 )2 CH2CO), 60.0 (NHCH), 67.3 (OCH2Ph), 116.9 (COCHCO), 128.0 (CH), 
128.2 (CH), 128.5 [(CH), 5C, Ar-K], 135.9 (OCH2P/0, 156.1 (CONH), 167.7
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(COOC=CH), 169.1 (NHCHCO), 199.0 (COOOCHCO); HRMS FAB (+ve) m/z 
374.1962 (M+H)+, C2 iH28NO5 requires 374.1967.
5.2. 3 N-allyloxycarbonyl-L-phenylalanine (35)2
O
Method A
To a stirred solution of Z-phenylalanine (1.0 g, 6.0 mmol) in sodium bicarbonate 
solution (25ml, 0.5M) was added a solution of allyl chloroformate (0.64 ml, 6.0 
mmol) in acetonitrile (25 ml). The resulting solution was stirred at room temperature 
overnight. The acetonitrile was the removed in vacua and the remaining solution 
acidified to pH 2 with 2M HC1, then extracted with EtOAc (3 x 30 ml). The 
combined organic phases were washed with water (10 ml) and dried (MgSO4) and 
the solvent removed in vacua to give a yellow oil (0.62g). Flash column 
chromatography on silica gel using 5 % methanol in dichloromethane as eluent 
afforded a pale yellow oil (0.53 g, 35 %); 5H (250 MHz, DMSO) 2.68 (1H, dd, J = 
4.4, 14.0, C#AHBPh), 2.90 (1H, dd, J = 4.4, 14.0, CHA/^Ph), 3.95-3.97 (1H, m, 
C//CH2Ph), 4.22-4.26 (2H, m, CH2=CHC//2), 4.94-5.09 (2H, m, C//2=CHCH2), 
5.63-5.74 (1H, m, CH2=C//CH2), 7.06-7.12 (5H, m, Ar-H), 7.36 (1H, d, J = 8.4, 
N#); 5C (63 MHz, DEPT, DMSO); 37.4 (CH2Ph), 56.5 (CHCH2Ph), 65.2 
(CH2=CHCH2), 117.7 (CH2=CHCH2), [127.2 (CH), 129.0 (CH), 129.9 (CH), 5C, Ar­ 
il], 134.4 (CH2=CHCH2), 139.0 (OCH2Ph), 156.6 (CONH), 174.5 (COOH); HRMS 
FAB (+ve) m/z 250.1079 (M+H)+ , Ci 3 Hi 6NO4 requires 250.1079.
MethodB
Phenylalanine (1.0 g, 6.0 mmol) was dissolved in sodium hydroxide (10 ml, 4.0 M) 
and cooled to 0°C. Allyl chloroformate (0.64 ml, 6.0 mmol) was added over 5 
minutes, the resulting solution allowed to warm to room temperature and stirred for a 
further 30 minutes. The solution was washed with diethyl ether (20 ml) to remove
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excess unreacted allyl chloroformate, the aqueous phase then acidified to pH 2 with 
2M HC1. The aqueous phase was then extracted with diethyl ether (2 x 50 ml). The 
combined organic phases were washed with water (5 ml) and dried (MgSO4) and the 
solvent removed in vacua to give a pale yellow oil (0.97 g, 65 %); analysis identical 
to Method A.
5.2,4 N-allyloxycarbonyl-L-phenylalaninylfluoride
Experimental procedure 5.2.1.A was followed using 7V-allyloxycarbonyl-L- 
phenylalanine (0.97 g, 3.89 mmol) and cyanuric fluoride (1.64 ml, 19.4 mmol) to 
yield a pale white oil (0.78 g, 80 %); vmax (nujol) 3321 (N-H), 1846 (acid fluoride), 
1703 (urethane, C=O), 1525 (amide II).
5. 2.5 3-(N-allyloxycarbonyl-L-phenylalaninyloxy)-5,5-dimethyl-cyclohex-2-
enone (37)
Experimental procedure 5.2.2 was followed using TV-ally loxycarbonyl-L- 
phenylalaninyl fluoride (0.26 g, 1.03 mmol), dimedone (0.14 g, 1.03 mmol) and 
DIPEA (0.36 ml, 2.06 mmol) in DCM (10 ml) to yield a pale yellow oil (0.24 g, 62 
%); Rf 0.57 (50 % EtOAc in Hexane); 5H (250 MHz, CDC13) 0.93 (6H, s, C(C//3 )2), 
2.10 (2H, s, C/f2C(CH3 )2), 2.16 (2H, s, C(CH3 )2C//2), 3.00 (2H, d,J = 6.3, C//2Ph), 
4.42 (2H, d, J= 5.6, CH2=CHC//2), 4.57 (1H, dd, J = 6.3, 14.1, C//CH2Ph), 5.05- 
5.18 (3H, m, C#2=CHCH2 & COC//CO ), 5.67-5.85 (2H, m, CH2=C//CH2 & N/f),
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7.00-7.04 (2H, m, Ar-H), 7.11-7.22 (3H, m, Ar-H); 5C (63 MHz, DEPT, CDC13) 28.3 
(C(CH3 )2), 33.3 (C(CH3)2), 38.2 (CH2Ph), 41.9 (COCH2C(CH3 )2), 50.9 
(C(CH3 )2 CH2C=0), 55.2 (NHCH), 66.2 (CH2=CHCH2), 116.8 (CO=CHCO), 118.3 
(CH2=CHCH2), [127.7 (CH), 129.0 (CH), 129.4 (CH), 5C, Ar-H], 132.5 
(CH2=CHCH2), 135.1 (OCH2Ph), 155.6 (CONH), 167.7 (COOC=CH), 168.9 
(NHCHCO), 199.0 (COOC=CHCO); HRMS FAB (+ve) m/z 372.179 (M+H)+ , 
C 2 iH26NO 5 requires 372.181.
5.2.6 N-allyloxycarbonyl-1-amino-l-cydopentanecarboxylic add (36)
O
Experimental procedure 5.2.3 was followed using 1-amino-l-cyclopentanecarboxylic 
acid (1.00 g, 7.74 mmol) and allyl chloroformate (0.82 ml, 7.74 mmol) to yield a 
white solid (0.6 g, 36 % [method A], 1.15 g, 69 % [method B]); 5H (250 MHz, 
DMSO) 1.71-1.77 (4H, m, CCH2 (C/f2)2 CH2), 1.90-1.95 (2H, m, 
CC//AHB(CH2)2C//AHB), 2.14-2.25 (2H, m, CCHA/7B(CH2)2 CHA//B), 4.50 (2H, d, J 
= 5.0, CH2=CHC//2), 5.12-5.27 (2H, m, C//2=CHCH2), 5.16 (1H, s, N//), 5.78-5.91 
(1H, m, CH2=C//CH2); §c (63 MHz, DEPT, DMSO) 25.1 (CCH2(CH2)2 CH2), 38.0 
(CCH2(CH2)2 CH2 ), 66.1 (CCH2 (CH2)2CH2), 66.2 (CH2=CHCH2), 118.3 
(CH2=CHCH2), 132.9 (CH2=CHCH2), 156.0 (CONH), 176.7 (COOH); HRMS FAB 
(+ve) m/z 214.1073 (M+H)+ , Ci 0Hi 5NO4 requires 214.1079; mp 74-77°C.
5.2. 7 N-allyloxycarbonyl-1-amlno-l-cydopentylfluoride
Experimental procedure 5.2.1.A was followed using A^-allyloxycarbonyl-l-amino-1- 
cyclopentanecarboxylic acid (0.75 g, 3.5 mmol) and cyanuric fluoride (1.47 ml, 17.5 
mmol) to yield a pale yellow oil (0.60 g, 80 %); vmax (nujol) 3333 (N-H), 1838 (acid 




Experimental procedure 5.2.2 was followed using 7V-(allyloxycarbonyl)-l-amino-l- 
cyclopentyl fluoride (0.23 g, 1.1 mmol) and dimedone (0.15 g, 1.1 mmol) to yield a 
yellow oil. Flash column chromatography on silica gel using 20 % ethyl acetate in 
hexane as eluent afforded a pale yellow oil (0.25 g, 70 %); Rf 0.13 (20 % EtOAc in 
hexane); 8H (250 MHz, CDC13 ) 1.03 (6H, s, C(C//3 )2), 1.73-1.77 (4H, m, 
CCH2(C//2)2 CH2), 1.88-1.94 (2H, m, CC/fAHB(CH2)2C//AHB), 2.20 (2H, s, 
C//2C(CH3 )2), 2.22-2.26 (2H, m, CCH^CH^CH*//3), 2.37 (2H, s, 
C(CH3 )2C//2), 4.50 (2H, d, J= 5.0, CH2=CHC#2), 5.12-5.28 (2H, m, C//2=CHCH2), 
5.17 (IH, s, N//), 5.77 (IH, s, CO=C//CO), 5.76-5.89 (IH, m, CH2=C//CH2); 8C (63 
MHz, DEPT, CDC13) 24.7 (CCH2 (CH2)2 CH2), 28.5 (C(CH3 )2), 33.7 (C(CH3 )2), 38.0 
(CCH2(CH2)2 CH2), 42.1 (COCH2C(CH3)2), 51.3 (C(CH3 )2CH2OO), 66.2 
(CCH2(CH2)2 CH2), 66.7 (CH2=CHCH2), 117.1 (CO=C#CO), 118.4 (CH2=CHCH2), 
132.9 (CH2=CHCH2), 155.8 (CONH), 167.7 (COOC=CH), 171.8 (NHCHCO), 199.8 




jV-Butyllithium (39.24 ml, 0.062 mol, 1.6 M solution in hexanes) was added 
dropwise to a dry stirred solution of diisopropylamine (8.80 ml, 0.062 mol) in THF 
(40 ml) at 0°C. After 40 min the reaction was cooled to -78°C and a solution of
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dimedone (4.00 g, 0.028 mol) in DMPU (15 ml) and THF (15 ml) was added over 5 
min. After stirring for 1 hour at -78°C a solution of benzyl bromide (3.73 ml, 0.031 
mol) and sodium iodide (4.70 g, 0.031 mol) in THF (5 ml) was added over 5 min and 
the solution allowed to reach room temperature overnight. The reaction was 
quenched by water (10 ml), diluted with ether (150 ml) and washed with 2M KHSO4 
solution (2 x 20 ml). The combined aqueous phases were extracted with ether (3 x 
50 ml), and the total organic phase washed with water (15 ml), saturated NaHCO3 
solution (2 x 20 ml), brine (20 ml), dried (MgSO4) and the solvent removed in vacua 
to give a dark yellow oil. Flash column chromatography on silica gel using 30 % 
ethyl acetate in hexane as eluent yielded a yellow oil (2.21 g, 34 %); Rf 0.35 (50 % 
EtOAc in hexane); 6H (250 MHz, CDC13 ) 0.79 (3H, s, C(C A//3 C BH3 )), 1.18 (3H, s, 
C(CAH3 CB//3)), 2.47 (1H, dd, J = 1.8, 14.9, C#AHB C(CH3)2), 2.59 (1H, d,J= 14.9, 
CHA/^C(CH3)2), 2.68-2.75 (2H, m, C#C//AHBPh), 3.07 (1H, dd, J = 10.0, 14.9, 
CHCHA//BPh), 3.25 (1H, dd, J = 1.8, 16.0, COC//AHB CO), 3.34 (1H, d, J = 16.0, 
COCHA/^CO), 7.08-7.24 (5H, m, Ar-H); 5C (63 MHz, DEPT, CDC13 ) 22.9 
(C(CAH3 C BH3)), 29.7 (C(CAH3 CBH3)), 30.4 (CH2Ph), 34.9 (C(CH3 )2), 55.9 
(COCH2 C(CH3 )2), 59.3 (COCH2 CO), 63.1 (C//CH2Ph), [126.8 (CH), 129.1 (CH), 
129.6 (CH), 5C, Ar-H], 141.3 (CH2?/0, 203.5 (COCH2CO), 203.7 (COCH2CO); 
HRMS FAB (+ve) m/z 231.1386 (M+H+), C 15H 19O2 requires 231.1385.
Method B
A solution of 44 (0.37 g, 1.5 mmol) in 2M HC1 (10 ml) and THF (10 ml) was stirred 
overnight at room temperature. The solution was then extracted with ethyl acetate (3 
x 25 ml), the combined organic phases then washed with water (10 ml), saturated 
NaHCO3 solution (2x5 ml), brine (5 ml) and dried (MgSO4). The solvent was 





Chlorotrimethylsilane (1.9 ml, 0.015 mol) was added to a solution of dimedone (2.0 
g, 0.014 mol) in methanol (20 ml). Diisopropylethylamine (5.19 ml, 0.03 mol) was 
added dropwise to the solution with white HC1 fumes evolved. The solution was 
stirred at room temperature for 2 hours, the solvent then removed in vacua. The 
residue was re-dissolved in ethyl acetate then washed with water (10 ml), saturated 
NaHCO3 solution (2x10 ml), brine (10 ml), dried (MgSO4) and the solvent removed 
in vacua to give a non-viscous yellow oil (2.16 g, 98 %); Rf 0.5 (50 % EtOAc in 
DCM); 6H (250 MHz, CDC13) 1.25 (6H, s, C(C/f3)2), 2.39 (2H, s, C//2 C(CH3 )2), 2.45 
(2H, s, C//2C(CH3 )2), 3.87 (3H, s, OC//3), 5.54 (1H, s, CO=C//CO); 5C (63 MHz, 
DEPT, CDC13) 27.8 (C(CH3 )2), 32.1 (C(CH3)2), 42.2 (COCH2C(CH3 )2), 50.3 
(C(CH3 )2 CH2OO), 55.2 (OCH3 ), 100.7 (CO=C//CO), 176.5 (CH3 OC=CH), 199.8 




7V-Butyllithium (27.5 ml, 0.036 mol, 1.6 M solution in hexanes) was added dropwise 
to a dry stirred solution of diisopropylamine (5.1 ml, 0.036 mol) in THF (10 ml) at 
0°C. After 40 min the reaction was cooled to -78°C and a solution of 41 (5.0 g, 0.032 
mol) in DMPU (15 ml) and THF (5 ml) was added over 5 min. After stirring for 1 
hour at -78°C a solution of methyl iodide (6.0 ml, 0.096 mol) in THF (35 ml) and 
DMPU (25 ml) was added over 5 min and the solution allowed to reach room 
temperature overnight. The reaction was quenched by water (10ml), diluted with 
ether (150 ml) and washed with 2M KHSCU solution (2 x 20 ml). The combined
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aqueous phases were extracted with ether (2 x 100 ml) then ethyl acetate (3 x 50 ml), 
and the total organic phase washed with water (15 ml), saturated NaHCO3 solution (2 
x 20 ml), brine (20 ml), dried (MgSO4) and the solvent removed in vacuo to give a 
yellow oil. Flash column chromatography on silica gel using 30 % ethyl acetate in 
petroleum ether 40-60 as eluent afforded a yellow oil (4.57 g, 85 %); Rf 0.40 (50 % 
ethyl acetate in petroleum ether 40-60); 8H (250 MHz, CDC13 ) 0.88 (3H, s, 
C(CA//3 CBH3 )), 1.03 (3H, d,J= 7.04, CHC//3 ), 1-04 (3H, s, C(CAH3 CB#3)), 2.11 
(1H, q, J= 7.0, C//CH3 ), 2.20 (1H, d, J= 17.4, COC/^HB C(CH3 )2), 2.29 (1H, d, J = 
17.4, COCHA/^C(CH3)2), 3.64 (3H, s, C//3 O), 5.28 (1H, s, CH3 OC=C//CO); 5C (63 
MHz, DEPT, CDC13 ) 10.1 (CHCH3 ), 22.4 (C(CAH3 C BH3 ), 28.7 (C(CAH3 CBH3 ), 35.1 
(C(CH3)2), 42.3 (CH3 OCCH2C(CH3)2), 51.0 (CHCH3 ), 55.5 (CH3 O), 100.4 
(CH3 OC=CHCO), 175.3 (CH3 OC=CH), 202.2 (CH3 OC=CHCO); HRMS El (+ve) 
m/z 488.2669, C 30H36N2O4 requires 488.2675.
5.2.12 6-allyl-5,5-dimethyl-3-methoxy-cyclohex-2-enone (43)
MeO
Experimental procedure 5.2.11 was followed using jV-butyllithium (27.5 ml, 0.036 
mol, 1.6 M solution in hexanes), diisopropylamine (5.1 ml, 0.036 mol), 41 (5.0 g, 
0.032 mol) and allyl bromide (16.9 ml, 0.16 mol) in THF (35 ml) and DMPU (25 
ml). Flash column chromatography on silica gel using 30 % ethyl acetate in 
petroleum ether 40-60 as eluent afforded a yellow oil (5.41 g, 87 %); Rf 0.44 (30 % 
ethyl acetate in hexane); 6H (250 MHz, CDC13 ) 1.17 (3H, s, C(CA//3 CBH3 )), 1.26 
(3H, s, C(CAH3 C B#3)), 2.24-2.29 (1H, m, CHC//AHB CH=CH2), 2.42-2.54 (4H, m, 
C//CH2 CH=CH2 , COC//2 C(CH3 )2 , CHCHA^CH=CH2), 3.85 (3H, s, OC//3 ), 5.11- 
5.23 (2H, m, CHCH2CH=C//2), 5.47 (1H, s, CO=C//CO), 5.97-6.10 (1H, m, 
CHCH2C//=CH2); Sc (63 MHz, DEPT, CDC13 ) 24.3 (C(CAH3 C BH3 ), 28.7 
(C(CAH3 CBH3 ), 30.8 (CH2CH=CH2 ), 35.2 (C(CH3 )2), 41.7 (CH3 OCCH2C(CH3 )2 ), 
55.5 (CH3 0), 57.0 (C(CH3 )2 CH), 100.4 (CH3 OC=CHCO), 115.3 (CH2CH=CH2 ),
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137.6 (CH2 CH=CH2), 175.1 (CH3 OC=CH), 201.3 (CH3 OC=CHCO); HRMS El 
(+ve) m/z 194.1307 (M)+ , C, 2HigO2 requires 194.1307.
5.2.13 6-benzyl-5,5-dimethyl-3-methoxy-cyclohex-2-enone (44)
MeO
Experimental procedure 5.2.11 was followed using jV-butyllithium (27.5 ml, 0.036 
mol, 1.6 M solution in hexanes), diisopropylamine (5.1 ml, 0.036 mol), 41 (5.0 g, 
0.032 mol) and benzyl bromide (4.18 ml, 0.036 mol) in DMPU (10 ml) and THF (10 
ml). Flash column chromatography on silica gel using 30 % ethyl acetate in 
petroleum ether 40-60 as eluent afforded a white solid (6.91 g, 89 %); Rf 0.55 (50 % 
EtOAc in hexane); 6H (250 MHz, CDC13 ) 0.85 (3H, s, C(CA//3 C BH3)), 0.94 (3H, s, 
C(CAH3 CB//3 )), 2.14 (2H, s, C#2C(CH3)2), 2.21 (1H, dd, J = 4.0, 14.0, C#CH2Ph), 
2.53 (1H, dd, J = 8.1, 14.0, CHC//AHBPh) 2.58 (1H, dd, J = 8.1, 14.0, 
CHCH^Ph), 3.48 (3H, s, OC#3 ), 5.15 (1H, s, COC//CO), 6.94-7.11 (5H, m, Ar- 
//); 5C (63 MHz, DEPT, CDC13 ) 23.6 (C(CH3 )2), 29.1 (C(CH3 )2), 31.8 (CH2Ph), 36.0 
(C(CH3 )2), 42.6 (COCH2 C(CH3 )2), 55.7 (OCH3 ), 59.2 (CHCH2Ph), 100.7 
(COCHCO), [125.9 (CH), 128.3 (CH), 129.0 (CH), 5C, Ar-H], 141.8 (CH2Ph), 
174.9 (CH3 OC=CH), 200.7 (CH3 OC=CHCO); HRMS FAB (+ve) m/z 245.1542 
(M+H)+, C 16H2 iO2 requires 245.1542; CHN analysis expected C 78.65 %, H 
8.25 %, N 0 %, found C 78.40 %, H 8.22 %, N 0.16 %.
5.2.7^ 5,5-dimethyl-3-methoxy-6-((E)-3-phenyl-allyl)-cyclohex-2-enone (45)
MeO
jV-Butyllithium (27.5 ml, 0.036 mol, 1.6 M solution in hexanes) was added dropwise 
to a dry stirred solution of diisopropylamine (5.1 ml, 0.036 mol) in THF (10 ml) at 
0°C. After 40 min the reaction was cooled to -78°C and a solution of 41 (5.0 g, 0.032
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mol) in DMPU (15 ml) and THF (5 ml) was added over 5 min. After stirring for 1 
hour at -78°C a solution of cinnamyl bromide (12.61 g, 0.064 mol) in DMPU (10 ml) 
and THF (10 ml) was added dropwise. Addition of the cinnamyl bromide solution 
resulted in precipitate crashing out in the reaction mixture which redissolved upon 
addition of further DMPU (15 ml) and THF (15 ml). The solution was allowed to 
reach room temperature overnight. The reaction was quenched by water (10ml), 
diluted with ethyl acetate (150 ml) and washed with 2M KHSO4 solution (2 x 20 ml). 
The combined aqueous phases were extracted ethyl acetate (3 x 100 ml), and the total 
organic phase washed with water (15 ml), saturated NaHCO3 solution (2 x 20 ml), 
brine (20 ml), dried (MgSO4) and the solvent removed in vacua to give a yellow oil. 
Flash column chromatography on silica gel using 30 % ethyl acetate in hexane as 
eluent afforded a white solid (6.54 g, 76 %); Rf 0.50 (50 % EtOAc in petroleum ether 
40-60); 5H (250 MHz, CDC1 3 ) 1.25 (3H, s, C(CA//3 C BH3 )), 1.36 (3H, s, 
C(CAH3 C B//3 )), 2.41 (IH, dd, J= 4.0, 8.4, C//CH2CH=CHPh), 2.53 (2H, d,J= 2.0, 
C772C(CH3 )2), 2.61-2.77 (2H, m CHC#2CH=CHPh), 3.91 (3H, s, OC//3), 5.56 (IH, 
s, OOC/fCO), 6.49-6.58 (IH, m, CHCH2Ctf=CHPh), 6.62 (IH, d, J = 16.0, 
CHCH2 CH=C#Ph), 7.40-7.58 (5H, m, Ar-ff); 5C (63 MHz, DEPT, CDC13 ) 23.9 
(C(C4H3 CBH3 )), 28.9 (C(CAH3 CBH3 )), 29.8 (CHCH2 CH=CH2), 35.4 (C(CH3 )2), 42.2 
(CH2C(CH3)2), 55.6 (OCH3), 57.2 (CHCH2CH=CH2), 100.5 (OOCHCO), [126.0 
(CH), 126.7 (CH), 128.4 (CH), 5C, Ar-H], 129.8 (CHCH2 CH=CHPh), 130.4 
(CHCH2 CH=CHPh), 137.6 (CH2Ph\ 175.1 (H3 COQ 201.0 (CO); HRMS FAB (+ve) 
m/z 257.1541 (M+H+), Ci 7H2) O2 requires 257.1542.
5.2.75 (6,6-dimethyl-4-methoxy-2-oxo-cyclohex-3-enyl)-acetic acid tert-butyl ester 
(46)
MeO
Experimental procedure 5.2.11 was followed using jV-butyllithium (27.5 ml, 0.036 
mol, 1.6 M solution in hexanes), diisopropylamine (5.1 ml, 0.036 mol), 41 (5.0 g, 
0.032 mol) and tert-butyl bromoacetate (9.45 ml, 0.064 mol) in THF (35 ml) and
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DMPU (30 ml). Flash column chromatography on silica gel using 20 % ethyl acetate 
in hexane as eluent afforded a pale yellow oil that solidified on standing to give a 
white solid (7.39 g, 86 %); Rf 0.45 (50 % ethyl acetate in hexane); 8H (250 MHz, 
CDC13) 0.86 (3H, s, C(CA//3 CBH3)), 1.09 (3H, s, C(CAH3CB//3)), 1.46 (3H, s, 
CO2C(C//3)3), 2.13 (1H, d, J= 17.4, C#AHBC(CH3)2), 2.17 (1H, dd, J= 4.5, 16.0, 
C//CH2), 2.53 (1H, dd, J= 1.6, 17.4, CHA/^C(CH3 )2), 2.63 (1H, dd, J= 8.2, 16.0 
CHC//AHBCO2C(CH3 ) 3), 2.80 (1H, dd, J = 4.5, 8.2, CHCHA/^CO2C(CH3)3), 3.67 
(3H, s, C//3 O), 5.35 (1H, d, J= 1.6, CH3OOC//CO); 8C (63 MHz, DEPT, CDC13 ) 
21.1 (C(CAH3CBH3 ), 27.8 (OC(CH3 ) 3), 28.7 (C(C AH3 CBH3 ), 30.5 (CHCH2), 35.4 
(C(CH3 )2), 52.8 (C(CH3 )2CH), 55.4 (CH3 O), 80.1 (OC(CH3 )3), 100.6 
(CH3OC=CHCO), 172.6 (CO2C(CH3 )3), 175.1 (CH3 OC=CH), 198.8 




(diastereomers A & B)
Experimental procedure 5.2.2 was followed using 7V-benzyloxycarbonyl-L- 
valinylfluoride (0.20 g, 0.79 mmol) and 40 (0.18 g, 0.79 mmol) to yield a yellow oil. 
Flash column chromatography on silica gel using 20 % ethyl acetate in hexane as 
eluent afforded a pale yellow oil (0.26 g, 70 %); Rf 0.53 (30 % EtOAc in hexane); 8H 
(360 MHz, CDC13 ) 0.92-0.97 (3H, m, CH(C A//3 C BH3 , A & B), 1.02-1.09 (6H, m, 
CH(CAH3 CB//3) & C(CA//3 C BH3 ), A & B), 1.14 (3H, s, C(CAH3 CB//3 ), A & B), 1.97- 
2.24 (1H, m, C//(CH3 )2 , A & B), 2.40-2.45 (3H, m, C//2 C(CH3 )2 & C//CH2Ph, A & 
B), 2.77-2.80 (1H, m, CHC//AHBPh, A & B), 2.99-3.06 (1H, m, CHCH^Ph, A & 
B), 4.39 (1H, dd, J= 4.7, 8.7 NHCfl, A & B), 5.12 (2H, s, OC//2Ph, A & B), 5.24
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(1H, d, J = 8.7, N//, A & B), 5.83 (1H, s, COC//CO, A), 5.85 (1H, s, COC//CO, 
B), 7.13-7.34 (10H, m, Ar-H, A & B); 5C (63 MHz, DEPT, CDC13) 17.0 
(CHCC^HaC8^), A & B), 17.4 (CH(CAH3 CBH3 ), A & B), 23.3(C(CAH3 C BH3 ), A & 
B), 28.6 (C(CAH3 CBH3), A & B), 30.4 (CH2Ph, A), 31.0 (CH(CH3 )2 , A & B), 31.1 
(CH2Ph, B), 36.2 (C(CH3 )2 , A), 36.3 (C(CH3)2 , B), 41.6 (NHCCH2C(CH3)2 , A & B), 
59.1 (C//CH2Ph, A), 59.3 (C//CH2Ph, B), 60.3 (NHCH, A & B), 67.2 (OCH2Ph, A 
& B), 116.3 (COCHCO, A), 116.4 (CO=CHCO, B), [125.9 (CH), 128.0 (CH), 
128.2 (CH), 128.3 (CH), 128.5 (CH), 128.8 (CH), 10C, Ar-H, A & B], 135.8 
(OCH2P/z, A & B), 140.7 (CR2Ph, A & B), 156.1 (CONH, A & B), 165.5 
(COOOCH, A & B), 169.1 (NHCHCO, A & B), 200.2 (COOC=CHCO, A & B); 
MS ES (+ve) 486.3 (M+Na)+ .
5.2. J 7 3-amino-5,5-dimethyl-cyclohex-2-enone (50) s
Ammonium acetate (9.25 g, 0.28 mol) was added to a stirring suspension of 
dimedone (8.3 g, 0.06 mol) in glacial acetic acid (3 ml) and toluene (150 ml). The 
reaction mixture was heated to reflux for 2 hours and water removed azeotropically 
using Dean-Stark apparatus. After cooling to room temperature the solution was 
washed with saturated NaHCO3 solution (2 x 20 ml), a precipitate formed upon 
washing that was collected by filtration each time and combined to give a yellow 
solid. The solid was recrystallised from EtOAc (50ml), collected by filtration then 
washed with Et2O (2x10 ml) and dried under reduced pressure to yield a pale 
yellow powder (7.83 g, 94 %); Rf 0.1 (10 % MeOH in DCM); 8H (250 MHz, CDC13 ) 
0.97 (6H, s, C(C#3 )2), 1-92 (2H, s, C/f2 C(CH3 )2), 2.13 (2H, s, C(CH3 )2C//2), 4.92 
(1H, s, NH2 C=C//CO), 6.7-7.2 (2H, s, br, N//2); 5C (63 MHz, DEPT, CDC13); 28.9 
(C(CH3 )2), 33.1 (C(CH3 )2), 42.4 (H2NCCH2C(CH3 ) 2), 50.7 (C(CH3 )2 CH2CO), 96.7 
(H2NC=CHCO), 176.5 (NH2C=CH), 195.0 (NH2C=CHCO); HRMS FAB (+ve) m/z 
140.1075 (M+H)+, C 8Hi 4NO requires 140.1075; CHN analysis expected C 69.03 %,
156
H 9.41 %, N 10.06 %, found C 69.31 %, H 9.59 %, N 10.05 %; mp 166-168°C (lit 
164-165°C).
5.2.18 Attempted preparation of 3-(N-benzyloxycarbonyl-L-valinyl-amino)-5,5- 
dimethyl-cyclohex-2-enone (62)
To a stirred solution of ./V-benzyloxycarbonyl-L-valine (0.9 g, 3.6 mmol) and 1- 
hydroxybenzotriazole (0.54 g, 4.0 mmol) in DMF was added N,N'- 
dicyclohexylcarbodiimide (0.82 g, 4.0 mmol) and 50 (0.5 g, 3.6 mmol). The solution 
was stirred overnight at room temperature. TLC analysis (50 % EtOAc in petroleum 
ether 40-60) indicated starting materials only. MS ES (+ve) 140.2 (50+H)+ .
Method B
N-benzyloxycarbonyl-L-valine (0.5 g, 2.0 mmol) and 1-hydroxybenzotriazole ((0.27 
g, 2.0 mmol) were dissolved in DMF and EDCI (0.38 g, 2.0 mmol) and 50 (0.3 g, 2.1 
mmol) were added. The solution was stirred overnight at room temperature. TLC 
analysis (50 % EtOAc in petroleum ether 40-60) indicated starting materials only. 
MS ES (+ve) 140.2 (50+H)+ .
Method C
To a stirred solution of 7V-carboxybenzyloxy-L-valine (0.9 g, 3.6 mmol), 1- 
hydroxybenzotriazole (0.54 g, 4.0 mmol) and DIPEA (0.93 ml, 5.4 mmol) in DMF 
was added TBTU (1.27 g, 4.0 mmol) and 50 (0.5 g, 3.6 mmol). The resulting 
solution was stirred overnight at room temperature. TLC analysis (50 % EtOAc in 





Experimental procedure 5.2.2 was followed using W-benzyloxycarbonyl-L-valinyl 
fluoride (0.48 g, 1.9 mmol), 50 (0.26 g, 1.9 mmol) and DIPEA (0.65 ml, 3.8 mmol) 
in DCM (20 ml). Flash column chromatography on silica gel using 20 % ethyl 
acetate in petroleum ether 40-60 as eluent afforded a pale yellow oil that solidified 
upon standing (0.28 g, 40 %); Rf 0.22 (50 % EtOAc in petroleum ether 40-60); 8H 
(250 MHz, CDC13) 0.98 (3H, d, J = 6.8, CH(CA//3 CBH3 )), 1.01 (3H, d, J = 6.8, 
CH(CAH3 CB/f3)), 1.08 (6H, s, C(CH3)2), 2.15-2.19 (1H, m, C#(CH3)2), 2.25 (2H, s, 
C//2 C(CH3 )2), 2.37 (2H, s, C(CH3 )2C//2), 4.14 (1H, dd, J = 5.0, 7.5, NHC//), 5.19 
(2H, s, OC//2Ph), 5.67 (1H, d, br, J = 7.5, N#), 6.69 (1H, s, NHC-C//CO), 7.42 
(5H, s, Ar-#), 5.67 (1H, s, br, N/f); 5C (63 MHz, DEPT, DMSO) 18.8 
(CH(CAH3 C BH3 )), 21.6 (CH(CAH3 CBH3 )), 28.5 (C(CAH3 C BH3 )), 28.8 
(C(CAH3 CBH3)), 31.0 (CH(CH3 )2), 33.1 (C(CH3)2), 42.0 (NHCCH2 C(CH3 )2), 50.9 
(C(CH3 )2 CH2C=O), 61.8 (NHCH), 66.4 (OCH2Ph), 110.4 (HNC=CHCO), [128.5 
(CH), 128.7 (CH), 129.2(CH), 5C, Ar-H], 137.8 (OCH2Ph), 154.65 (NHC=CH), 
157.2 (CONH), 173.4 (NHCHCO), 199.0 (NHC=CHCO); HUMS El (+ve) m/z 
372.2044 (M)+, C2 iH28N2O4 requires 372.2049.
Method B
To a stirred solution of vV-benzyloxycarbonyl-L-valine (0.82 g, 3.3 mmol), 50 (0.5 g, 
3.6 mmol) and DIPEA (1.14 ml, 6.6 mmol) was added PyBOP (1.7 g, 3.3 mmol). 
After stirring for 2 h at room temperature the solution was washed with 1M KHSCU 
solution (2x5 ml), saturated NaHCO3 solution (2x5 ml), water (2x5 ml), dried 
(MgSC>4) and the solvent removed in vacua to give a dark yellow oil (2.13 g). Flash
158
column chromatography on silica gel using 30 % ethyl acetate in hexane as eluent 
afforded a pale yellow solid (0.57 g, 47 %). Analysis identical to Method A.
Method C
W-Benzyloxycarbonyl-L-valine (0.151 g, 0.6 mmol), PyBroP (0.279 g, 0.6 mmol) 
and DMAP (0.146 mg, 1.2 mmol) were dissolved in DCM (5ml) and stirred at room 
temperature. After 5 minutes, 50 (0.055 g, 0.4 mmol) was added and the solution 
stirred at room temperature. After 2 hours the DCM was evaporated in vacuo and 
EtOAc (5 ml) was added to the residue. A white precipitate formed which dissolved 
upon addition of water (2 ml). The organic layer was separated and washed with 1M 
KHSO4 solution (2 ml), water (2 ml), saturated NaHCO3 solution (2 ml), water (2 
ml), dried (MgSC>4) and the solvent removed in vacuo to give a yellow oil. Flash 
column chromatography on silica gel using 40 % ethyl acetate in hexane as eluent 




Experimental procedure 5.2.2 was followed using JV-(allyloxycarbonyl)-L- 
phenylalaninyl fluoride (0.26 g, 1.03 mmol), 50 (0.14 g, 1.03 mmol) and DIPEA 
(0.36 ml, 2.06 mmol) in DCM (10 ml) to yield a pale yellow solid. Flash column 
chromatography on silica gel using 50 % ethyl acetate in hexane as eluent afforded a 
white solid (0.30 g, 79 %); Rf = 0.22 (50 % EtOAc in Hexane); 8H (250 MHz, 
CDC13 ) 1.03 (6H, s, C(C#3 )2), 1-98 (2H, s, C//2C(CH3 )2), 2.20 (2H, s, C(CH3 )2CH2), 
3.09 (2H, d, J = 7.3, CHC//2Ph), 4.48 (1H, dd, J= 7.3, 7.5, C//CH2Ph), 4.55 (2H,
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ddd, J = 1.3, 1.4, 5.6, CH2=CHC//2), 5.24 (1H, ddd, J = 1.3, 1.4, 10.4, 
C//AHB=CHCH2), 5.29 (1H, ddd, J= 1.3, 1.4, 14.8, CHA/^=CHCH2), 5.64 (1H, d, J 
= 7.5, N#), 5.88 (1H, ddd, J = 5.6, 10.4, 14.8, CH2=C//CH2), 6.67 (1H, s, 
NHC=C//CO), 7.17-7.21 (2H, m, Ar-//), 7.26-7.32 (3H, m, Ar-#), 8.03 (1H, s, br, 
NH); 8C (63 MHz, DEPT, CDC13 ) 27.6 (C(CAH3 CBH3 )), 28.0 (C(CAH3 CBH3 )), 32.3 
(C(CH3 )2), 37.9 (CH2Ph), 41.7 (NHCCH2C(CH3)2), 50.0 (C(CH3 )2CH2OO), 56.8 
(C//CH2Ph), 65.8 (CH2=CHCH2), 111.2 (CO=CHCO), 117.81 (CH2=CHCH2), 
[126.9 (CH), 128.5 (CH), 128.8 (CH), 5C, Ar-H], 135.4 (CH2=CHCH2), 135.4 
(OCH2/>/0, 152.2 (NHOCH), 155.6 (CONH), 170.21 (NHCHCO), 199.6 




Experimental procedure 5.2.2 was followed using jV-(allyloxycarbonyl)-l-amino-l- 
cyclopentyl fluoride (0.6 g, 2.8 mmol), 50 (0.39 g, 2.8 mmol) and DIPEA (0.97 ml, 
5.6 mmol) in DCM (20 ml). Flash column chromatography on silica gel using 20 % 
ethyl acetate in hexane as eluent afforded a white solid (0.20 g, 21 %); Rf 0.18 (50% 
EtOAc in hexane); 5H (250 MHz, CDC13 ) 1.01(6H, s, C(C//3 )2 ), 1.70-1.78 (4H, m, 
CCH2(C//2)2CH2), 1.91-1.98 (2H, m, CC//AHB(CH2)2C//AHB), 2.16 (2H, s, 
C//2C(CH3 )2), 2.19-2.27 (2H, m, CCHA//? (CH2 )2 CHA/fB ), 2.32 (2H, s, 
C//2C(CH3 )2), 4.52 (2H, d,J = 5.6, CH2=CHC//2), 5.15-5.21 (2H, m, C//2=CHCH2 ), 
5.28 (1H, s, NHOC//CO), 5.78-5.91 (1H, m, CH2=C//CH2), 6.55 (1H, s, Nfl), 8.98 
(1H, s, N/f>; 5C (63 MHz, DEPT, CDC13 ) 23.7 (CCH2 (CH2)2 CH2), 28.4 (C(CH3 )2), 
32.8 (C(CH3)2), 36.5 (CCH2(CH2)2 CH2), 42.6 (COCH2C(CH3 )2), 50.7 
(C(CH3 )2 CH2C=0), 66.4 (CH2=CHCH2 ), 68.5 (CCH2 (CH2 )2 CH2), 111.1 
(NHC=C//CO), 118.51 (CH2=CHCH2), 132.2 (CH2=CHCH2), 153.7 (NHC=CHCO),
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156.6 (CONH), 172.7 (NHCOO), 199.8 (NHC=CHCO); HRMS FAB (+ve) m/z 
335.1972 (M+H)+, Ci 8H27N2O4 requires 335.1971.
5.2.22 5,5-dimethyl-3-(methylamino)-cyclohex-2-enone (6S) 6
Experimental procedure 5.2.17 was followed using methylamine (1.2 ml, 14 mmol, 
40 % solution in water) and dimedone (1.0 g, 7 mmol) in glacial acetic acid (2 ml) 
and toluene (30 ml) to yield a yellow solid. Recrystallisation from ethyl acetate gave 
a pale yellow powder (0.69 g, 65 %); 8H (250 MHz, DMSO) 1.25 (6H, s, C(C//3 )2), 
2.13 (2H, s, C//2C(CH3 )2), 2.32 (2H, s, C(CH3 )2C//2), 2.77 (3H, d, J = 4, C#3NH), 
4.91 (1H, s, CO=C//CO), 7.18 (1H, d, J = 4, CH3N//); 5C (63 MHz, DEPT, DMSO) 
28.8 (C(CH3 )2), 29.7 (CH3NH), 33.15 (C(CH3 )2), 42.8 (COCH2C(CH3 )2), 51.2 
(C(CH3 )2 CH2C=O), 93.9 (CO=C//CO), 164.5 (NH2C=CH), 194.5 (CH3 OC=CHCO); 
HRMS FAB (+ve) m/z 154.1229 (M+H)+, C 9Hi 6NO requires 154.1232; CHN 
analysis expected C 70.55 %, H 9.87 %, N 9.14 %, found C 70.26 %, H 9.73 %, N 
9.28 %; mp 154-156°C (lit 153-154°C).
5.2.23 3-(N-allyloxycarbonyl-L-phenylalaninyl-methylamino)-5,5-dimethyl- 
cyclohex-2-enone (66)
Experimental procedure 5.2.2 was followed using jV-allyloxycarbonyl-L- 
phenylalaninyl fluoride (0.26 g, 1.0 mmol) and 65 (0.16 g, 1.0 mmol) and DIPEA 
(0.36 ml, 2.0 mmol) in DCM (10 ml). Flash column chromatography on silica gel
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using 50 % ethyl acetate in hexane as eluent afforded a yellow oil (0.07 g, 18 %); Rf 
0.47 (50 % EtOAc in Hexane); 5H (250 MHz, CDC13) 0.94 (3H, s, C(CA#3 CBH3)), 
0.98 (3H, s, C(CAH3 CB//3 )), 2.30 (2H, d, ,7= 18.1, C//AHBC(CH3 )2), 2.15 (2H, d,J = 
3.6, C/f2C(CH3)2), 2.30 (2H, d, J= 18.1, CHA/^C(CH3)2), 2.89 (3H, s, NC//3), 2.93 
(2H, d,J = 8.2, CHC//2Ph), 4.47 (2H, dd,J= 1.3, 5.5, CH2=CHC//2 ), 4.70-4.76 (1H, 
dd, 7= 8.2, 8.5, C//CH2Ph), 5.14 (2H, ddd,J= 1.3, 1.4, 10.4, CHA/^=CHCH2), 5.22 
(2H, dd, ,7= 1.4, 16.0, CHA/^=CHCH2), 5.36 (1H, s, NC=C#CO), 5.42 (1H, d, J = 
8.5, N/0, 5.82 (1H, ddd, J= 5.5, 10.4, 16.0, CH2=C//CH2), 7.06-7.10 (2H, m, Ar-H), 
7.19-7.25 (3H, m, Ar-H); 5C (63 MHz, DEPT, CDC13) 27.7 (C(CAH3 CBH3)), 28.3 
(C(CAH3 CBH3 )), 32.2 (C(CH3 )2), 35.1 (NCH3 ), 40.6 (CH2Ph), 42.6 
(NCCH2C(CH3)2), 50.8 (C(CH3 )2 CH2C=O), 60.5 (C//CH2Ph), 65.9 (CH2=CHCH2), 
112.0 (CH2=CHCH2), 123.6 (NC=CHCO), [127.5 (CH), 128.9 (CH), 129.5 (CH), 
5C,Ar-H\, 132.6 (CH2=CHCH2), 136.0 (OCH2/Vi), 155.4 (NOCH), 159.8 (CONH), 
171.5 (NHCHCO), 199.2 (NC=CHCO); MS ES (+ve) 407.3 (M+Na)+ .
5.2.24 4,5,5-trimethyl-cyclohexane-l,3-dione (73) 3
O ^^ O
A solution of 42 (4.57 g, 0.027 mol) in 2M HCI (30 ml) and THF (30 ml) was stirred 
overnight at room temperature. TLC analysis showed some starting material 
remaining so further 2M HCI (20 ml) was added and the solution stirred for 1 hour. 
The solution was then extracted with ethyl acetate (3 x 50 ml), the combined organic 
phases then washed with water (20 ml), saturated NaHCO3 solution (2 x 20 ml), 
brine (20 ml) and dried (MgSO4). The solvent was removed in vacua to yield a white 
solid (3.59 g, 86 %); Rf 0.20 (50 % ethyl acetate in petroleum ether 40-60); 8H (250 
MHz, CDC13 ) 0.75 (3H, s, C(C A//3 C BH3 )), 1.11 (3H, s, C(C AH3 C B//3 )), 1.12 (3H, d, 
J = 7.2, CHC//3 ), 2.20 (1H, q, J = 7.2, C//CH3 ), 2.51 (1H, dd, J = 14.7, 2.0, 
COC/^HBC(CH3)2), 2.61 (1H, d, J = 14.7, COCHA/^C(CH3)2), 3.30 (1H, dd, J = 
16.8, 2.0, COC//ACHBCO), 3.40 (1H, d, J = 16.8, COCHAC7^CO); 5C (63 MHz,
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DEPT, CDC13) 8.8 (CHCH3), 21.4 (C(CAH3 CBH3)), 28.5 (C(CAH3 CBH3)), 33.7 
(C(CH3 )2), 54.0 (CHCH3 ), 55.3 (COCH2C(CH3 )2), 57.5 (COCH2CO), 203.5 (CO), 
205.3 (CO); HRMS FAB (+ve) found m/z 155.1071, C9H, 5O2 requires 155.1072.
5.2.25 4-allyl-5,5-dimethyl-cyclohexane-l,3-dione (74?
O
A solution of 43 (5.14 g, 0.028 mol) in 2M HC1 (30 ml) and THF (30 ml) was stirred 
at room temperature for 2 hours. TLC analysis showed some starting material 
remaining so further 2M HC1 (20 ml) was added and the solution stirred overnight. 
The solution was extracted with ethyl acetate (3 x 50 ml), the combined organic 
phases then washed with water (20 ml), saturated NaHCO3 solution (2 x 20 ml), 
brine (20 ml) and dried (MgSO4). The solvent was removed in vacua to yield a pale 
yellow oil (4.44 g, 88 %); Rf 0.20 (50 % ethyl acetate in petroleum ether 40-60); 8H 
(250 MHz, CDC13 ) 0.83 (3H, s, C(CA//3 C BH3 )), 1.11 (3H, s, C(CAH3 CB#3 )), 2.24- 
2.35 (1H, m, CHC#AHBCH=CH2), 2.43-2.55 (4H, m, C//CH2 CH=CH2; 
COC//2C(CH3 )2 , CHCHA/^CH=CH2), 3.32 (1H, dd, J 16.5, 1.5, COC//AHBCO), 
3.41 (1H, d, J 16.5, COCH^CO), 4.98-5.12 (2H, m, CHCH2CH=C//2), 5.76-5.87 
(1H, m, CHCH2 C//=CH2); 5C (63 MHz, DEPT, CDC13 ) 22.8 (C(CAH3 C BH3 )), 28.8 
(C(CAH3 CBH3 )), 28.9 (CHCH2CH=CH2), 33.6 (C(CH3 )2), 54.4 (COCH2C(CH3 )2 ), 
57.9 (COCH2CO), 60.0 (CHCH2CH=CH2), 116.3 (CHCH2CH=CH2), 136.3 
(CHCH2CH=CH2), 203.0 (CO), 203.9 (CO); HRMS FAB (+ve) m/z 181.1228 
(MH+), C nHI7O2 requires 181.1228.
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5.2.26 5,5-dimethyl~4-((E)-3-phenyl-allyl)-cyclohexane-l,3-dione(75)
2M HC1 (30 ml) was added to a stirred solution of 45 (5.5 g, 0.02 mol) in THF (30 
ml) at room temperature. Addition of the HC1 resulted in some white precipitate 
formation which redissolved after stirring for 10 minutes. After 1 hour TLC analysis 
showed some starting material remaining so further 2M HC1 (20 ml) was added and 
the solution stirred overnight. The solution was extracted with ethyl acetate (3 x 50 
ml), the combined organic phases then washed with water (20 ml), saturated 
NaHCO3 solution (2 x 20 ml), brine (20 ml) and dried (MgSO4). The solvent was 
removed in vacuo to yield a yellow oil (4,87 g, 95 %); Rf 0.36 (50 % ethyl acetate in 
hexane); 5H (250 MHz, CDC13 ) 0.82 (3H, s, C(CA//3 CBH3)), 1.15 (3H, s, 
C(CAH3 CB//3)), 2.15-2.74 (5H, m, COC//2C(CH3)2, C//CH2CH=CHPh, 
CHC//2CH=CHPh), 3.33 (1H, dd, J = 1.5, 16.3, COC#AHB CO), 3.44 (1H, d, J = 
16.3, COCH^CO), 6.15-6.23 (1H, m, CHCH2C//=CHPh), 6.40 (1H, d, 7= 16.0, 
CHCH2CH=C#Ph) 7.14-7.29 (5H, m, Ar-#); 5C (63 MHz, DEPT, CDC13) 22.6 
(C(CAH3 C BH3 )), 27.9 (C(CAH3 CBH3 )), 28.8 (CHCH2 CH=CH2), 33.8 (C(CH3)2), 54.9 
(COCH2 C(CH3)2), 58.2 (COCH2CO), 60.1 (CHCH2CH=CH2), [126.8 (CH), 129.1 
(CH), 129.6 (CH), 5C, Ar-H], 128.1 (CHCH2 CH=CHPh), 131.6 
(CHCH2CH=CHPh), 137.0 (CH2Ph), 203.0 (CO), 203.8 (CO); HRMS FAB (+ve) 
m/z 257.1541 (M+H+), C, 7H2 iO2 requires 257.1541.
5.2.27 (6,6-dimethyl-2,4-dioxo-cyclohexyl)-acetic acid tert-butyl ester (76)
2M HC1 (30 ml) was added to a stirred solution of 46 (5.9 g, 0.022 mol) in THF (30 
ml) at room temperature. After 1 hour TLC analysis showed some starting material 
remaining so further 2M HCl (20 ml) and THF (20 ml) was added and the solution
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stirred overnight. The solution was extracted with ethyl acetate (3 x 50 ml), the 
combined organic phases then washed with water (20 ml), saturated NaHCO3 
solution (2 x 20 ml), brine (20 ml) and dried (MgSO4). The solvent was removed in 
vacua to yield a yellow oil (5.26g, 94 %); Rf 0.43 (50 % ethyl acetate in hexane); 6H 
(250 MHz, CDC13) 0.69 (3H, s, C(CA//3 CBH3 )), 1.15 (3H, s, C(CAH3CB//3)), 1.47 
(9H, s, CO2C(C//3)3 ), 2.31 (1H, dd, J = 3.8, 16.7, C(CH3 )2C#), 2.46 (1H, dd, J= 2.5, 
14.7, COC//AHB C(CH3)2), 2.68 (1H, dd, J = 9.4, 16.7, C(CH3)2CHC//ACHB), 2.75 
(1H, d, J = 14.7, COCHA/^C(CH3 )2), 3.14 (1H, dd, J = 3.8, 9.4, 
C(CH3 )2CHCHA^B), 3.27 (1H, dd, J = 2.5, 16.5, COC//AHBCO), 3.51 (1H, d,J = 
16.5, COCHA/^CO); 5C (63 MHz, DEPT, CDC13) 21.0 (C(CAH3 CBH3), 27.9 
(OC(CH3 ) 3 ), 28.2 (C(CAH3 CBH3 ), 29.9 (CHCH2), 33.4 (C(CH3 )2), 55.6 
(C(CH3 )2 CH), 55.9 (OCCH2CCH3 ), 58.1 (OCCH2CO) 80.9 (OC(CH3 )3 ), 171.9 
(CO2C(CH3 ) 3 ), 202.8 (CO), 202.9 (CO); MS ES (+ve) 255.0 (M+H)+ , (-ve) 253.0 
(M-H)'.
5.2.28 3-amino-4,5,5-trimethyl-cyclohex-2-enone (77)
Experimental procedure 5.2.17 was followed using 73 (3.50 g, 0.023 mol) and 
ammonium acetate (3.50 g, 0.046 mmol) in glacial acetic acid (2 ml) and toluene 
(100 ml) to give a viscous yellow oil. Recrystallisation from ethyl acetate afforded a 
pale yellow powder (2.92 g, 83 %); Rf 0.42 (10 % MeOH in DCM); 5H (250 MHz, 
CDC13 ) 0.89 (3H, s, C(C A//3 CBH3)), 1.02 (3H, d, J = 7.1, CHC//3 ), 1.03 (3H, s, 
C(CAH3 C B//3 )), 2.01 (1H, q, J = 7.1, C//CH3 ), 2.14 (1H, d, J = 16.8, 
H2NC//AHBC(CH3 )2), 2.22 (1H, d, J = 16.8, HzNCH^CCCHjfc), 5.12 (1H, s, 
H2NOC//CO), 5.22 (1H, s, br, N//2); 6C (63 MHz, DEPT, CDC13 ) 10.2 (CHCH3 ), 
23.2 (C(CAH3C BH3 ), 28.6 (C(CAH3 CBH3 ), 35.1 (C(CH3 )2), 41.4 (H2NCCH2 C(CH3 )2), 
50.0 (CHCH3), 97.6 (H2NOCHCO), 163.5 (H2NC=CH), 200.6 (H2NC=CHCO); 
HRMS FAB (+ve) 153.1152, C9Hi 5NO requires 153.1153; CHN analysis expected C
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70.55 %, H 9.87 %, N 9.14 %, found C 69.21 %, H 9.79 %, N 8.92 %; mp 122- 
124°C.
5.2.29 6-allyl-3-amino-5,5-dimethyl-cyclohex~2-enone (78)
Experimental procedure 5.2.17 was followed using 74 (4.20 g, 0.023 mol) and 
ammonium acetate (3.50 g, 0.046 mol) in glacial acetic acid (2 ml) and toluene (100 
ml) to give a viscous dark yellow oil. Recrystalisation from ethyl acetate afforded a 
white powder (3.63 g, 88 %); SH (360 MHz, CDC13) 0.97 (3H, s, C(C A#3 CBH3)), 
1.05 (3H, s, C(CAH3 CB#3)), 1.96 (IH, t, J= 6.7, C//CH2 CH=CH2), 2.07 (IH, d, J = 
17.0, H2NCC//AHBC(CH3 )2), 2.25-2.34 (2H, t, J= 6.7CHC//2 CH=CH£), 2.31 (IH, d, 
J= 17.0, H2NCCHA/^C(CH3)2), 4.87-5.02 (2H, m, CHCH2CH=C//2), 5.12 (IH, s, 
H2 NC=C#CO), 5.17 (2H, s, br, N/fc), 5.82-5.93 (IH, m, CHCH2 C//=CH2); Sc (63 
MHz, DEPT, CDC13) 24.9 (C(CAH3 C BH3), 28.9 (C(CAH3 CBH3), 31.8 (CH2 CH=CH2), 
35.4 (C(CH3 )2), 41.1 (NH2 CCH2 C(CH3 )2), 55.9 (C(CH3 )2 CH), 98.0 (H2NOCHCO), 
114.9 (CH2CH=CH2), 138.1 (CH2CH=CH2), 162.8 (H2NC-CH), 199.7 
(H2NC=CHCO); HRMS El (+ve) m/z 179.1306, CnHi 9NO requires 179.1310; CHN 
analysis expected C 73.70 %, H 9.56 %, N 7.81 %, found C 73.37 %, H 9.43 %, N 
8.08%;mpl08-110°C.
5.2.30 3-amino-6-benzyl-5,5-dimethyl-cyclohex-2-enone (79)
Experimental procedure 5.2.17 was followed using 40 (0.28 g, 1.2 mmol) and 
ammonium acetate (0.18 g, 2.4 mmol) in glacial acetic acid (0.25 ml) and toluene (15 
ml) to give a viscous yellow oil. Recrystalisation from ethyl acetate afforded a pale
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yellow powder (0.24 g, 86 %); Rf 0.48 (10 % MeOH in DCM); 6H (250 MHz, 
CDC13) 0.94 (3H, s, C(CA//3 C BH3 )), 1.01 (3H, s, C(CAH3 C B//3)), 2.11 (2H, s, 
C//2C(CH3 )2), 2.22 (1H, dd, J = 4.4, 7.7, C//CH2Ph), 2.64 (1H, dd, J = 4.4, 14.0, 
CHC/^HBPh), 2.94 (1H, dd, J = 7.7, 14.0, CHCHA/^Ph), 4.64 (2H, s, NH2), 5.08 
(1H, s, NH2 C=C//CO), 7.06-7.19 (5H, m, Ar-H); 5C (63 MHz, DEPT, CDC13) 23.8 
(C(CAH3CBH3)), 28.9 (C(CAH3 CBH3)), 32.4 (CH2Ph), 36.0 (C(CH3)2), 41.7 
(NH2CC//2C(CH3 )2), 57.9 (C//CH2Ph), 98.0 (NH2C=CHCO), [125.4 (CH), 
127.9(CH), 128.9 (CH), 5C, Ar-H], 142.1 (CH2Ph\ 162.0 (NH2OCHCO), 198.9 
(NH2 C=CHCO); HRMS ES (+ve) m/z 229.1463 M+, C 15Hi 9NO requires 229.1466; 
mp 127-130°C.
5.2.31 4-amino-6-((E)-3-phenyl-allyl)-5,5-dimethyl-cyclohex-2-enone(80)
Experimental procedure 5.2.17 was followed using 75 (5.04 g, 0.020 mol) and 
ammonium acetate (3.03 g, 0.040 mol) in glacial acetic acid (2 ml) and toluene (150 
ml) to give a yellow solid. Recrystalisation from ethyl acetate afforded a white 
powder (4.34 g, 85 %); 5H (250 MHz, CDC13 ) 1.27 (3H, s, C(CA//3 C BH3)), 1.35 (3H, 
s, C(CAH3 CB//3 )), 2.33 (1H, d, J= 7.9, C/^HB C(CH3 )2), 2.34 (1H, dd, J = 5.0, 7.8, 
C(CH3 )2C#), 2.51 (1H, d, J = 7.9, CHA/^C(CH3 )2), 2.70-2.83 (2H, m, 
CHC//2CH=CHPh), 5.09 (2H, s, N//2), 5.43 (1H, s, H2NC=C//CO), 6.47-6.65 (2H, 
m, CHCH2 C#=CM>h), 7.40-7.58 (5H, m, Ar-H); 5C (63 MHz, DEPT, CDC13 ) 24.6 
(C(CAH3 CBH3 )), 30.0 (C(CAH3 CBH3 )), 30.9 (CHCH2CH=CH2), 35.5 (C(CH3 )2), 41.4 
(H2NCCH2C(CH3 )2), 56.1 (CHCH2CH=CH2), 98.3 (H2NOCHCO), [126.0 (CH), 
126.7 (CH), 128.4 (CH), 5C, Ar-H], 130.0 (CHCH2 CH=CHPh), 130.2 
(CHCH2CH=CHPh), 137.7 (CH2Ph), 162.5 (H2NQ, 200.0 (CO); HRMS El (+ve) 
m/z 255.1621, Ci 7H2 ,NO requires 255.1623; CHN analysis expected C 79.96 %, H 
8.29 %, N 5.49 %, found C 79.77 %, H 8.27 %, N 5.51 %; mp 145-148°C.
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5.2.32 (4-amino-6,6-dimethyl-2-oxo-cyclohex-3enyl)-acetic acid tert-butyl ester 
(81)
Experimental procedure 5.2.17 was followed using 76 (3.0 g, 0.012 mol) and 
ammonium acetate (1.8 g, 0.024 mol) in glacial acetic acid (2 ml) and toluene (100 
ml) to give a dark yellow solid. Recrystallisation from ethyl acetate afforded a white 
powder (2.43 g, 80 %); 5H (250 MHz, CDC13 ) 0.86 (3H, s, C(C A//3 C BH3 )), 1.06 (3H, 
s, C(CAH3 CB//3 )), 1.45 (9H, s, CO2C(C//3 ) 3 ), 2.00 (IH, d, J = 16.6, 
NH2CC//AHBC(CH3 )2), 2.13 (IH, dd, J = 4.5, 15.6, CHC//AHB CO2C(CH3 )3), 2.48 
(IH, d, J = 16.6, NH2CCHA/^C(CH3 )2), 2.59 (IH, dd, J = 8.0, 15.6, 
CHCHA/^C02 C(CH3)3 ), 2.70 (IH, dd, J= 4.5, 8.0, C//CH2), 4.99 (2H, s, br, N#2), 
5.12 (IH, d, J = 1.0, NH2OC#CO); 6C (63 MHz, DEPT, CDC13) 21.4 
(C(CAH3 CBH3 ), 27.9 (OC(CH3 ) 3 ), 28.9 (C(CAH3 CBH3 ), 31.2 (CHCH2), 35.6 
(C(CH3)2), 43.9 (CH2C(CH3)2), 51.9 (C(CH3)2CH), 79.9 (OC(CH3)3), 98.0 
(NH2C=CHCO), 162.7 (NH2 C=CHCO), 173.2 (CO2C(CH3)3), 196.9 
(NH2C=CHCO); HRMS El (+ve) m/z 253.1679, C 14H23NO3 requires 253.1677; mp 
142-145°C.
5.2. 33 6-allyl-3-(N-benzyloxycarbonyl-L-valinyl-amino)-5,5-dimethyl-cydohex-2- 
enone (82)
(diastereomers A & B)
yV-benzyloxycarbonyl-L-valine (0.146 g, 0.58 mmol), PyBroP (0.270 g, 0.58 mmol) 
and DMAP (0.143 mg, 1.17 mmol) were dissolved in DCM (5ml) and stirred at room 
temperature. After 5 minutes, 78 (0.069 g, 0.39 mmol) was added and the solution
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stirred at room temperature. After 2 hours the DCM was evaporated in vacuo and 
EtOAc (5 ml) was added to the residue. A white precipitate formed which dissolved 
upon addition of water (2 ml). The organic layer was separated and washed with 1M 
KHSO4 solution (2 ml), water (2 ml), saturated NaHCO3 solution (2 ml), water (2 
ml), dried (MgSO4) and the solvent removed in vacuo to give a yellow oil. Flash 
column chromatography on silica gel using 30 % ethyl acetate in petroleum ether 40- 
60 as eluent afforded a white solid (0.148 g, 92 %). 5C (63 MHz, DEPT, DMSO) 
17.7 (CH(C4H3 CBH3 ), A & B), 19.3 (CH(CAH3 CBH3 ), A & B), 24.1 (C(CAH3 CBH3 ), 
A & B), 28.6 (C(CAH3 CBH3), A & B), 30.4 (CH2CH=CH2 , A & B), 30.7 (CH(CH3 )2 , 
A & B), 35.5 (C(CH3)2 , A & B), 41.3 (NHCCH2C(CH3)2 , A & B), 56.7 (C(CH3)2CH, 
A & B), 61.1 (NHCH, A & B), 67.4 (PhCH2 O, A & B), 111.0 (HNOCHCO, A & 
B), 115.5 (CH2CH=CH2 , A & B), [127.9 (CH), 128.4 (CH), 128.6 (CH), 5C, Ar-H, A 
& B], 135.7 (PhCH2O, A & B), 137.4 (CH2 CH=CH2 , A & B), 151.2 (NHOCH, A 
& B), 156.8 (CONH, A & B), 170.9 (NHCHCO, A & B), 201.7 (NHOCHCO, A & 
B); HRMS El (+ve) m/z 412.2363 (M+), C24H32N2O4 requires 412.2362.
The diasteromers were separated by using a HPLC fitted with a Chiralcel OD-H 




Peak area 8H (600 MHz, CDC13)
0.96 (3H, d, J = 6.8, CH(CA//3 CB H3 )), 0.99 
(3H, d, J= 6.8, CH(CA H 3 C B//3 )), 1.00 (3H, s, 
C(CA//3 CBH3 )), 1.09 (3H, s, C(C A H3 CB//3 )), 
2,11 (1H, dd, y = 4.2, 9.0, C//CH2 CH=CH2 ), 
2.17-2.36 (5H, m, C//(CH3 ) 2 , C//2 C(CH3 )2 , 
CHC//2CH=CH2), 3.97 (1H, dd, J = 7.0 7.1, 
NHC/f), 4.95-5.03 (2H, m, CHCH 2CH=C//2), 
5.13 (2H, s, PhC//20), 5.28 (1H, d, J = 7.1, 
br, N//), 5.83-5.87 (1H, m, CHCH2 C//=CH2 ), 
6.52 (1H, s, NHC=C//CO), 7.32-7.38 (5H, m, 
Ar-H), 7.76(1 H, s, br, N//)
31.85 6938054(49.98%)
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B 40.49 6944140 (50.02 %) 0.95 (3H, d, J = 6.8, CH(CA//3 CBH3)), 0.99
(3H, d, 7= 6.8, ), 1.00 (3H, s,
C(C A//3 CBH3 )), 1.08 (3H, s, C(CAH3 CB//3 )), 
2.12 (1H, dd, y= 4.2, 8.9, C//CH2CH=CH 2), 
2.17-2.24 (1H, m, CH(C//ACHB)CH=CH2), 
2.25-2.43 (4H, m, C//2C(CH3 )2 C//(CH3 )2 , 
CH(CHAC/^)CH=CH2), 3.96 (1H, dd, J = 
6.8, 8.4, NHCfl), 4.96-5.03 (2H, m, 
CHCH2CH=C//2), 5.13 (2H, s, PhC//2O), 
5.29 (1H, d, J = 8.4, N//), 5.82-5.86 (1H, m, 
CHCH2C#=CH2), 6.52 (1H, s, NHC=C//CO), 
7.33-7.38 (5H, m, Ar-fl), 7.77 (1H, s, br, N//)
5.2. 34 3-(N-benzyloxycarbonyl-L-valinyl-amino)-5,5-dimethyl-6-((E)-3-phenyl- 
allyl)-cyclohex-2-enone (83)
(diastereomers A & B)
W-Benzyloxycarbonyl-L-valine (0.146 g, 0.58 mmol), PyBroP (0.270 g, 0.58 mmol) 
and DMAP (0.143 mg, 1.17 mmol) were dissolved in DCM (5ml) and stirred at room 
temperature. After 5 minutes, 80 (0.100 g, 0.39 mmol) was added and the solution 
stirred at room temperature. After 2 hours the DCM was evaporated in vacua and 
EtOAc (5 ml) was added to the residue. A white precipitate formed which dissolved 
upon addition of water (2 ml). The organic layer was separated and washed with 1M 
KHSO4 solution (2 ml), water (2 ml), saturated NaHCO3 solution (2 ml), water (2 
ml), dried (MgSCU) and the solvent removed in vacua to give a yellow oil. Flash 
column chromatography on silica gel using 30 % ethyl acetate in petroleum ether 40- 
60 as eluent afforded a white solid (0.179 g, 94 %); 6H (360 MHz, CDC13 ) 0.91 (3H, 
d, J = 6.8, CH(CA//3CBH3), A), 0.92 (3H, d, J= 6.8, CH(CA//3CBH3 ), B), 0.95 (3H, 
d, J= 6.8, CH(CAH3C B//3 ), A), 0.96 (3H, d, J= 6.8, CH(C AH3C B//3 ), B), 0.98 (3H, s, 
C(CA//3C BH3), A), 0.99 (3H, s, C(C A//3 C BH3 ), B), 1.08 (3H, s, C(C AH3 C B//3), A),
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1.09 (3H, s, C(CAH3 CB#3 ), B), 2.11-2.52 (6H, m, C#CH2CH=CH, C//(CH3 )2 , 
CHC//2CH=CH, C//2C(CH3 )2, A & B), 4.09-4.12 (1H, m, NHCfl, A & B), 5.10 (2H, 
s, PhCH2O, A & B), 5.56 (1H, d,J= 7.5, N//, A), 5.58 (1H, d,J= 7.5, N#, B) 6.23- 
6.38 (2H, m, CH2CH=CHPh, A & B), 6.59 (1H, s, NHC=C//CO, A & B), 7.15-7.34 
(10H, m, Ar-H, A & B), 8.25 (1H, s, br, N//, A), 8.28 (1H, s, br, N//, B); 8C (63 
MHz, DEPT, DMSO) 17.6 (CH(CAH3 C BH3), A & B), 19.1 (CH(CAH3 CBH3 ), A & 
B), 23.7 (C(CAH3 C BH3 ), A), 23.8 (C(CAH3 C BH3 ), B), 28.6 (C(CAH3 CBH3), A & B), 
29.4 (CH2CH=CH2 , A), 29.5 (CH2CH=CH2 , B), 30.9 (CH(CH3 )2 , A & B), 35.5 
(C(CH3 )2 , A), 35.6 (C(CH3 )2 , B), 41.5 (NHCCH2 C(CH3 )2 , A & B), 56.7 
(C(CH3 )2 CH, A), 56.8 (C(CH3 )2 CH, B), 60.9 (NHCH, A & B), 67.1 (OCH2Ph, A & 
B), 110.9 (HNC=CHCO, A & B, [125.8 (CH), 126.7 (CH), 127.7 (CH), 128.1 (CH), 
128.2 (CH), 128.4 (CH) 10C, Ar-H, A & B], 129.4 (CHCH2CH=CHPh, A & B), 
130.5 (CHCH2 CH=CHPh, A & B), 135.7 (CHPh, A & B), 137.7 (CH2P/z, A & B), 
151.6 (NHOCH, A & B), 156.7 (CONH, A & B), 171.2 (NHCHCO, A & B), 201.7 




(diastereomers A & B)
Experimental procedure 5.2.2 was followed using yV-benzyloxycarbonyl-L- 
valinylfluoride (0.13 g, 0.5 mmol) and 79 (0.13 g, 0.55 mmol) and DIPEA (0.19 ml, 
1.1 mmol) in DCM (20 ml). Flash column chromatography on silica gel using 30 % 
ethyl acetate in hexane as eluent afforded a yellow oil (0.09 g, 39 %); Rf 0.6 (50 % 
EtOAc in hexane); 8H (360 MHz, CDC13) 0.87 (3H, d, J = 6.9, CH(CA//3 CBH3), A & 
B), 0.91 (3H, d,J= 6.9, CH(C AH3 C B//3 ), A & B), 0.93 (3H, s, C(C A//3 C BH3 ), A & 
B), 1.02 (3H, s, C(C AH3 C B//3 ), A & B), 2.11-2.15 (1H, m, C//(CH3)2 , A & B), 2.36-
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2.41 (3H, m, C//2C(CH3 )2 & C//CH2Ph, A & B), 2.69 (1H, dt, J = 3.6, 3.6, 14.1, 
CHC/^HBPh, A & B), 3.00 (1H, dd, J= 8.1, 14.1, CHCH^Ph, A & B), 4.01-4.06 
(1H, m, NHC//, A & B), 5.09 (2H, s, OC//2Ph, A & B), 5.52 (1H, d, J = 8.4, NH, A 
& B), 6.54 (1H, s, NHC=C//CO, A), 6.56 (1H, s, NHOC//CO, B), 7.11-7.36 (10H, 
m, Ar-//, A & B), 8.25 (1H, s, N/7, A & B); 8C (63 MHz, DEPT, CDC13) 18.0 
(CH(CAH3 CBH3 ), A & B), 19.5 (CH(CAH3 CBH3), A & B), 23.5 (C(CAH3CBH3), A & 
B), 29.1 (C(CAH3 CBH3), A & B), 29.8 (CH2Ph, A), 30.5 (CH(CH3)2, A & B), 31.5 
(CH2Ph, B), 36.3 (C(CH3 )2 , A & B), 42.3 (NHCCH2C(CH3 )2 , A & B), 59.0 
(C//CH2Ph, A), 59.1 (C//CH2Ph, B), 61.6 (NHCH, A & B), 67.7 (OCH2Ph, A & B), 
111.4 (NHOC//CO, A & B), [125.9 (CH), 128.2 (CH), 128.4 (CH), 128.6 (CH), 
128.8 (CH), 129.1 (CH), 10C, Ar-H, A & B], 135.9 (OCH2Ph, A & B), 141.6 
(CH2Ph, A & B), 150.8 (NHC=CH, A & B), 157.1 (CONH, A & B), 170.9 
(NHCHCO, A & B), 201.2 (NHC=CHCO, A & B); HRMS FAB (+ve) m/z 
463.2596, C2gH35N2O4 requires 463.2596.
5.2.36 N-allyloxycarbonyl-1-amino-l-cyclopentanecarboxylic acid 1
H 9^^-Yv^oH
o ^A^
Experimental procedure 5.2.3.B was followed using L-valine (3.00 g, 25.7 mmol) 
and allyl chloroformate (3.9 ml, 37.5 mmol) dissolved in sodium hydroxide (25 ml, 
4.0 M) to yield a colourless oil (3.86 g, 77 %); 5H (250 MHz, CDC13 ) 0.92 (3H, d, J 
= 6.8, CH(C A#3 C BH3 )), 0.99 (3H, d, J = 6.8, CH(CAH3 CB//3 )), 2.18-2.21 (1H, m, 
C//(CH3 )2), 4.30 (1H, dd, 7= 4.4, 6.9, NHC//), 5.00 (2H, d, J= 5.4, CH2=CHC#2), 
5.20-5.32 (1H, m, C//2=CHCH2), 5.84-5.99 (1H, m, CH2=C//CH2), 5.92 (1H, d, / = 
6.9, NH); 5C (63 MHz, DEPT, CDC13 ) 17.2 (CH(CAH3 CBH3 )), 18.9 
(CH(CAH3 CBH3 )), 30.9 (CH(CH3)2), 58.6 (NHCH), 65.9 (CH2=CHCH2), 117.8 
(CH2=CHCH2 ), 132.3 (CH2=CHCH2), 156.2 (CONH), 176.5 (CO2H); MS ES m/z 
202.2 (M+H)+ , 200.2 (M-H)'.
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5.2.37 Valine template library (3x6) synthesis
R 1 = Ph-, Alloc-, Boc-


































Stock solutions of the reagents were prepared as in table 5.1. The PyBroP (0.5 ml) 
and DMAP (0.5 ml) solutions were dispensed into each of the 18 tubes being used in 
a MiniBlock™. Each valine derivative solution (1 ml) was manually dispensed into a 
vertical line of 6 tubes in the MiniBlock, the MiniBlock was then shaken on the 
Shaking and Washing Station for 5 minutes. The Miniblock was removed from the 
shaker and each amino-dimedone derivative solution (1 ml) was manually dispensed 
into a horizontal line of 3 tubes, the MiniBlock was then shaken overnight. The 
MiniBlock was drained into a 48 well plate and the DCM solutions transferred 
manually onto pre-packed silica columns. These were then subject to flash column 
chromatography in parallel on a Biotage QUAD 3 purification system using 30 % 
ethyl acetate in petroleum ether 40-60 as eluent.
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Table 5.2 Array products
Ligand Structure Yield and Analysis62 0.088 g, 80 %. Analysis same as 5.2.19.
85
0.065 g, 67 %; 5 H (360 MHz, MeOD) 0.93 (3H, d, J = 6.8, CH(CA//3 CBH3)), 1.00 (3H, d, 
J = 6.8, CH(CAH3CB//3)), 1.07 (6H, s, 
C(C//3)2), 2.19-2.26 (IH, m, C//(CH3)2), 2.27 
(2H, s, C//2C(CH3)2), 2.38 (2H, s, C//2C(CH3)2), 4.30 (IH, dd, J = 5.5, 71, 
NHC//), 4.49-4.52 (2H, m, CH2=CHC//2), 
5.13-5.30 (2H, m, C//2=CHCH2), 5.86-5.91 
(IH, m, CH2=C//CH2), 6.78 (IH, s, 




0.062 g, 62 %; 5 H (250 MHz, MeOD) 0.94 
(3H, d, J = 6.8, CH(CA//3CBH3)), 0.98 (3H, d, J = 6.8, CH(CAH3 CB//3),), 1.03 (6H, s, 
C(C//3 )2), 1.41 (9H, s, C(C//3)3 ,), 2.13-2.16 
(IH, m, C//(CH3)2), 2.22 (2H, s, 
C//2C(CH3)2), 2.34 (2H, s, C(CH3)2C//2), 4.20 
(IH, dd, J= 4.0, 7.0, NHC//), 5.12 (IH, d, J 




II i H O ^^
(diastereomers A & B)
0.095 g, 82 %; 5H (250 MHz, CDC13) 0.93 (3H, d, J= 7.8, CH(CA//3 CBH3), A & B), 0.94 
(3H, s, C(CA//3 CBH3 ), A & B), 0.95 (3H, d, J = 7.8, CH(CAH3 CB//3 ), A & B), 0.99 (3H, d, J 
= 6.9, CHC//3, A & B), 1.02 (3H, s, 
C(CAH3 CB//3), A & B), 2.05-2.09 (IH, m, 
C//(CH3 )2), 2.14-2.27 (3H, m, C//2C(CH3 )2 , 
C(CH3)2C//, A & B), 3.98 (IH, dd, J = 7.2, 
8.1, NHC//, A & B), 5.12 (2H, s, PhC//2O, A 
& B), 5.54 (IH, d, J= 8.1.N//, A& B), 6.70 
(IH, s, NHC=C//CO, A) , 6.71 (IH, s, 
NHC=C//CO, B), 7.25-7.35 (5H, m, Ar-//, A 
& B); MS ES (+ve) m/z 387.2 (M+H)+ , 385.2 
(M-H)'. _____________________88
(diastereomers A & B)
0.066 g, 65 %; 8 H (250 MHz, CDC1 3) 0.85 
(3H, d, J= 7.9, CH(CA//3 CBH 3 ), A & B), 0.92 
(3H, s, C(CA//3 CB H3 ), A & B), 0.94 (3H, d, J 
= 7.9, CH(CAH3 CB//3), A & B), 1.00 (3H, d, J 
= 7.1, CHC//3 , A & B), 1.02 (3H, s, 
C(CAH3 CB//3 ), A & B), 2.05-2.38 (4H, m, 
C//CH3 , C//(CH3 )2 , C//2C(CH3 )2 , A & B), 
4.06 (IH, dd, J = 7.4, 7.9, NHC//, A & B), 
4.52 (2H, d, J = 5.5, CH2CH=C//2O, A & B), 
5.18 (IH, dd, J = 1.3, 10.4, 
(C//AHB)CH=CH2O, A & B), 5.19 (IH, dd, J
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= 1.3, 17.2, (CHA//3)CH=CH2O, A & B), 5.54 
(IH, d, J = 7.9, N//, A & B), 5.84 (IH, ddd, J 
= 5.5, 10.4, 17.2, CH2C//=CH2O, A & B), 
6.57 (IH, s, NHC=C//CO, A & B), 8.36 (IH, 
s, br, N//, A & B); MS ES (+ve) m/z 337.1 
(M+H)+, 335.1 (M-HV.
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(diastereomers A & B)
0.078 g, 74 %; 8H (250 MHz, CDCI 3) 0.91 
(3H, d, J= 6.9, CH(CA//,CBH3 ), A & B), 0.95 
(3H, s, C(CA//3 CBH3 ), A & B), 0.98 (3H, d, J 
= 6.9, CH(C AH3 CB//3 ), A & B), 1.04 (3H, d, J 
= 7.0, CHC//3, A & B), 1.05 (3H, s, 
C(CAH3 C B//3 ), A & B), 1.73 (9H, s, C(C//3 )3 , 
A & B), 2.11-2.39 (4H, m, C//CH3 , 
C//(CH3)2, C//2C(CH3 )2, A & B), 4.20 (IH, 
dd, J = 4.3, 8.4, NHC//, A & B), 5.12 (IH, d, 
J = 8.4, N//, A & B), 6.62 (IH, s, 
NHC=C//CO, A), 6.64 (IH, s, NHC=C#CO, 
B), 8.05 (IH, s, br, N//, A & B); MS ES (+ve) 
m/z 353.2 (M+H)+ , 351.2 (M-H)'.
82 0.086 g, 70 %. Analysis same as 5.2.33.
(diastereomers A & B)
90
(diastereomers A & B)
0.086 g, 79 %; 5H (250 MHz, MeOD) 0.90 
(3H, d, 7= 6.9, CH(C A//3 CBH3 ), A & B), 0.93 
(3H, s, C(C A//3 CBH3 ), A & B), 0.94 (3H, d, J 
= 6.9, CH(CAH3 CB//3 ), A & B), 1.02 (3H, s, 
C(CAH3 C B//3 ), A & B), 2.08-2.35 (4H, m, 
C//CH2 , C//(CH3 )2 , C//2 C(CH3 )2 , A & B), 
4.10-4.19 (IH, m, NHC//, A & B), 3.96-4.03 
(2H, m, CH2CH=C//2 , A & B), 4.52 (2H, d, J 
= 5.3, CHCH 2CH=C//2 , A & B), 5.13-5.31 
(IH, m, C//2CH=CH2 , A & B), 5.56 (IH, d, J 
= 7.7, N//, A & B), 5.76-5.99 (2H, m, 
CH2C//=CH2 , CHCH2 C//=CH2 , A & B), 6.66 
(IH, s, NHC=C//CO, A), 6.68 (IH, s, 




(diastereomers A & B)
0.075 g, 66 %; 8 H (250 MHz, CDC13 ) 0.86 
(3H, d, J = 7.2, CH(C A//3 C BH3 ), A & B), 0.90 
(3H, d,J= 7.2, CH(CAH3 CB//3 ), A & B), 0.91 
(3H, s, C(CA//3 C BH3 ), A & B), 1.00 (3H, s, 
C(CAH3 CB//f), A & B), 1.39 (9H, s, C(C//3 )3 , 
A), 1.40 (9H, s, C(C//3 )3 , B), 1.98-2.06 (IH, 
m, C//(CH 3 )2 , A & B), 2.13-2.30 (3H, m, 
C7/2 C(CH3 )2 , C//CH2 ), 3.90-4.05 (IH, m, 
NHC//, A" & B), 4.86-4.99 (2H, m, 
CHCH2CH=C//2 ), 5.43 (IH, d, J= 5.0, N//, A 
& B), 5.85-5.94 (IH, m, CHCH2 C//=CH2 ), 
6.60 (IH, s, NHC=C//CO, A & B), 8.50 (IH, 
s, br, N//, A & B); MS ES (+ve) m/z 379.3 
(M+H) + , 377.3 (M-H)'.____________
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84
(diastereomers A & B)
0.104 g, 75 %. Analysis same as 5.2.35.
92
(diastereomers A & B)
0.089 g, 72 %; 8H (250 MHz, CDC13 ) 0.94 
(3H, d, J = 6.9, CH(C A//3 CBH3 ), A & B), 0.97 
(3H, d, J = 6.9, CH(CAH3 CB//3 ), A & B), 1.02 
(3H, s, C(CA//3 CBH3 ), A & B), 1.12 (3H, s, 
C(CAH3 CB#3 ), A & B), 2.12-2.23 (IH, m, 
C//(CH3)2), A & B), 2.38-2.46 (3H, m, 
C//2C(CH3 )2 , C//CH2Ph, A & B), 2.68 (IH, 
dd, J = 7.2, 14.1, CHC//AH BPh, A & B), 3.02 
(IH, dd, 7=8.4, H.^CHCH^Ph, A& B), 
4.06 (IH, dd, J = 6.5, 7.2, NHC//, A & B), 
4.58 (2H, d, J = 5.6, CH2CH=C//2 , A & B), 
5.20-5.36 (3H, m, C//2CH=CH2 , N//, A & B), 
5.86-5.93 (IH, m, CH2C//=CH2 , A & B), 6.54 
(IH, s, NHC=CMX>, A), 6.56 (IH, s, 
NHC=C//CO, B), 7.14-7.22 (5H, m, Ar-H, A 
& B), 8.16 (IH, s, br, N//, A & B); MS ES 
(+ve) m/z 413.3 (M+H)+, 411.2 (M-H)\
93
(diastereomers A & B)
0.102 g, 80 %; 5 H (250 MHz, CDC1 3 ) 0.87 
(3H, d, J = 6.6, CH(CA//3 CBH3 ), A & B), 0.88 
(3H, d, J= 6.6, CH(C AH3 CB//3 ), A & B), 0.90 
(3H, s, C(CA//3 CBH3 ), A), 0.91 (3H, s, 
C(CA//3 CBH3 ), B), 1.00 (3H, s, C(CAH3CB//3),
A), 1.01 (3H, s, C(CAH3 CB//3 ), B), 1.37 (9H, 
s, C(C//3 )3 , A), 1.38 (9H, s, C(C//3 )3 , B), 1.98- 
2.06 (IH, m, C//(CH3 )2 , A & B), 2.16-2.34 
(3H, m, C//2 C(CH 3 )2 , C//CH2Ph), 2.61 (IH, 
dd, .7=7.4, 14.1,CHC//AH BPh, A), 2.63 (IH, 
dd, 7=7.4, 14.1, CHC//AHBPh, B), 2.96 (IH, 
dd, J= 8.0, 14.1, CHCH^Ph, A), 2.97 (IH, 
dd, 7= 8.0, 14.1, CHCH^Ph, B), 3.90-4.05 
(IH, m, NHC//, A& B), 5.43 (IH, d, 7=5.0, 
N//, A & B), 6.60 (IH, s, NHC=C//CO, A &
B), 7.05-7.16 (5H, m, Ar-H, A & B), 8.50 
(IH, s, br, N//, A & B); 6 C (63 MHz, DEPT, 
CDC13 ) 17.9 (CH(CAH3 C B H3 ), A & B), 19.3 
(CH(C AH3 CBH3 ), A & B), 23.2 
(C(CAH3 CBH3), A & B), 28.3 (C(CH3 )3 , A & 
B), 28.9 (C(CAH3 CBH3 ), A & B), 30.5 
(CH(CH3 )2 , A & B), 31.1 (CH2Ph, A), 31.3 
(CH2Ph, B), 35.9 (C(CH3 )2 , A), 36.0 
(C(CH 3 )2 , B), 42.1 (NHCCH2C(CH3 ) 2 , A), 
42.3 (NHCCH 2C(CH3 ) 2 , B), 58.8 (C//CH2Ph,
A), 58.9 (C//CH2Ph, B), 60.7 (NHCH, A &
B), 80.4 (C(CH3 )3 , A & B), 111.1 
(NHC=C//CO, A & B), [125.6 (CH), 128.1 
(CH), 128.8 (CH), 5C, Ar-H, A & B], 141.3 
(CH 2Ph, A), 141.6 (CH2^, B), 150.8 
(NHC=CH, A & B), 156.4 (CONH, A & B), 
171.6 (NHCHCO, A & B), 201.0
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(NHC=CHCO, A), 201.1 (NHC=CHCO, B); 
MS ES (+ve) m/z 429.3 (M+H) + , 427.3 (M- 
HV.
83 0.105 g, 72 %. Analysis same as 5.2.34.
(diastereomers A & B)
94
(diastereomers A & B)
0.090 g, 68 %; 8 H (250 MHz, CDC13 ) 0.92 
(3H, d, J= 6.8, CH(CA//3 C BH3 ), A & B), 0.96 
(3H, d, J = 6.8, CH(C AH3 CB//3 ), A & B), 0.98 
(3H, s, C(CA//3 CBH3 ), A & B), 1.08 (3H, s, 
C(CAH3 CB//3 ), A & B), 2.15-2.49 (6H, m, 
C//CH2CH=CH, C//2C(CH3 )2 , C//(CH3 )2) 
CHC//2CH=CH, A & B), 4.09-4.12 (IH, m, 
NHC//, A & B), 4.59 (2H, d, J = 5.8, 
CH2CH=C//2 , A & B), 5.22-5.35 (3H, m, 
C//2CH=CH2 , N//, A & B), 5.87-5.95 (IH, m, 
CH 2C//=CH2 , A & B), 6.20-6.35 (2H, m, 
CH2C//=C//Ph, A & B), 6.61 (IH, s, 
NHC=C//CO, A & B), 7.41-7.57 (5H, m, Ar- 
//, A & B), 7.97 (IH, s, br, N//, A & B); MS 
ES (+ve) m/z 439.3 (M+H)+ , 437.3 (M-H)'.
95
(diastereomers A & B)
0.113 g, 83 %; 6H (250 MHz, MeOD) 0.93 
(3H, d, J = 6.9, CH(CA//3 CBH3 ), A & B), 0.95 
(3H, d, J = 6.9, CH(C AH3 CB//3 ), A & B), 1.05 
(3H, s, C(CA//3 CBH3 ), A & B), 1.11 (3H, s, 
C(C AH3 CB//3 ), A & B), 1.42 (9H, s, C(C//3 )3 , 
A & B), 2.12-2.45 (6H, m, C//CH2CH=CH, 
C//2C(CH3 )2 , C//(CH3 )2 , CHC//2CH=CH, A 
& B), 3.92-3.96 (IH, m, NHC//, A & B), 
6.15-6.39 (2H, m, CH2C//=C//Ph, A & B), 
6.74 (IH, s, NHC=C//CO, A & B), 7.13-7.30 
(5H, m, Ar-//, A & B), 7.90 (IH, s, br, N//, A 





(diastereomers A & B)
0.114 g, 78 %; 5 H (250 MHz, CDC1 3 ) 0.84 
(3H, d, J= 2.5, CH(C A//3 C BH 3 ), A), 0.91 (3H, 
d, J = 2.5, CH(C A//3 CBH3 ), B), 0.93 (3H, s, 
C(C A//3 CB H3 ), A & B), 0.96 (3H, d, J = 6.8, 
CH(C AH 3 C B//3 ), A), 0.99 (3H, d, J = 6.8, 
CH(C AH3 CB//3 ), B), 1.03 (3H, s, 
C(C AH3 CB//3 ), A & B), 1.45 (9H, s, C(C//3 ) 3 , 
A & B), 2.07-2.24 (2H, m, C//AHB C(CH 3 )2 , 
CHC//A H B), 2.54-2.67 (2H, m, CHCHV3 , 
CH A//BC(CH3 )2 ), 2.83 (IH, dd, J = 4.6, 8.0, 
C7/CH 2 , A & B), 4.09-4.12 (IH, m, NHC//, A 
& B), 5.09 (2H, s, PhC//2O, A), 5.10 (2H, s, 
PHC//A B), 5.40 (IH, d, J = 8.6, N//, A), 
5.77 (IH, d, 7 = 8.6, N//, B), 6.59 (IH, s, 
NHC=C//CO, A & B), 7.32 (5H, s, Ar-//, A), 
7.35 (5H, s, Ar-//, B), 8.39 (IH, s, br, N//, A), 
8.42 (IH, s, br, N//, B); 8C (63 MHz, DEPT, 
DMSO) 17.2 (CH(CA H 3 C BH 3 ), A) 17.7
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(CH(CAH3 CBH3), B), 18.9 (CH(CAH3 CBH3 ),
A), 19.2 (CH(CAH3 CBH3 ), B), 21.1 
(C(CAH3 C BH3 ), A & B), 27.8 (C(CH3 )3 , A &
B), 28.7 (C(CA H3 CBH3 ), A & B), 30.4 
(CH2CO2 C(CH3 )3 , A & B), 30.9 (CH(CH3 )2 , 
A & B), 35.6 (C(CH3)2 , A & B), 43.5 
(NHCCH2C(CH3)2 , A & B), 52.6 
(C(CH 3 )2CH, A & B), 58.7 (NHCH, A & B), 
66.9 (OCH2Ph, A), 67.3 (OCH2Ph, B), 80.3 
(C(CH3)3 , A & B), 111.3 (HNC=CHCO, A & 
B), [127.9 (CH), 128.0 (CH), 128.1 (CH), 
128.3 (CH), 128.4 (CH), 128.5 (CH), Ar-H, A 
& B], 135.6 (OCH2Ph, A), 135.7 (OCH2Ph, 
B), 151.4 (NHC=CH, A & B), 156.3 (CONH, 
A & B), 156.9 (CONH, A & B) 175.4 
(NHCHCO, A & B), 199.6 (NHC=CHCO, A 
& B); MS ES (+ve) m/z 487.3 (M+H)+, 485.3 
(M-HV.
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(diastereomers A & B)
0.080 g, 61 %; 8H (250 MHz, CDC13 ) 0.84 
(3H, d, J = 6.2, CH(CA//3 CBH3 ), A & B), 0.88 
(3H, s, C(CA#3 CBH3 ), A & B), 0.91 (3H, d, J 
= 6.2, CH(CA H3 CB//3 ), A & B), 1.04 (3H, s, 
C(CAH3 CB//3 ), A & B), 1.47 (9H, s, C(C//3 )3 , 
A & B), 2.02-2.17 (2H, m, C//AHBC(CH3 K 
CHC//AHB , A & B), 2.50-2.62 (2H, m, 
CH A//3 C(CH3 )2 CHCHW*, A & B), 2.70 
(IH, dd, J = 4.5, 7.9, C//CH2 , A & B), 4.09- 
4.12 (IH, m, NHC//, A & B), 4.59 (2H, d, J = 
5.8, CH2CH=C//2 , A & B), 5.20-5.32 (3H, m, 
C//2CH=CH2, N//, A & B), 5.86-5.96 (IH, m, 
CH2C//=CH2 , A & B), 6.50 (IH, s, 
NHC=C//CO, A & B), 8.30 (IH, s, br, N//, A 





(diastereomers A & B)
0.079 g, 58 %; 8 H (250 MHz, CDC1 3 ) 0.82 
(3H, d, J = 7.0, CH(C A//3 C BH 3 ), A & B), 0.90 
(3H, s, C(C A//3 C BH3 ), A & B), 0.94 (3H, d, J 
= 7.0, CH(CAH3 C B//3 ), A & B), 1.01 (3H, s, 
C(C AH3 CB//3 ), A & B), 1.50 (9H, s, C(C//3 ) 3 , 
A & B), 1.55 (9H, s, C(C//3 )3 , A & B), 2.00- 
2.16 (2H, m, C//AH B C(CH3 )2 , CHC//AHB , A 
& B), 2.48-2.60 (2H, m, CHA//3 C(CH3 )2 
CHCH A/^, A & B), 2.68-2.73 (IH, m, 
C//CH 2 , A & B), 4.01-4.09 (IH, m, NHCH, A 
& B), 5.54 (IH, d, J = 7.0, N//, A & B), 6.47 
(IH, s, NHC=C//CO, A & B); MS ES (+ve) 
m/z 453.4 (M+H)+ , 451.4 (M-H)'.________
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5.2.38 5,5-dimethyl-3-(L-phenylalanine methyl ester)-cyclohex-2-enone (99)
Z-phenylalanine methyl ester hydrochloride (0.31 g, 1.43 mmol) was added to a 
stirring suspension of dimedone (0.2 g, 1.43 mmol) in glacial acetic acid (0.25 ml) 
and toluene (20 ml). The reaction mixture was heated to reflux for 2 hours and water 
removed azeotropically using Dean-Stark apparatus. After cooling to room 
temperature the solvent was evaporated in vacua and the residue redissolved in 
EtOAc (10 ml), washed with water (5 ml) then saturated NaHCO3 solution (5 ml) 
and dried (MgSO4). Flash column chromatography on silica gel using 3 % methanol 
in dichloromethane as eluent afforded a yellow oil (0.41 g, 97 %); SH (250 MHz, 
CDC13 ) 0.94 (3H, s, C(C A#3 C BH3 )), 0.96 (3H, s, C(C AH3 CB//3 )), 2.06 (2H, s, 
C//2 C(CH3 )2), 2.08 (2H, s, C//2C(CH3 )2 ), 3.05 (2H, dd, J = 5.7, 13.8, CHC#2Ph) 
3.63 (3H, s, OC//3 ), 4.22-4.29 (IH, m, C//CH2Ph), 4.86 (IH, d, J= 7.8, N//), 5.02 
(IH, s, NHOC//CO), 6.91-6.95 (3H, m, Ar-H), 7.14-7.18 (2H, m, Ar-ff); 5C (63 
MHz, DEPT, CDC13 ) 28.8 (C(CAH3 C BH3 )), 28.9 (C(C AH3 CBH3 )), 33.5 (C(CH3 )2), 
37.5 (CH2Ph), 44.1 (NCCH2 C(CH3 )2 ), 50.8 (C(CH3 )2 CH2OO), 53.2 (OCH3 ), 56.3 
(C//CH2Ph), 97.4 (NC=CHCO), [128.0 (CH), 129.3 (CH), 129.8 (CH), 5C, Ar-H], 
135.7 (QCHiPh), 161.4 (NC=CH), 172.1 (COOCH3 ), 198.0 (NC=CHCO); HRMS 
FAB (+ve) m/z 302.1749, Ci 8H24NO3 requires 302.1756.
5.2. 39 5,5-dimethyl-3-(L-valine methyl ester)-cyclohex-2-enone (100)
Experimental procedure 5.2.38 was followed using Z-valine methyl ester 
hydrochloride (0.24 g, 1.43 mmol) and dimedone (0.2 g, 1.43 mmol) in glacial acetic
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acid (0.25 ml) and toluene (20 ml). Flash column chromatography on silica gel using 
3 % methanol in dichloromethane as eluent afforded a yellow solid (0.33 g, 92 %); Rf 
0.17 (3 % MeOH in DCM); 5H (300 MHz, CDC13 ) 0.93 (3H, d, J = 6.9, 
CH(CA#3 C BH3 )), 1.01 (3H, d, J= 6.9, CH(CAH3 C B//3 )), 1.06 (3H, s, C(CA//3 CBH3)), 
1.07 (3H, s, C(CAH3 CB#3)), 2.11-2.22 (1H, m, C//(CH3 )2), 2.18 (2H, s, 
C//2C(CH3 )2), 2.25 (2H, s, C//2C(CH3 )2), 3.76 (3H, s, OC//3 ), 3.91 (1H, dd, J = 5.1, 
8.0, NHC/f), 5.07 (1H, s, NHC=C#CO), 5.15 (1H, d, J - 8.0, N#); 8C (75 MHz, 
DEPT, CDC13) 18.7 (CH(CAH3 CBH3 )), 18.9 (CH(CAH3 CBH3 )), 28.4 (C(CAH3 C BH3 )), 
28.5 (C(C AH3 CBH3 )), 31.2 (CH(CH3 )2 ), 33.0 (C(CH3 )2 ), 43.8 (NCCH2 C(CH3 )2), 50.5 
(C(CH3 )2 CH200), 53.2 (OCH3), 60.7 (NHCH), 96.7 (NOCHCO), 162.1 
(NC=CH), 172.2 (COOCH3 ), 197.4 (NC=CHCO); MS ES (+ve) 254.0 (M+H)+ .
5.2.40 5,5-dimethyl-3-(L-tyrosine methyl ester)-cyclohex-2-enone (101)
HO,
I-tyrosine methyl ester hydrochloride (0.33 g, 1.43 mmol) was added to a stirring 
suspension of dimedone (0.2 g, 1.43 mmol) in glacial acetic acid (0.25 ml) and 
toluene (20 ml). The reaction mixture was heated to reflux for 5 hours and water 
removed azeotropically using Dean-Stark apparatus. After cooling to room 
temperature the solvent was evaporated in vacua and the residue redissolved in 
EtOAc (10 ml), washed with water (5 ml) then saturated NaHCO3 solution (5 ml) 
and dried (MgSO4). Flash column chromatography on silica gel using 1 % methanol 
in ethyl acetate as eluent afforded a white solid (0.20 g, 74 %); Rf 0.42 (3 % MeOH 
in EtOAC); 5H (300 MHz, CDC13 ) 1.06 (3H, s, C(CA#3 C BH3)), 1.08 (3H, s, 
C(CAH3 C 8//3 )), 2.14-2.27 (4H, m, C//2 C(CH3 )2 , C(CH3 )2C//2), 2.24 (2H, s, 
C#2 C(CH3)2), 2.95 (1H, dd, J = 5.4, 14.1, C A//CBHPh), 3.06 (1H, dd, J = 5.4, 14.1, 
CAHC B#Ph), 3.74 (3H, s, OC#3 ), 4.22-4.29 (1H, dd, J = 5.4, 7.0, NHCH), 5.16 (1H, 
s, NHC=C//CO), 5.23 (1H, br, d, J = 6.9, N#), 6.79 (2H, d, J = 8.8, Ar-ff), 6.86
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(2H, d, J = 8.8, Ar-H), 7.14-7.18 (2H, m, Ar-H); 6C (75 MHz, DEPT, CDC13 ) 28.3 
(C(CAH3 CBH3)), 28.5 (C(CAH3 CBH3 )), 33.1 (C(CH3 )2), 36.4 (CH2Ph), 43.8 
(NCCH2 C(CH3)2), 50.1 (C(CH3 )2CH2C=0), 52.9 (OCH3 ), 56.3 (C//CH2Ph), 96.5 
(NC=CHCO), [116.1 (CH), 130.5 (CH), 4C, Ar-H], 125.9 (OCH2P/0, 130.6 
(PhOH), 156.6 (NC=CH), 171.8 (COOCH3 ), 198.5 (NC=CHCO); MS ES (+ve) 
254.0 (M+H)+ .
5.2. 41 (6,6-dimethyl-4-methoxy-2-oxo-cydohex-3enyl)-acetic acid (102)
Trifluoroacetic acid (9.2 ml, 0.09 mol) was added to a solution of 46 (2.56 g, 0.009 
mol) and triethylsilane (3.79 ml, 0.02 mol) in DCM (20 ml) and the solution stirred 
at room temperature for 2 hours. The DCM was evaporated in vacua and the residue 
redissolved in EtOAc (15 ml) and washed with water (5 ml) then dried (MgSC^). The 
EtOAc solution was concentrated in vacua to give pale yellow oil. Flash column 
chromatography on silica gel using 50 % ethyl acetate in petroleum ether 40-60 as 
eluent afforded a white solid (1.64 g, 81 %); 8H (250 MHz, CDC13) 0.87 (3H, s, 
C(CA#3 C BH3 )), 1.12 (3H, s, C(C AH3 CB//3 )), 2.16 (1H, d, J= 11 A, C//'4HB C(CH3 )2), 
2.31 (1H, dd, J = 1.9, 14.3, CHC#AHB CO2H), 2.57 (1H, dd, J = 1.1, 17.4, 
CHA//3C(CH3 )2), 2.70-2.84 (1H, m, CHCHA//3CO2H, C//CH2), 3.70 (3H, s, CH3 O), 
5.40 (1H, d, J= 1.1, CH3 OC=C//CO), 9.31 (1H, 2, br, COO//); §c (63 MHz, DEPT, 
CDC13 ) 20.9 (C(CAH3 CBH3 ), 28.7 (C(C AH3 CBH3 ), 29.6 (CHCH2), 35.6 (C(CH3 )2), 
44.2 (CH2 C(CH3 )2), 52.5 (C(CH3 )2 CH), 55.7 (CH3 O), 100.6 (CH3 OC=CHCO), 175.9 
(CO2H), 178.1 (CH3 OC), 199.3 (CH3 OC=CHCO); HRMS El (+ve) m/z 212.1048, 
CiiH, 6O4 requires 212.1048; mp 115-117°C.
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5.2.42 (6,6-dimethyl-4-methoxy-2-oxo-cyclohex-3enyl)-acetyl-L-valinyl methyl 
ester (103)
(diastereomers A & B)
PyBOP (0.489 g, 0.94 mmol), DIPEA (0.16 ml, 1.88 mmol) and 102 (0.200 g, 0.94 
mmol) were dissolved in DCM (10 ml) and stirred at room temperature. After 5 
minutes, I-valine methyl ester hydrochloride (0.158 g, 0.94 mmol), was added and 
the solution stirred at room temperature. After 2 hours the DCM was evaporated in 
vacua and the residue redissolved in EtOAc (10 ml). The solution was washed with 
1M KHSO4 solution (2 ml), water (2 ml), saturated NaHCO3 solution (2 ml), water 
(2 ml), dried (MgSO/i) and the solvent removed in vacua to give a yellow oil. Flash 
column chromatography on silica gel using 40 % ethyl acetate in petroleum ether 40- 
60 as eluent afforded a viscous yellow oil (0.21 g, 74 %); 5H (250 MHz, (CD3 )2CO) 
0.80 (3H, s, C(CA//3 C BH3 ), A), 0.81 (3H, s, C(CA//3 CBH3 ), B), 0.87 (3H, d, J = 6.8, 
CH(CA//3 C BH3 ), A & B), 0.90 (3H, d, J= 6.8, CH(CAH3 CB#3 ), A & B), 1.03 (3H, s, 
C(CAH3 CB//3 ), A), 1.04 (3H, s, C(CAH3 C B//3), B), 2.02-2.21 (3H, m, C/f4HB(CH3 )2 , 
CHC//2 , A & B), 2.48-2.75 (3H, m, CHA/^(CH3 )2 , C#(CH3 )2 , C#CH2 , A & B), 3.62 
(3H, s, C//30, A), 3.63 (3H, s, C#3 O, B), 3.66 (3H, s, C//3 O, A), 3.67 (3H, s, C//3 O, 
B), 4.32 (1H, d,J= 5.7, NHCtf, A & B), 5.27 (1H, d, J= 1.6, CH3 OC=C//CO, A), 
5.28 (1H, d, J= 1.6, CH3 OC=C//CO, B); 5C (63 MHz, DEPT, (CD3 ) 2CO) 17.7 
(CH(CAH3 C BH3 , A & B), 18.8 (CH(C AH3 CBH3 , A & B), 20.8 (C(C4H3 C BH3 , A & B), 
28.2 (C(CAH3 CBH3 , A & B), 30.7 (CHCH2 , A & B), 30.7 (CH(CH3)2 , A & B), 35.7 
(C(CH3 )2 , A), 35.9 (C(CH3 )2 , B), 44.0 (CH2C(CH3 )2 , A & B), 49.0 (CO2 CH3 , A & 
B), 52.7 (CHCH2 , A), 52.9 (CHCH2 , B), 55.6 (CH3 O, A & B), 57.6 (NHCH, A & B), 
100.5 (CH3 OOCHCO, A & B), 172.3 (CONH, A), 172.4 (CONH, B), 172.9 
(C02 CH3 , A), 173.0 (C02CH3 , B), 175.6 (CH3 OC, A), 175.8 (CH3 OC, B), 198.9 
(CH3 OC=CHCO, A), 199.0 (CH3 OC=CHCO, B); HRMS El (+ve) m/z 325.1893, 




(diastereomers A & B)
Experimental procedure 5.2.42 was followed using PyBOP (0.435 g, 0.7 mmol), 
DIPEA (0.15 ml, 1.4 mmol), 71 (0.150 g, 0.7 mmol) and (S)-a methyl benzylamine 
(0.09 ml, 0.7 mmol) in DCM (10 ml). Flash column chromatography on silica gel 
using 50 % ethyl acetate in petroleum ether 40-60 as eluent afforded a yellow oil 
(0.181 g, 82 %); 8H (250 MHz, CH3 OD); 1.00 (3H, s, C(CA//3 C BH3), A & B), 1.21 
(3H, s, C(CAH3 CB//3), A & B), 1.53 (3H, d, J = 7.0, CH3 , A), 1.54 (3H, d, J = 7.0, 
CH3 , B), 2.31 (IH, d, J= 17A, C/^HB C(CH3)2 , A & B), 2.37 (IH, dd, J= 4.5, 15.1, 
CHC//AHB , A & B), 2.31 (IH, d, J = 17.4, C//AHB C(CH3)2 , A & B), 2.67 (IH, d, J = 
17.4, CHA//B C(CH3 )2 , A & B), 2.73 (IH, dd, J = 7.9, 15.1, CHCH^/f8 , A & B), 
2.94 (IH, dd, J = 4.5, 7.9, C//CH2 , A & B), 3.81 (3H, s, CH3 O, A), 3.82 (3H, s, 
CH3 O, B), 5.04-5.16 (IH, m, NHC//, A & B), 5.46 (IH, d, J= 1.3, CH3 OOCHCO, 
A & B), 7.30-7.50 (5H, m, Ai-H, A & B), 8.43 (IH, d, J= 7.6, N//, A & B); 5C (63 
MHz, DEPT, CH3 OD) 21.6 (C(CAH3 C BH3 , A & B), 22.5 (CH3 , A), 22.6 (CH3 , B) 
28.9 (C(CAH3 CBH3 , A & B), 32.3 (CHCH2 , A & B), 36.8 (C(CH3 )2 , A & B), 44.8 
(CH2 C(CH3 )2 , A & B), 50.0 (NHCH, A & B), 53.9 (CHCH2 , A & B), 56.4 (CH3 O, A 
& B), 101.0 (CH3 OC=CHCO, A & B), [127.1 (CH), 127.8 (CH), 129.3 (CH), 5C, 
Ar-H, A & B], 145.1 (CH(CH3 )/V», A) 145.2 (CH(CH3 )/>/z, B), 174.5 (CONH A & 
B), 178.5 (CH3 OC A & B), 202.4 (CH3 OOCHCO A & B); HRMS El (+ve) m/z 
315.1833, Ci 9H25NO3 requires 315.1889.
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5. 2.44 5,5-dimethyl-3-methoxy-6-(2-(2-methyl-piperidin-l-yl)-2-oxo-ethyl)- 
cyclohex-2-enone (105)
Experimental procedure 5.2.42 was followed using PyBOP (0.186 g, 0.3 mmol), 
DIPEA (0.06 ml, 0.6 mmol), 71 (0.064 g, 0.3 mmol) and 2-methyl piperidine (0.04 
ml, 0.3 mmol) in DCM (10 ml). Flash column chromatography on silica gel using 50 
% ethyl acetate in petroleum ether 40-60 as eluent afforded a yellow oil (0.069 g, 79 
%); MS ES (+ve) m/z 294.1 (M+H)+ .
5. 2.45 6-allyl-3-(N-benzyloxycarbonyl-D-valinyl-amino)-5,5-dimethyl-cyclohex-2- 
enone (106)
(diastereomers A & B)
Experimental procedure 5.2.33 was followed using 7V-benzyloxycarbonyl-D-valine 
(0.2lOg, 0.84 mmol), PyBroP (0.391 g, 0.84 mmol), DMAP (0.205 mg, 1.68 mmol) 
and 78 (0.100 g, 0.56 mmol) in DCM (10 ml). Flash column chromatography on 
silica gel using 30 % ethyl acetate in petroleum ether 40-60 as eluent afforded a 
white solid (0.206 g, 89 %); 8H (250 MHz, CH3 OD) 0.97 (3H, d, J = 6.8, 
CH(CA//3 C BH3 ), A & B), 0.99 (3H, d, J= 6.8, CH(CAH3 CB//3 ), A & B), 1.02 (3H, s, 
C(CA//3 C BH3 ), A & B), 1.05 (3H, s, C(CAH3 CB//3 ), A & B), 2.17-2.36 (6H, m, 
C//(CH3 )2 , C//2 C(CH3 )2 , CHC//2 CH=CH2 , C//CH2CH=CH2 , A & B), 3.34-3.39 (1H, 
m, NHCtf, A & B), 4.95-5.03 (2H, m, CHCH2CH=C/f2 , A & B), 5.20 (2H, s, 
PhC//20, A & B), 5.28 (1H, d, J = 7.1, br, N//, A & B), 5.83-5.87 (1H, m, 
CHCH2C//=CH2 , A & B), 6.53 (1H, s, NHC=C//CO, A), 6.55 (1H, s, NHOC//CO,
184
B) 7.23-7.33 (5H, m, Ar-//, A & B), 7.76 (1H, s, br, N#, A & B); 8C (63 MHz, 
DEPT, MeOD) 18.4 (CHCC^C8^), A & B), 19.6 (CH(CAH3 CBH3), A & B), 24.6 
(C(CAH3CBH3), A & B), 28.8 (C(CAH3CBH3), A & B), 30.7 (CH2CH=CH2 , A & B), 
30.8 (CH(CH3 )2 , A & B), 36.2 (C(CH3 )2 , A & B), 41.7 (NHCCH2C(CH3)2 , A & B), 
57.1 (C(CH3)2CH, A & B), 61.8 (NHCH, A & B), 67.7 (OCH2Ph, A & B), 110.8 
(HNOCHCO, A & B), 115.9 (CH2CH=CH2 , A & B), [128.7 (CH), 129.0 (CH), 
129.6 (CH), 5C, Ar-H, A & B], 136.2 (OCH2P/z, A & B), 137.4 (CH2 CH=CH2 , A & 
B), 151.2 (NHC=CH, A & B), 156.8 (CONH, A & B), 170.9 (NHCHCO, A & B), 
203.1 (NHOCHCO, A & B) HRMS FAB (+ve) m/z 412.2363, C24H32N2O4 requires 
412.2362.
5. 2.46 6-allyl-3-(N-benzyloxycarbonyl-L-leucyl-amino)-5,5-dimethyl-cydohex-2- 
enone (107)
(diastereomers A & B)
Experimental procedure 5.2.33 was followed using N-benzyloxycarbonyl-L-leucine 
(0.111 g, 0.42 mmol), PyBroP (0.195 g, 0.42 mmol), DMAP (0.102 mg, 0.84 mmol) 
and 78 (0.050 g, 0.28 mmol) in DCM (3 ml). Flash column chromatography on silica 
gel using 30 % ethyl acetate in petroleum ether 40-60 as eluent afforded a white solid 
(0.104 g, 87 %); Rf 0.77 (50 % EtOAc in petroleum ether 40-60); 5H (250 MHz, 
CDC13 ) 0.85-1.06 (12H, m, CH(C//3)2 , C(C//3 )2 , A & B), 1.51-1.67 (3H, m, 
CH2C//(CH3 )2 , C//2CH(CH3 )2 , A & B), 2.07-2.39 (5H, m, C//2C(CH3 )2 , 
C//CH2CH=CH2 , CHC#2CH=CH2 , A & B), 4.10-4.16 (1H, m, NHC7/, A & B), 
4.91-5.02 (2H, m, CHCH2CH=C#2 , A & B), 5.11 (2H, s, PhC//2O, A & B), 5.63- 
5.81 (2H, m, N/f, CHCH2C//=CH2 , A & B), 6.56 (1H, s, NHC=C//CO, A & B), 
7.28-7.35 (5H, m, Ar-H, A & B), 8.40 (1H, s, br, N#, A & B); 5C (63 MHz, DEPT, 
CDC13 ) 22.1 (CH(CAH3 C BH3 ), A & B), 23.2 (CH(CAH3 CBH3 ), A & B), 24.7
185
(C(CAH3 C BH3 ), A & B), 24.9 (CH(CAH3 CBH3), 29.0 (C(CAH3 CBH3 ), A & B), 30.3 
(CH2CH=CH2 , A & B), 30.9 (CH2CH(CH3 )2 , A & B), 35.8 (C(CH3)2 , A & B), 41.7 
(NHCCH2C(CH3 )2 , A & B), 57.2 (NHCH, A & B), 67.3 (PhCH2 , A & B), 111.2 
(NHC=C//CO, A & B), 115.9 (CH2CH=CH2 , A & B), [128.4 (CH), 128.8 (CH), 
128.9 (CH), 5C, Ar-H, A & B], 137.9 (PhCH2O, A & B), 137.2 (CH2 CH=CH2 , A & 
B), 151.8 (NHOCH, A & B), 152.4 (CONH, A & B), 171.9 (NHCHCO, A & B), 
202.2 (NHC=CHCO, A & B); MS ES 427.0 (M+H)+ , 425 (M-H)'.
5. 2.4 7 6-allyl-3-(N-benzyloxycarbonyl-L-isoleucyl-amino)-5,5-dimethylcyclohex-2- 
enone (108)
(diastereomers A & B)
Experimental procedure 5.2.33 was followed using N-benzyloxycarbonyl-L- 
isoleucine (0.111 g, 0.42 mmol), PyBroP (0.195 g, 0.42 mmol), DMAP (0.102 rng, 
0.84 mmol) and 78 (0.050 g, 0.28 mmol) in DCM (3 ml). Flash column 
chromatography on silica gel using 30 % ethyl acetate in petroleum ether 40-60 as 
eluent afforded a white solid (0.099 g, 83 %); Rf 0.78 (50 % EtOAc in petroleum 
ether 40-60); 5H (250 MHz, CDC13 ) 0.80-0.93 (6H, m, (CH(C//3 )CH2C//3 ), A & B), 
0.95 (3H, s, C(CA//3 C BH3 ), A & B), 1.04 (3H, s, C(CAH3 CB//3 ), A & B), 1.22-1.40 
(2H, m, (CH(CH3 )C//2CH3 ), 1.88-2.39 (6H, m, C//2C(CH3 )2 , C//CH2CH=CH2 , 
CHC//2CH=CH2 , C//(CH3)CH2CH3 , A & B), 4.10-4.16 (1H, m, NHC//, A), 4.29- 
4.31 (1H, m, NHC//, B), 4.91-5.02 (2H, m, CHCH2CH=C//2 , A & B), 5.09 (2H, s, 
PhC//20, A & B), 5.63-5.81 (2H, m, N//, CHCH2C//=CH2 , A & B), 6.53 (1H, s, 
NHC=C//CO, A), 6.54 (1H, s, NHC=C//CO, B), 7.26-7.35 (5H, m, Ar-H, A & B), 
8.53 (1H, s, br, N//, A & B); 5C (63 MHz, DEPT, CDC13 ) 10.9 (CH(CH3 )CH2CH3 , A 
), 11.4 (CH(CH3 )CH2CH3 , B), 14.1 (CH(CH3 )CH2 CH3 , A), 15.4 (CH(CH3)CH2CH3 , 
B), 24.0 (C(CAH3 C BH3), A & B), 24.4 CH(CH3 )CH2 CH3 , A & B), 28.5
186
(C(CAH3 CBH3), A & B), 30.3 (CH2CH=CH2 , A & B), 35.4 (C(CH3)2 , A & B), 36.9 
(CH(CH3)CH2CH3), 41.1 (NHCCH2C(CH3)2 , A & B), 56.6 (C//CH2Ph, A & B), 67.2 
(NHCH, A & B), 67.3 (PhCH2 , A & B), 110.7 (NHOC//CO, A & B), 115.4 
(CH2CH=CH2 , A & B), [127.8 (CH), 128.2 (CH), 128.5 (CH), 5C, Ar-H, A & B], 
135.9 (PhCH20, A & B), 137.2 (CH2CH=CH2 , A & B), 150.8 (NHC=CH, A & B), 
151.1 (CONH, A & B), 171.1 (NHCHCO, A & B), 201.8 (NHOCHCO, A & B); 
MS ES 427.0 (M+H)+ , 425 (M-H)'.
5.2.48 6-allyl-3-(N-a-benzyloxycarbonyl-N-s-tert-butoxycarbonyl-L-lysyl-amino)- 
5,5-dimethyl-cyclohex-2-enone (109)
(diastereomers A & B)
Experimental procedure 5.2.33 was followed using TV-a-benzyloxycarbonyl-TV-e-/^/1- 
butoxycarbonyl-L-lysine (0.171g, 0.45 mmol), PyBroP (0.391 g, 0.45 mmol), DMAP 
(0.073 mg, 0.60 mmol) and 78 (0.054 g, 0.30 mmol) in DCM (10 ml). Flash column 
chromatography on silica gel using 50 % ethyl acetate in hexane as eluent afforded a 
white solid (0.143 g, 88 %); 8H (250 MHz, MeOD) 0.99 (3H, s, C(CA//3 C BH3), A & 
B), 1.06 (3H, s, C(CAH3 CB//3), A & B), 1.40 (9H, s, C(C//3)3 , A & B), 1.62-1.81 
(4H, m, (C//2)2 , A & B), 2.05-2.50 (7H, m, C#CH2CH=CH2 , C//2C(CH3 )2 , 
CHC//2 CH=CH2 , CH2 , A & B), 2.97-3.02 (2H, m, CH2 , A & B), 4.06-4.16 (1H, m, 
NHC//, A & B), 5.06 (2H, s, PhC//2O, A & B), 5.75-5.85 (1H, m, CHCH2 C//=CH2 ), 
6.67 (1H, s, NHOC//CO, A), 6.69 (1H, s, NHC=C//CO, B), 7.24-7.34 (5H, m, Ar- 
//, A & B); 5C (63 MHz, DEPT, MeOD) 22.3 ((CH2)2 , A & B), 24.7 (C(CH3 )2 , A & 
B), 29.6 (CH2 , A & B), 30.5 (CH2 CH=CH2 , A & B), 30.8 (C(CH3 ) 3 , A & B), 31.8 
(CH2, A & B), 35.5 (C(CH3)2 , A & B), 41.0 (NHCCH2C(CH3)2 , A & B), 57.3 
(C(CH3)2CH, A & B), 58.1 (NHCH, A & B), 67.7 (PhCH2O, A), 67.8 (PhCH2 O, B),
187
110.9 (HNC=CHCO, A & B), 116.0 (CH2CH=CH2 , A & B), [128.0 (CH), 128.6 
(CH), 128.7 (CH), 5C,^r-H, A & B], 138.1 (OCH2?/z, A & B), 138.7 (CH2 CH=CH2 , 
A & B), 151.2 (NHC=CH, A & B), 156.8 (CONH, A & B), 158.7 (CONH, A & B), 
171.2 (NHCHCO, A & B), 202.1 (NHC=CHCO, A & B); MS ES (+ve) m/z 542.4 
(M+H)+, 564.4 (M+Na)+ .
5.2.49 6-allyl-3-(N-benzyloxycarbonyl-L-prolyl-amino)-5,5-dimethyl-cyclohex-2- 
enone (110)
(diastereomers A & B)
Experimental procedure 5.2.33 was followed using 7V-benzyloxycarbonyl-L-proline 
(0.209g, 0.84 mmol), PyBroP (0.391 g, 0.84 mmol), DMAP (0.205 mg, 1.68 mmol) 
and 78 (0.100 g, 0.56 mmol) in DCM (10 ml). Flash column chromatography on 
silica gel using 40 % ethyl acetate in hexane as eluent afforded a white powder 
(0.196 g, 85 %); 5H (360 MHz, CDC13 ) 0.99 (3H, s, C(CA//3 C BH3 ), A & B), 1.07 
(3H, s, C(CAH3 C B//3), A & B), 1.85-2.35 (9H, m, C//2C(CH3)2 , CHC//2CH=CH2 , 
C//CH2 CH=CH2 , (C//2)2 , A & B), 3.35-3.52 (CH2 , A & B), 4.45 (IH, d, J = 7.4, 
C//(CH2) 3 , A & B), 4.94-5.22 (4H, m, PhC//2O, CHCH2CH=C//2 , A & B), 5.81-5.89 
(IH, m, CH2C//=CH2 , A & B), 6.59 (IH, s, NHC=C//CO, A & B), 7.36-7.40 (5H, 
m, Ai-H, A & B), 9.20 (IH, s, N//, A & B); 5C (90 MHz, DEPT, CDC13 ) 24.0 
(C(CAH3 C BH3 ), A & B), 24.1 (CH2 , A & B), 26.4 (CH2 , A & B), 28.5 
(C(CAH3 CBH3 ), A & B), 30.4 (CHCH2CH=CH2), 41.2 (NHCCH2C(CH3 )2 , A), 41.4 
(NHCCH2C(CH3 )2 , B), 56.7 (CHCH2Ph, A & B), 60.9 (NHCH, A & B), 67.7 
(PhCH20, A & B), 110.4 (NHC=C//CO, A & B), 115.3 (CHCH2CH=CH2), [127.8 
(CH), 128.2 (CH), 128.5 (CH), 5C, Ar-H, A & B], 135.9 (PhCU2O, A & B), 137.3 
(CHCH2CH=CH2), 151.2 (NHC=CH, A & B), 157.1 (CONH, A & B), 169.9 




(diastereomers A & B)
Trifluoroacetic acid (0.05 ml, 0.067 mmol) was added to a solution of 47 (0.06 g, 
0.12 mmol) and triethylsilane (0.06 ml, 0.36 mmol) in DCM (3 ml) and the solution 
stirred at room temperature for 2 hours. The DCM was evaporated in vacuo and the 
residue redissolved in EtOAc (5 ml) and washed with water (1 ml) then dried 
(MgSO4). The EtOAc solution was concentrated in vacuo to give pale yellow oil. 
Flash column chromatography on silica gel using 50 % ethyl acetate in petroleum 
ether 40-60 as eluent afforded a white solid (0.043 g, 83 %); 5H (250 MHz, CDC13 ) 
0.91 (3H, d, J = 6.8, CH(CA//3 CBH3), A & B), 0.95 (3H, d,J= 6.8, CH(CAH3 C B//3 ), 
A & B), 0.98 (3H, s, C(CA//3 CBH3), A & B), 1.08 (3H, s, C(CAH3 C B//3), A & B), 
2.11-2.52 (6H, m, C//CH2 CO2H, C//(CH3 )2 , CHC//2CO2H, C//2C(CH3 )2 , A & B), 
4.09-4.12 (IH, dd, J= 4.3, 4.5, NHC//, A & B), 5.10 (2H, s, PhC//2O, A & B), 5.56 
(IH, d, J = 7.5, N//, A & B), 6.58 (IH, s, NHC=C//CO, A), 6.61 (IH, s, 
NHC=C//CO, B) 7.25-7.29 (5H, m, Ai-H, A & B), 8.26-8.32 (IH, s, br, CO2//), 8.75 
(IH, s, br, N//, A & B); 8C (63 MHz, DEPT, CDC13 ) 18.0 (CH(CAH3 C BH3 ), A & B), 
19.1 (CH(CAH3 CBH3 ), A & B), 23.6 (C(CAH3 C BH3 ), A & B), 28.6 (C(CAH3 CBH3 ), A 
& B), 30.4 (CH2C02H, A & B), 31.0 (CH(CH3 )2 , A & B), 35.6 (C(CH3)2 , A & B), 
42.4 (NHCCH2 C(CH3 )2 , A & B), 55.5 (C(CH3 )2 CH, A & B), 60.9 (NHCH, A & B), 
67.1 (PhCH20, A & B), 110.9 (HNC=CHCO, A & B, [128.0 (CH), 128.2 (CH), 
128.4 (CH) 5C, Ar-H, A & B], 137.7 (PhCH2 , A & B), 151.8 (NHOCH, A & B), 
156.7 (CONH, A & B), 171.2 (NHCHCO, A & B), 175.5 (CO2H), 201.7 





(diastereomers A & B)
Af-Methylmorpholine-jV-oxide (0.053 g, 0.44 mmol) and osmium tetroxide (0.028 ml, 
0.02 mmol) were added to stirred solution of 25 (0.093 g, 0.22 mmol) in acetone (4 
ml) and water (1 ml) at 0°C. The reaction mixture was allowed to warm to room 
temperature and stirred for 2 hours. TLC analysis showed some starting material 
remaining so further osmium tetroxide (0.028 ml, 0.02 mmol) was added and stirred 
for 2 hours. The solvent was removed in vacua and the residue redissolved in EtOAc 
(10 ml) then washed with saturated NaiSiOa solution (5 ml), water (5 ml), dried 
(MgSO4) and the solvent removed in vacua to give a light brown oil (0.082 g, 84 %); 
HRMS FAB (+ve) m/z 447.2496, C24H3 5N2O6 requires 447.2495.
5. 2.52 (4-(N-benzyloxycarbonyl-L-valinyl-amino)-6,6-dimethyl-2-oxo-cyclohex-3- 
enyl)-acetaldehyde (113)
(diastereomers A & B)
A solution of sodium periodate (0.072 mg, 0.33 mmol) in water (1 ml) was added to 
a sturred slurry of silica (1 g) in DCM (3 ml) followed by a solution of 51 (0.10 g, 
0.22 mmol) in DCM (2 ml). The reaction mixture was stirred at room temperature for 
2 hours then filtered, the silica residue then washed with DCM (2x2 ml). The 
combined DCM solution was evaporated in vacua to give a brown oil (0.080 g, 87 
%); 6H (250 MHz, CDC13 ) 0.79 (3H, s, C(CA//3 C BH3 ), A & B), 0.86 (3H, d, J= 7.0,
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CH(CA#3 CBH3), A & B), 0.89 (3H, d, J= 7.0, CH(CAH3 CB//3 ), A & B), 0.98 (3H, s, 
C(CAH3 CB//3), A & B), 2.14-2.65 (6H, m, C//CH2COH, C//(CH3)2 , CHC//2COH, 
C//2C(CH3 )2 , A & B), 4.04-4.12 (1H, m, br, NHC//, A & B), 5.02 (2H, s, PhC//2O, 
A & B), 5.56 (1H, d, br, J= 3.0, N/f, A & B), 6.62 (1H, s, NHOC//CO, A & B) 
7.25-7.30 (5H, m, Ai-H, A & B), 8.52 (1H, s, br, CO//); 5C (63 MHz, DEPT, CDC13 ) 
17.9 (CH(CAH3 CBH3 ), A & B), 19.3 (CH(CAH3 CBH3 ), A & B), 21.2 (C(CAH3 C BH3 ), 
A & B), 29.0 (C(CAH3 CBH3 ), A & B), 30.5 (CH(CH3 )2 , A & B), 35.6 (C(CH3 )2 , A & 
B), 37.9 (CHCH2COH), 43.6 (NHCCH2C(CH3 )2 , A & B), 51.6 (C//CH2COH, A & 
B), 61.6 (NHCH, A & B), 67.7 (PhCH2O, A & B), 110.8 (NHC=C//CO, A), 110.9 
(NHC=C#CO, B), [127.9 (CH), 128.3 (CH), 128.4 (CH), 128.6 (CH), 5C, Ar-H, A 
& B], 135.8 (PhCU20, A & B), 152.3 (NHC=CH, A & B), 157.1 (CONH, A & B), 
171.4 (NHCHCO, A & B), 199.4 (COH, A & B), 201.4 (NHC=CHCO, A & B); 
HUMS FAB (+ve) m/z 415.2231, C23 H3 iN2O5 requires 415.2233.
5.2.53 6-allyl-3-(L-valinyl-amino)-5,5-dimethyl-cyclohex-2-enone (114)
O
(diastereomers A & B)
lodotrimethylsilane (0.54 ml, 3.78 mmol) was added to a stirred solution of 82 (1.3 g, 
3.15 mmol) in MeCN (10 ml) at room temperature. After 30 minutes, MeOH (3 ml) 
mixed with aq. 2M HC1 (1 ml) was added and the solution stirred for 10 minutes. 
The solvent was then evaporated in vacua and the residue redissolved in EtOAc (20 
ml) and washed with saturated NaHCO3 solution (2x5 ml). The EtOAc layer was 
then extracted with dilute acetic acid (30 %, 3x5 ml), the combined aqueous layer 
evaporated in vacua to yield a white solid (0.737 g, 84 %); 8H (250 MHz, MeOD) 
1.00 (3H, d,J= 7.0, CH(C A//3 C BH3 ), A & B), 1.03 (3H, s, C(C A//3 C BH3 ), A & B), 
1.07 (3H, d,J= 7.0, CH(CAH3C B//3 ), A & B), 1.09 (3H, s, C(CAH3 CB//3), A & B), 
2.07-2.51 (6H, m, br, C//2C(CH3 )2 C//(CH3 )2 , CHC//2CH=CH2 , C//CH2CH=CH2 , A 
& B), 3.50-3.64 (1H, m, NH2C//, A & B), 4.96-5.03 (2H, m, CHCH2 CH=C//2 , A &
191
B), 5.73-5.84 (1H, m, CHCH2C#=CH2 , A & B), 6.72 (1H, s, NHC=C//CO, A), 6.76 
(1H, s, NHOC//CO, B); 8C (63 MHz, DEPT, DMSO) 17.5 (CH(C*H3CBH3), A & 
B), 19.1 (CH(CAH3 CBH3), A & B), 21.1 (C(CAH3 CBH3 ), A & B), 28.8 
(C(CAH3 CBH3), A & B), 31.9 (CH2CH=CH2 , A & B), 31.9 (CH(CH3)2 , A & B), 36.5 
(C(CH3)2, A & B), 41.7 (NHCCH2C(CH3)2 , A & B), 57.1 (C(CH3 )2 CH, A & B), 60.4 
(NH2CH, A & B), 111.2 (HNC=CHCO, A & B), 116.0 (CH2CH=CH2 , A & B), 
137.7 (CH2CH=CH2 , A & B), 151.4 (NHC=CH, A & B), 156.8 (CONH, A & B), 
169.9 (NHCHCO, A & B), 201.7 (NHC=CHCO, A & B); MS ES 279.0 (M+H)+, 
277.0 (M-H)-





































The reagents were prepared as in table 5.2. The ligand 114 solution (1.0 ml) was 
manually dispensed into each of the 9 tubes being used in the MiniBlock. The 
aldehyde derivatives were manually added to the individual MiniBlock tubes 
followed by 4A molecular sieves, the MiniBlock was then shaken on the Shaking and 
Washing Station for 1 hour. The Miniblock was removed from the shaker station and 
(polystyrylmethyl)trimethylammonium cyanoborohydride was manually added to
192
each of the 9 tubes being used, the MiniBlock was then shaken overnight. The 
Miniblock was removed from the shaker and 4-benzyloxybenzaldehyde polystyrene 
resin was added and the MiniBlock shaken overnight. The MiniBlock was drained 
into a 48 well plate, the crude solutions were then subject to purification using the 
Biotage Parallex Flex preparative HPLC system.
Table 5.4 Array products
Ligand Structure Yield and Analysis
115
o
(diastereomers A & B)
0.021 g, 54 %; 5H (250 MHz, CDC13 ) 0.99- 
1.09 (12H, m, CH(C//3 )2 , C(C//3 ) 2 , A & B), 
2.12-2.43 (6H, m, C//(CH3 ) 2 , C//2C(CH 3 ) 2 , 
C//CH2CH=CH2 , CHC//2CH=CH2 , A & B), 
3.01-3.17(4H, m, br, Ph(C//2)2NH, A & B), 
4.33-4.35 (1H, m, br, NHC//, A & B), 4.91- 
5.03 (2H, m, CHCH2CH=C//2, A & B), 5.78- 
5.89 (1H, m, CHCH2C//=CH2 , A & B), 7.09- 
7.31 (6H, m, Ar-H, NHC=C//CO, A & B), 
10.01 (1H, s, br, N//); MS ES (+ve) m/z 383.1
116
O
(diastereomers A & B)
0.020 g, 52 %; 8 H (250 MHz, MeOD) 0.98- 
1.08 (12H, m, CH(C//3)2 , C(C//3 )2 , A & B), 
2.07-2.37 (6H, m, C//(CH3 )2 , C//2 C(CH3 )2 , 
C//CH2CH=CH2 , CHC//2CH=CH2 , A & B), 
3.42-3.44 (2H, m, ArC//2NH, A & B), 3.65- 
3.72 (1H, m, NHC//, A & B), 4.07-4.23 (2H, 
m, ArC//2NH, A & B), 5.01-5.13 (1H, m, 
CHCH2CH=C//2 , A & B), 5.74-5.85 (1H, m, 
CHCH2 C//=CH2), 6.76 (1H, s, NHC=C//CO, 
A), 6.78 (1H, s, NHC=C//CO, B), 6.96-7.01 
(2H, m, Ar-H, A & B), 7.19-7.26 (1H, m Ar- 
H, A & B), 7.37-7.41 (1H, m, Ar-H, A & B); 





(diastereomers A & B)
0.021 g, 53 %; 6H (250 MHz, MeOD) 0.99- 
1.08 (12H, m, CH(C//3 )2 , C(C//3 )2 , A & B), 
2.09-2.34 (6H, m, C//(CH3 )2 , C//2C(CH3 ) 2 , 
C//CH2 CH=CH 2 , CHC//2CH=CH2 , A & B), 
3.40-3.43 (2H, m, ArC//2NH, A & B), 3.66- 
3.74 (1H, m, NHC//, A & B), 4.10-4.24 (2H, 
m, ArC//,NH, A & B), 5.04-5.15 (1H, m, 
CHCH2CH=C//2 , A & B), 5.78-5.87 (1H, m, 
CHCH2C//=CH2), 6.81 (1H, s, NHC=C//CO, 
A & B), 6.96-7.01 (2H, m, Ar-H, A & B), 




(diastereomers A & B)
0.023 g, 60 %; 8H (250 MHz, MeOD) 1.00- 
1.07 (12H, m, CH(C//3)2 , C(C//3 )2 , A & B), 
2.07-2.14 (IH, m, C//CH2CH=CH2> A & B), 
2.21-2.48 (5H, m, C//(CH3)2 , C//2C(CH3)2, 
CHC//2CH=CH2 , A & B), 3.76-3.79 (IH, m, 
NHC//, A & B), 4.10-4.25 (2H, m, 
ArC//2NH, A & B), 4.92-5.00 (IH, m, 
CHCH2CH=C//2), 5.73-5.85 (IH, m, 
CHCH2C//=CH2), 6.61 (IH, s, NHC=C//CO, 
A), 6.63 (IH, s, NHC=C//CO, B), 7.16-7.40 
(4H, m, Ar-//, A & B); MS ES (+ve) m/z 
387.1 (M+H)+ , 409.0 (M+Na)+ .119
(diastereomers A & B)
0.021 g, 54 %; 5H (250 MHz, MeOD) 0.99- 
1.06 (12H, m, CH(C//3 )2 , C(C//3)2 , A & B), 
2.07-2.13 (IH, m, C//CH2CH=CH2 , A & B), 
2.23-2.40 (5H, m, C//(CH3)2 , C//2C(CH3)2 , 
CHC//2CH=CH2 , A & B), 3.76-3.81 (IH, m, 
NHC//, A & B), 4.17-4.23 (2H, m, 
ArC//2NH, A & B), 4.94-5.02 (IH, m, 
CHCH2CH=C//2), 5.72-5.83 (IH, m, 
CHCH2C//=CH2), 6.59 (IH, s, NHC=C//CO, 
A), 6.61 (IH, s, NHC=C//CO, B), 7.11-7.18 
(2H, m, Ar-//, A & B), 7.42-7.53 (2H, m, Ar- 
//, A & B); MS ES (+ve) m/z 387.1 (M+H)+ , 
409.0 (M+Na)+ .__________________120
(diastereomers A & B)
0.026 g, 62 %; 5H (250 MHz, MeOD) 0.97- 
1.08 (12H, m, CH(C//3)2 , C(C//3)2 , A & B), 
2.05-2.12 (IH, m, C//CH2CH=CH2 , A & B), 
2.23-2.46 (5H, m, C//(CH3 )2 , C7/2C(CH3 )2 , 
CHC/72CH=CH,, A & B), 3.84-3.88 (IH, m, 
NHC//, A & B), 4.34 (2H, dd, J = 4.3, 13.2, 
ArC//2NH, A & B), 4.94-5.03 (IH, m, 
CHCH2CH=C//2), 5.72-5.83 (IH, m, 
CHCH2C//=CH2), 6.57 (IH, s, NHC=C//CO, 
A), 6.69 (IH, s, NHC=C//CO, B), 7.56 (IH, 
d, J = 8.7, Ar-//, A & B), 7.72 (IH, d, J = 8.7, 
Ar-//, A & B), 8.21 (IH, d, J = 8.7, Ar-//, A 
& B), 8.26 (IH, d, J = 8.7, Ar-//, A & B); MS 
ES (+ve) m/z 436.1 (M+Na)+ ._________
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(diastereomers A & B)
0.022 g, 53 %; §H (250 MHz, MeOD) 0.94- 
1.04 (12H, m, CH(C//3 )2 , C(C//3 )2 , A & B), 
2.03-2.46 (6H, m, C//(CH3 ) 2 , C//2C(CH3 )2 , 
CHC//2CH=CH 2 , C//CH2CH=CH2 , A & B), 
2.93 (3H, s, (C//3 )2N, A), 2.94 (3H, s, 
(C//3)2N, B), 3.78-3.82 (IH, m, NHC//, A & 
B), 4.17-4.23 (2H, m, ArC//2NH, A & B), 
4.97-5.05 (IH, m, CHCH2CH=C//2 ), 5.69- 
5.86 (IH, m, CHCH2C//=CH2), 6.51 (IH, s, 
NHC=C//CO, A), 6.5"3 (IH, s, NHC=C//CO, 
B), 6.81 (2H, d, J = 7.3, Ar-//, A & B), 7.32 
(2H, d, J = 7.3, Ar-//, A & B); MS ES (+ve) 
m/z 412.1 (M+H)+ . _______
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122
(diastereomers A & B)
0.027 g, 59 %; 8H (250 MHz, MeOD) 0.98- 
1.06 (12H, m, CH(C//3 )2 , C(C//3 )2 , A & B), 
2.06-2.13 (1H, m, C//CH2CH=CH2, A & B), 
2.27-2.39 (5H, m, C//(CH3 )2 , C//2C(CH3 )2 , 
CHC//2CH=CH2 , A & B), 3.84 (1H, dd, J = 
1.3, 4.6, NHC//, A & B), 4.19-4.30 (2H, m, 
ArC//2NH, A & B), 4.95-5.04 (1H, m, 
CHCH2CH=C//2), 5.73-5.85 (1H, m, 
CHCH2C//=CH2), 6.61 (1H, s, NHC=C//CO, 
A), 6.62 (1H, s, NHC=C//CO, B), 7.30 (2H, 
d, J= 8.7, Ar-H, A & B), 7.61 (2H, d, J = 8.7, 
Ar-H, A & B); MS ES (+ve) m/z 453.1
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(diastereomers A & B)
0.017 g, 46 %; 6H (250 MHz, CDC13 ) 1.00 
(3H, d, J= 6.9, CH(C A//3 CBH3 ), A & B), 1.02 
(3H, d, J = 6.9, CH(CAH3 CB//3 ), A & B), 1.07 
(3H, s, C(CA//3 CBH3 ), A & B), 1.09 (3H, s, 
C(CAH3 CB//3 ), A & B), 2.08-2.41 (6H, m, 
C//(CH3 )2 , C//2C(CH3 )2 , C//CH2CH=CH2 , 
CHC//2CH=CH2) A & B), 4.02 (1H, dd, J = 
2.0, 4.5, NHC//, A & B), 4.40-4.48 (2H, m, 
CHCH2CH=C//2), 4.93-5.02 (3H, m, ArC//2 , 
N//, A & B), 5.73-5.84 (1H, m, 
CHCH2C//=CH2), 6.64 (1H, s, NHC=C//CO, 
A), 6.66 (1H, s, NHC=C//CO, B), 7.06 (1H, 
d, 7=5.1, Ar-H, A), 7.08 (1H, d, J= 5.1, Ar- 
//, B), 7.24-7.26 (1H, m, Ar-H, A & B), 7.56 
(1H, d, J= 5.1, Ar-//, A), 7.57 (1H, d, 7= 5.1, 
Ar-H, B); MS ES (+ve) m/z 375.0 (M+H)+ .
5.2.55 Attempted preparation of 6-allyl-3-(N-fluorescein-thiourea-L-valinyl- 
amino)-5,5-dimethyl-cyclohex-2-enone
Fluorescein isothiocyanate isomer 1 (0.056 g, 0.14 mmol) and 61 (0.040 g, 0.14 
mmol) were dissolved in DMF (1 ml) and stirred at room temperature for 1 hour. 
Water (2 ml) and EtOAc (2 ml) were added, the aqueous layer separated and 
extracted with EtOAc (2x3 ml). The combined organic layers were dried (MgSO4) 
and evaporated in vacuo to give a yellow oil. TLC analysis (50 % EtoAc in
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petroleum ether 40-60) indicated the presence of two distinct compounds. One 
corresponded to fluorescein isothiocyante (Rf 0.6), this was supported by mass 
spectroscopy (MS ES 390 (FITC+H)+ , 388 (FITC-H)'). Analysis by mass 
spectroscopy of the second compound (Rf 0.4) indicated a mass of 487 (M-23).
5.2.56 6-allyl-3-(N-dansyl-L-valinyl-amino)-5,5-dimethyl-cyclohex-2-enone(126)
(diastereomers A & B)
Dansyl-L-valine cyclohexylammonium salt (0.125 g, 0.36 mmol) was dissolved in 
EtOAc (5 ml) and washed with 2M KHSO4 solution (3x3 ml) to remove the 
cyclohexylamine. The combined aqueous layers were washed with EtOAc (5 ml), the 
organic phases combined and the solvent evaporated in vacua to give a yellow oil. 
The oil was dissolved in DCM (2 ml) and PyBroP (0.168 g, 0.36 mmol) and DMAP 
(0.088 g, 0.72 mmol) were added. The solution was stirred at room temperature for 5 
minutes then 78 (0.045 g, 0.25 mmol) was added. After 1 hour the DCM was 
evaporated in vacuo and the residue redissolved in EtOAc (5 ml) and water (2 ml). 
The organic layer was separated and washed with 1M KHSO4 solution (2 ml), water 
(2 ml), saturated NaHCO3 solution (2 ml), water (2 ml), dried (MgSO4) and the 
solvent removed in vacuo to give a yellow oil. Flash column chromatography on 
silica gel using 30 % ethyl acetate in petroleum ether 40-60 as eluent afforded a 
yellow solid (0.101 g, 79 %). 5H (250 MHz, CDC13 ) 0.67 (3H, d, J = 6.8, 
CH(CA#3 C BH3 ), A), 0.68 (3H, d, J= 6.8, CH(C A//3 C BH3 ), B), 0.77 (3H, d, J= 6.8, 
CH(CAH3 C B//3 ), A & B), 0.83 (3H, s, C(CA//3 C BH3 ), A), 0.84 (3H, s, C(C A//3 C BH3 ), 
B), 0.93 (3H, s, C(C AH3 C B//3 ), A), 0.94 (3H, s, C(C AH3 C B//3 ), B), 1.88-2.25 (6H, m, 
C//(CH3 ) 2 , C//CH2CH=CH2 , CHC#2CH=CH2 , C//2C(CH3 )2 , A & B), 2.86 (6H, s, 
N(C//3 )2 , A & B), 3.67 (1H, dd, J = 5.2, 7.7, NHC//, A & B), 4.91-5.00 (2H, m, 
CHCH2CH=C//2 , A & B), 5.64-5.84 (2H, m, N//, CHCH2C//=CH2 , A & B), 6.14 
(1H, s, NHC=C//CO, A), 6.17 (1H, s, NHC=C7/CO, B), 7.19 (1H, d, J = 7.5, Ai-H,
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A & B), 7.49 (1H, dd, J = 7.4, 8.5, Ar-H, A & B), 7.60 (1H, dd, J = 7.5, 8.6, Ar-//, 
A & B), 7.91 (1H, s, N//, A), 7.94 (1H, s, N//, B), 8.23 (1H, d, J = 7.4, Ar-//, A), 
8.24 (1H, d, J = 7.4, Ar-//, B), 8.32 (1H, d, J = 8.6, Ar-//, A & B), 8.53 (1H, d, J = 
8.5, Ar-//, A & B); 8C (90 MHz, DEPT, CDC13) 17.1 (CH(CAH3CBH3), A), 17.2 
(CH(CAH3 CBH3), B), 18.7 (CH(CAH3CBH3), A), 18.9 (CH(CAH3 CBH3 ), B), 23.7 
(C(CAH3CBH3), A), 24.0 (C(CAH3 CBH3 ), B), 28.3 (C(CAH3 CBH3), A), 28.4 
(C(CAH3CBH3), B), 30.1 (CH2CH=CH2 , A), 30.3 (CH2CH=CH2 , B), 30.6 (CH(CH3)2 , 
A & B), 35.1 (C(CH3)2 , A), 35.2 (C(CH3)2 , B), 40.5 (NHCCH2C(CH3 )2 , A & B), 
40.8 (NHCCH2C(CH3 )2 , B), 45.2 (N(CH3 )2 , A), 45.3 (N(CH3 )2 , B), 56.5 
(C(CH3 )2CH, A), 56.6 (C(CH3 )2 CH, B), 63.1 (NHCH, A & B), 110.3 (HNC=CHCO, 
A), 110.4 (HNOCHCO, B), 115.2 (Ar-H, A), 115.3 (Ar-H, B), 115.4 (CH2CH=CH2, 
A), 115.5 (CH2CH=CH2 , B), 118.0 (Ar-H, A & B), 123.0 (Ar-H, A & B), 128.8 (Ar- 
H, A), 128.9 (Ar-H, B), 129.4 ((CH3 )2NC, A), 129.5 ((CH3 )2NC, B), 130.2 (Ar-H, A 
& B), 131.3 (CSO2 , A), 133.4 (CSO2 , B), 137.2 (CH2CH=CH2 , A), 137.4 
(CH2CH=CH2 , B), 150.9 (NHC=CH, A), 151.0 (NHOCH, B), 169.7 (NHCHCO, A 
& B), 201.8 (NHOCHCO, A), 201.9 (NHOCHCO, B); HRMS El (+ve) m/z 
512.2580, C28H37N3 O4S requires 512.2583.
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